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  2Abstract 
 
 
Mitochondrial dysfunction has been implicated in the early pathogenesis of 
Type 2 Diabetes.   The uncoupling proteins 2 and 3 are mitochondrial proteins 
found in man that have been implicated in protecting mammals from the effects 
of over-nutrition.  Examination of the effect of genetic variation in the UCP2-
UCP3 genetic cluster has so far been inconclusive.  The aim of this thesis was 
to examine, using a genetic strategy, the hypothesis that the role of the 
uncoupling proteins 2 and 3 in the pathogenesis of Type 2 Diabetes is via 
modification of oxidative stress.   
 
In a prospective study of nearly 3000 men the risk of type 2 diabetes at 10 
years was increased for both the UCP2-866AA (1.94 [1.18-3.19]: p=0.009) and 
the UCP3-55TT (2.06 [1.06-3.99]: p=0.03) homozygotes.  This increased risk 
was not explained by the association with any measured conventional risk 
factors. Paradoxically, in a Europe-wide cross-sectional study of 598 subjects 
the UCP2-866A variant was associated with lower waist-hip ratio (GX v AA,1.00 
[0.06] v 0.98 [0.07]; p=0.003), although also associated with lower insulin 
secretion (42.6 [24.6] v 35.6 [18.6]; p=0.03). The UCP3 variant was not 
significantly associated with any metabolic trait. 
 
The significant heritability of plasma markers of oxidative stress (TAS 0.54, 
TOAS 0.49) suggests anti-oxidant function is a plausible mechanism to 
determine Type 2 Diabetes risk.  The predictors of anti-oxidant stress in a family 
study were examined, as was the impact of UCP2-UCP3 gene cluster variation. 
Genetic variation in the UCP2-UCP3 was found to increase the risk of the Type 
2 diabetes.   While UCP2 may modify insulin secretion directly, the mechanism 
of action for UCP3 is likely to involve novel risk factors for Type 2 Diabetes such 
as modification of mitochondrial oxidative stress.   Finally, the development of a 
human model is described to examine genetic influences on oxidative stress 
burden using a meal rich in used cooking oil. 
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1.1 Type 2 Diabetes Mellitus 
 
1.1.1 Definition  
 
Diabetes Mellitus is a disorder characterised by hyperglycaemia.  Diabetes is 
diagnosed on the basis of World Health Organisation (WHO) recommendations 
(Table  1.1)  which  also  defines  the  pre-diabetic  states  of  impaired  glucose 
tolerance and Impaired fasting glucose.   
 
Table 1.1  The diagnosis of diabetes mellitus and pre-diabetes states from the 
Expert  Committee  on  the  Diagnosis  and  classification  of  diabetes  mellitus 
(Diabetes Care: 20: 1183-1197:1997) 
 
  Glucose concentration in venous plasma 
(mmol/L) 
Diabetes mellitus  Fasting ≥ 7·0 or 2-h post-glucose load ≥11·1 
 
Impaired glucose tolerance  Fasting (if measured) <7·0 and  
2-h post-glucose load ≥ 7·8 and <11·1 
Impaired fasting glucose  Fasting ≥ 6·1 and <7·0 and  
2 h post-glucose load (if measured) <7·8 
 
Glycaemia is regulated by a number of hormones but the key hormone is insulin.  
Failure to maintain normal glucose homeostasis is due to the inability of the 
organism to maintain normal insulin secretion from the β-cells of the pancreas 
or  to  maintain  normal  insulin  action,  a  state  defined  as  insulin  resistance.   
Insulin resistance is present when the biological effects of insulin are less than 
expected  for  both  glucose  disposal  in  skeletal  muscle  and  suppression  of 
endogenous  glucose  production,  primarily in  the liver  (Dineen  S,1992).    The 
WHO  criteria  for  the  classification  of  diabetes  are  based  on  current 
understanding of the aetiology of the disease.  Type 1 diabetes results from a 
cell-mediated autoimmune attack on β cells [reviewed by Daneman D, 2006].  In 
summary, a genetic susceptibility to type 1 diabetes is inherited, mainly in the 
HLA-genotype, and the condition is triggered by an as yet unidentified, probably   21 
infective, environmental trigger.  The abnormal activation of the T-cell-mediated 
immune system in susceptible individuals leads to an inflammatory response 
within  the  islets  (insulitis)  as  well  as  to  a  humoral  (B  cell)  response  with 
production of antibodies to β-cell antigens.  Continuing destruction of β cells 
leads  to  progressive  loss  of  insulin-secretory  reserve  and,  when  insulin 
secretion falls below a critical amount to a state of absolute insulin deficiency 
(Daneman D,2006). 
 
Type  2  diabetes  is  by  far  the  most  common  form  of  diabetes,  it  is  a 
heterogeneous condition, diagnosed empirically by the absence of features of a 
secondary cause or features suggesting type 1 diabetes. 
 
Table  1.2.  Classification  of  diabetes  mellitus  according  to  aetiology  (World 
Health Organization (1998) 
 
Type 1   β-Cell  destruction,  usually 
leading  to  absolute  insulin 
deficiency  
15–20% of cases in Europe and 
the United States 
Type 2   Some  degree  of  insulin 
resistance,  with  relative  insulin 
deficiency  
75–80% of cases in Europe and 
the United States 
Other   Other types with specific causes   5% of cases in Europe and the 
United States 
 
 
1.1.2 Demographics 
 
Diabetes Mellitus is now considered as one of the main threats to human health 
in  the  21
st  Century  (Zimmet  P,2000).    Changes  in  the  human  environment, 
behaviour  and lifestyle have resulted in  escalating  rates  of  both  obesity  and 
diabetes and the number of people with diabetes is expected to double between 
2000 and 2030 (Wild S,2004).  The diabetes epidemic relates mainly to type 2 
diabetes which accounts for over 90% of cases globally (Zimmet P,2004) which 
explains the increase in the older population (Fig1.1).  Estimates suggest that   22 
5.2% of World all cause mortality is attributable to diabetes (2.9 million deaths in 
2000),  which  is  equivalent  to  one  in  ten  deaths  in  economically  productive 
individuals aged 35-64 years in most developing countries.(Roglic G,2005). 
 
Fig. 1.1. Global diabetes prevalence by age and sex for 2000.(Wild S,2004) 
 
 
The increase in mortality is in part due to a significant increase in the risk of 
coronary artery disease, where men with type 2 diabetes have the same risk of 
myocardial infarction as men without type 2 diabetes who have already had a 
myocardial  infarction  (Fig.1.2).    This  is  equivalent  to  the  increased  risk  of 
myocardial infarction  associated  with  an increase in  age  of  15  years  (Booth 
GL,2006).  
 
The link between type 2 diabetes and cardiovascular disease is partly explained 
by  a  cluster  of  adverse  changes  to  lipid  profiles  and  blood  pressure.    This 
cluster  has  been  termed  the  metabolic  syndrome.  An  attempt  to  define  this 
syndrome  was  first  made  by  the WHO  in  1998,  of  which  abnormal  glucose 
tolerance  was  a  key  factor.    A  clinical  definition  of  metabolic  syndrome  was 
produced  by  the  National  Cholesterol  Education  Program-  Adult  treatment 
program  III  in  2001,  which  includes  abdominal  obesity,  dyslipidaemia, 
hypertension,  insulin  resistance  and  prothrombotic  and  inflammatory  states 
(Expert  Panel  on  Detection  EaToHBCiA,2001).    There  is,  however,  much   23 
debate  as  to  whether  current  definitions  identify  an  entity  that  adds  any 
cardiovascular disease risk above the individual components in the definition or 
other primary risk factors not included in the definition, such as smoking and 
LDL  cholesterol,  which  also  tends  to  cluster  with  hypertension  etc.  (Alberti 
KGMM,2005; Kahn R,2005). 
 
Fig. 1.2.  Relation between age and rates of AMI by diabetes status and sex [All 
lines  fitted  according  to  a  polynomial  equation,  R  >0·99  for  each  fitted  line 
(Booth GL,2006)] 
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1.2 Pathogenesis of type 2 diabetes 
 
 
The  core  elements  involved  in  the  pathogenesis  of  type  2  diabetes  are  
impaired  insulin  action,  known  as  insulin  resistance,  and  impaired  insulin 
secretion  leading  to  a  relative  insulin  deficiency.  The  core  elements  can  be 
influenced both genetically and environmentally.  Longitudinal studies suggest 
that a defect in insulin action precedes the development of type 2 diabetes, and 
the  pre  diabetic  states,  with  the  disease  only  becoming  evident  when  β-cell 
failure  means that insulin secretion is unable to compensate for the increased 
requirements (Weyer C,1999).  Adiposity, especially central adiposity leads to 
increased  release  and  circulating  levels  of  non-esterified  fatty  acids  [NEFA] 
which aggravates insulin resistance in liver and muscle (Boden G,1997).  The 
excess lipid is also stored in ectopic sites, such as skeletal muscle, where it 
further impairs insulin action (Pan DA,1997).   
 
Fig. 1.3.  A summary of the pathogenesis of type 2 diabetes 
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1.2.1 Genetic predisposition to Type 2 Diabetes 
 
1.2.1a  Evidence for a genetic basis for type 2 diabetes 
 
The recent epidemic of type 2 diabetes is a clear indication of the importance of 
environmental  factors in  type  2 diabetes  onset.      However,  there is  also  an 
abundance of evidence concerning the presence of a genetic component. 
 
Ethnic Differences 
 
There is wide variation in the prevalence of type 2 diabetes by ethnic group, 
with very low levels in some, such as rural Chinese, to extremely high rates 
found  in  the  Pima  Indians  in  Arizona  (WHO  Ad  Hoc  Diabetes  Reporting 
Group,1993).    However,  this  could  be  due  to  non-genetic  cultural  and 
environmental factors, but as the prevalence of type 2 diabetes reduces with the 
extent of Pima/European American interbreeding (Williams RC,2000) this is less 
likely.  The prevalence of type 2 diabetes also differs between ethnic groups 
that  share  similar  environments,  such  as  the  United  Kingdom  where  the 
prevalence of type 2 diabetes in Caucasians is 2.4% but prevalence is 3-6 fold 
higher in individuals of South Asian descent (Simmons D,1991). 
 
Family Studies 
 
A  higher  prevalence  in  family  members  is  thought  to  be  because  of  an 
increased number of shared genes, including those that play a role in disease 
predisposition shared between family members.  Such a relationship has been 
described a number of times, most recently in the Framingham Offspring study 
where risk of type 2 diabetes increased by 3.5 times with one affected parent 
and to 6.1 with both parents affected (Meigs J,2000).  However, there is still the 
possibility of  these results  being  confounded  by  shared  culture,  environment 
and habits.   This can be addressed by twin studies.  Several twin studies have 
been  carried  out  and  although  concordance  rates  vary  they  are  higher  in   26 
monozygotic  twins  than  dizygotic  twins  (Barroso  I,2005).    The  fact  that 
concordance in monozygotic twins may be as high as 80% (Ghosh S,1996), 
together with the other studies, suggest that type 2 diabetes has a substantial 
genetic component. 
 
1.2.1b  The role of insulin resistance 
 
The  requirement  for  over  fifty  essential  nutrients  in  modern  man  to  achieve 
maximum health and longevity means that a diverse diet has been linked to 
health and that this relationship developed early in hominid pre-history (Hockett 
B,2003).   The survival of the genes predisposing to type 2 diabetes, not only in 
man but in other species, such as Free-Ranging Baboons (Kemnitz JW,2002) 
would imply that they may have been selected for in the past.   Pre-human 
ancestors (2-4 million years) consumed a significant proportion of carbohydrate 
in  their  diet  (Colagiuri  S,2002),  as  a  result  the  brain  developed  a  specific 
requirement of glucose  as a source of fuel.    Brain stores of glycogen are 
sufficient for only a few minutes survival without blood flow, so systems had to 
develop to ensure a robust supply of glucose (Kitano H,2004).  These systems 
evolved in past environments far different to those found today and our genome 
remains largely adapted to our Palaeolithic existence (Johanson D,1998).  This 
pre-agricultural age diet overlaps little with current foods and was based mainly 
on  meat  protein  (Hunter)  and  protein  from  nuts  and  shellfish,  with  little 
carbohydrate  from  fruits  and  vegetables  (Gatherer)(Colagiuri  S,2002).      To 
maintain  blood  glucose  for  the  brain  the  organism  would  develop  reduced 
peripheral blood glucose utilisation and increased hepatic glucose production 
i.e., insulin resistance (Rossetti L,1989), a state that is also a feature of periodic 
starvation (Newman WP,1983).  At the end of the last Ice Age the population 
was  insulin  resistant.    The  advent  of  agriculture  increased  the  amount  of 
carbohydrate in the human diet (Eaton SB,1985), although it was not until the 
industrial revolution that highly processed carbohydrate was  widely available, 
which,  coupled  with  the  lack  of  energy  (activity)  spent  in  food  procurement 
(Eaton SB,2002), and high calorie diet, produced an environment where this 
adaptation  started  to  become  deleterious.    This  then  confers  higher 
susceptibility to a number of chronic degenerative diseases.     27 
 
 
1.2.1c   Using Genetics in the study of type 2 Diabetes 
 
Epidemiology is “the study of distribution determinants [and control] of health 
related  states  and  events  in  populations”.    The  concept  of  “genetic 
epidemiology”  is  less  well  defined  but  regarded  as  the  study  of  the  genetic 
determinants  of  disease,  and  also  the  joint  effect  of  genes  and  non-genetic 
determinants  (Burton  PR,2005).    The  disease-exposure  association  of 
traditional  epidemiology  is  essentially  replaced  with  the  genetic  variation-
exposure association.  There are a number of methods available to locate and 
identify causative genes.     
 
Learning from Monogenic Disorders 
 
A  small  proportion  of  diabetes  cases  are  due  to  mutation  in  a  single  gene.  
There are three main groups of disorders, MODY [maturity onset diabetes of the 
young], neonatal diabetes and Mitochondrial diabetes.  The understanding of 
the  genetic  basis  for  these  conditions  has  improved  understanding  of  the 
physiology  of  metabolism  and  energy  balance  and  the  pathophysiology  of 
polygenic diabetes (McCarthy MI, 2008).      
 
Although 10% of cases MODY do not have a cause identified the remaining 
cases fall into two types  (Vaxillaire M, 2006).  Glucokinase mutations account 
for 14% and give rise to a non-progressive mild impairment of glucose sensing 
in the pancreatic β-cell (Hattersley AT, 1993).  The remaining cases are due to 
mutations in the genes for a number of transcription factors that are thought to 
play key roles in pancreatic development and function, including TCF-1,TCF-2, 
IDF-1, Nuerod 1 and CEL (McCarthy MI, 2008).      
 
Neonatal diabetes presents in the first six months of life.  The genes identified 
all  code  for  proteins  that  form  an  ATP  dependant  potassium  channel 
[KCNJII/ABCC8].  Identification of the underlying genetic aetiology has enabled 
an effective and tailored treatment strategy to be developed for these` patients   28 
using  the  sulponylurea  group.    Mitochondrial  diabetes  is  discussed  in  a 
following section on insulin resistance. 
 
Unravelling the genetic variation –exposure in polygenic disease 
 
One  option is  to  move  straight  to  the  obvious  candidate  genes,  however, in 
complex diseases such as type 2 diabetes there are a very large number of 
plausible  candidate  genes.    Linkage  analysis  can  be  used  to  identify  broad 
genomic regions that might contain a disease gene, even without a plausible 
candidate being present in that area (Teare MD,2005).   Two genetic loci are 
linked if they are transmitted together from parent to offspring more often than 
expected  under  independent  inheritance  (c.f.  Linkage  disequilibrium,  which 
refers  to  loci  found  together  on  haplotypes  in  the  population  at  a  frequency 
greater than expected).  Linkage analysis identifies markers that are passed 
down  through  a  family,  that  consistently  accompany  the  disease  of  interest. 
They  have  been  more  successfully  used  for  monogenic  conditions  than 
complex  polygenic  conditions  (Botstein  D,2003).    To  date,  over  50  type  2 
diabetes linkage studies  have been conducted in a variety of populations, in 
which some chromosomal regions have now been replicated in multiple studies 
(Barroso  I,2005).      This  is  in  part  due  to  the  intrinsic  limitations  of  linkage 
analysis  studies  due  to low  statistical  power,  which  can  also  be  reduced  by 
missing  pedigree  information,  genetic  differences  between  populations  and 
genotype  errors,  such  that  the  sample  size  to  detect  genetic  linkage  of  the 
modest size expected in complex traits may be unobtainable (Risch N,2000).    
The power of linkage analysis in type 2 diabetes is also reduced by difficulty 
defining the phenotype, with the possibility that early onset type 2 diabetes may 
have different genetic determinants, and the difficulty in identifying subjects who 
may have latent autoimmune diabetes.  The power of the study will be diluted 
further  by  the  possibility  of  genetic  heterogeneity  within  families,  where  a 
different combination of genes may determine a complex trait within a family 
(Teare MD,2005). However, despite these difficulties, a number of regions have 
now been replicated (reviewed by (Florez JC,2003), and at least two important 
genes  have  been  identified  by  this  approach  namely,  calpain  10  (Horikawa   29 
Y,2000)  and  TCF7L2  (Grant  SFA,2006),  neither  of  which  were  plausible 
candidate genes. 
 
Association studies have more in common with traditional epidemiology, where 
the risk is a particular allele, genotype or haplotype of a genetic marker.  Most 
performed so far employ a case-control design, and have been of the candidate 
gene type.  They have also not been well replicated, because of poor matching 
of  cases  and  controls,  use  of  convenient  samples,  small  study  size,  limited 
number  of  markers  per  gene  and  failure  to  take  into  account  environmental 
interaction (Barroso I,2005) although, these can somewhat be overcome if a 
prospective  sample  is  used  (Humphries  SE,2003).    The  presence  of  an 
association  does not  always  imply  causation,  but  may  reflect  an  association 
with a nearby causal variant (i.e. in strong linkage disequilibrium with the variant 
studied)  or  be  due  to  some  underlying  stratification  or  admixture  of  the 
population  (Cordell  HJ,2005).    Genetic  association  studies  have  identified  a 
number  of  polymorphisms  reproducibly  associated  with  type  2  diabetes, 
including  Pro12Ala  in  PPAR-gamma  (Altshuler  D,2000).    A  review  of  the 
published candidate gene polymorphism association studies can be found in 
Barroso I(2005). 
 
New techniques in genetic epidemiology 
 
The Genome Wide Association study 
 
The development of high performance genotyping (Fan JB, 2006) coupled with 
the identification of most known patterns of common variation by the HapMap 
consortium  (The  International  HapMap  Conssortium,  2003)  have  enabled 
researchers  who  have  either  through  collaboration  or  design  amassed  more 
suitable sample sizes to perform  genome wide association studies (McCarthy 
MI, 2008).  This approach is not based on any plausible biological basis but 
aims to capture most of the common variation in the whole genome in one study.   
This approach .has led to a recent increase in the number of replicated gene-
type  2  diabetes  association  studies.    The  following  have  been  identified  as   30 
important  genes  by  genome  wide  association  studies,  HHEX/IDE,  SLC30A8, 
FTO, CDKAL1, CDKN2A and IGF2BP2 (McCarthy MI, 2008).      
 
Mendelian Randomisation 
 
When a robust finding from observational studies [vitamin C and CHD (Khaw 
KT, 2001)] is not backed up by interventional studies (Heart Protection Study 
Collaborative  group,  2002)  one  of  the  likely  causes  is  the  presence  of 
confounding variables.   Mendelian randomisation overcomes some of problems 
as the association can be tested on the basis of random genetic variation.  A 
genetic variant that alters a biological exposure eg CRP should increase the 
prevalence of the related disease as predicted by its effect on the risk factor 
(Smith GD, 2007).  If this is not the case then the disease-risk factor relationship 
observed is likely to be due to confounding factors.   
 
  
1.2.2  Molecular Mechanisms in type 2 diabetes- gene-lifestyle interaction 
 
 
The  cardinal  features  of  type  2  diabetes  are  the  development  of  insulin 
resistance and the failure of insulin secretion.   Both of these develop from a 
combination of genetic predisposition and environmental influences.  There is 
continued debate about which is the initial abnormality.  Early studies suggested 
that insulin resistance was the strongest predictor of type 2 diabetes in Pima 
Indians  (Lillioja  S,1993)  and  that  insulin  resistance  was  present  at  least  ten 
years before development of the disease, whilst reduction in insulin secretion 
occurred  only  a  few  years  prior  to development  of  type  2  diabetes  (Warram 
JH,1990).  However, recently this data has been questioned, with evidence that 
β-cell dysfunction is present in normal glucose tolerant individuals predisposed 
to type 2 diabetes (van Haeften TW,1998), and that people with type 2 diabetes 
may  not  be  more  insulin  resistant  than  appropriate  obese  controls  (Weyer 
C,1999).    Certainly  both  are  present  at  time  of  hyperglycaemia  (Chiasson 
JL,2004), and it may be the relationship between them that is more important 
than each individually (see 1.2.2b).     31 
 
 
1.2.2a The development of insulin resistance 
 
 
Insulin  is  a  peptide  hormone  secreted  from  the  β-cells  of  the  islets  of 
Langerhans, in the pancreas.   The actions of insulin include increased glucose 
uptake  into  muscle  and  fat,  decreased  hepatic  glucose  production,  and 
increased  protein,  glycogen and lipid  synthesis  with  concurrent  reductions in 
breakdown and cell growth and differentiation (Saltiel AR,2001).  Sensitivity to 
insulin  action  is  influenced  by  age,  genetics,  exercise  and  fitness,  diet, 
medication  and  obesity  (Kahn  SE.,2003).    Insulin  resistance  is  strongly 
associated with “over-nutrition” driving obesity, although, the over-nutrition may 
not  be  all  dietary,  as  defects  in  mitochondrial  fat  oxidation  have  also  been 
described  in  type  2  diabetes.      The  consequences  of  obesity  and  insulin 
resistance include impaired glucose tolerance, hypertension and dyslipidemia 
(low High Density Lipoprotein [HDL], high Very Low Density Lipoprotein [VLDL] 
and a preponderance of small dense Low Density Lipoprotein [LDL]) and can 
even be detected in obese children (Weiss R,2004).  The metabolic changes all 
promote  vascular  damage,  and  cardiovascular  disease  and  mortality  and 
morbidity is increased in the presence of insulin resistance (Laasko M,1996). 
 
 
Normal Insulin Action (Fig.1.4) 
 
The insulin receptor consists of two α and two β subunits. The α units make up 
the  extracellular ligand binding  domain and  normally inhibit  the  action  of  the 
intracellular tyrosine kinases domain (β subunits).  When insulin binds to the 
receptor this inhibition of tyrosine kinase activity is reduced, and conformational 
changes occur in the β subunits which enhance tyrosine kinase activity (Patti 
MR,1998).   The β-subunits activate, by phosphorylation, a cascade of insulin-
receptor substrate proteins (IRS), which act as docking proteins for and activate 
phosphatidylinositol-3 kinase [PI(3)K] (Kahn BB,1996).  The IRS cascade also   32 
activates  Mitogen-Activated  Kinase  [MAP-Kinase],  which  is  responsible  for 
some of the cell growth and proliferation effects and is not down-regulated in 
insulin resistance (Cusi K,2000).  PI(3)K activates a number of pathways related 
to glucose metabolism, through activation of protein kinase B/Akt and protein 
kinase C (Schinner S,2005).  These include transposition of GLUT-4 glucose 
uptake proteins to the cell membrane, and the reduction of glycogen synthase 
kinase 3 activity which allows glycogen synthesis to occur (Shulman GI,2000).  
The  activation  of  a  number  of  forkhead  transcription  factors  (FkHR/FOXO) 
inhibits  the  key  enzymes  of  glycogenolysis,  phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (Schmoll D,2000), whilst 
activation  of  the  mTOR  pathway  can  control  the  translation  of  a  number  of 
proteins  with  metabolic  actions,  either  directly  or  through  P70
rsk  activation 
(Saltiel AR,2001).  There is also a second pathway of GLUT-4 activation, the 
Cbl/CAP  pathway.    On  binding  of  insulin  to  the  insulin  receptor  Casitas  B-
lineage lymphoma protein (Cbl) is activated, which then forms a complex with 
Cbl  associated  protein  (CAP).    This  complex  locates  the  G-protein  TC10  in 
membrane  rafts  and    activates  it,  which  then  provides  a  signal  for  GLUT-4 
activation (Chiang SH,2001) . 
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Fig 1.4. Signal transduction in insulin action (Saltiel AR,2001). 
 
Insulin receptor pathways are terminated by protein tyrosine-phosphatase 1B which 
dephosphorylates the signal pathways.  The insulin signal can also be inhibited by 
serine/threonine phosphorylation (Zick Y,2001) by atypical Protein Kinase C isoforms 
or the C-Jun Pathway (White MF,2002) or by enhanced degradation of the IRS proteins 
as occurs in SOCS signalling (Rui L,2002). 
 
Consequences of Obesity 
 
Adipose  tissue is  an  important  determinant  of  whole  body  insulin  sensitivity.  
The distribution of the excess body fat is also important, with central fat being 
more  important  in  driving  insulin  resistance  than  peripheral  fat  (Fujimoto 
WY,1994).    Central  fat  is  intra-abdominal  visceral  fat  which  tends  to  collect 
around  the  waist,  which  is  itself  a  strong  predictor  of  type  2  diabetes 
(Wahrenberg H,2005).   Visceral fat has a different phenotype, with increased 
lipolysis compared to subcutaneous fat (Abate N,1995).   The important role of 
adipose tissue in whole body insulin sensitivity is indicated by animal models.  
The GLUT-4 adipose tissue specific mouse is severely insulin resistant  (Abel 
ED,2001) while the skeletal muscle tissue specific GLUT-4 knockout has mild 
diabetes only (Zisman A,2000).   This may be because Insulin Growth factor   34 
signalling can compensate in skeletal muscle (Shefi-Friedman L,2001) but the 
adipose  tissue  GLUT-4  over-expression  model is  also  more  insulin  sensitive 
despite being more obese (Shepherd PR,1993).  Adipose tissue specific GLUT-
4 over-expression also corrects the mild insulin resistance seen in the muscle 
specific knockout, without any direct effect on skeletal muscle but by increasing 
the number of small adipocytes (Carvalho E,2005).  In man, GLUT-4 expression 
is reduced in adipose tissue and not skeletal muscle in those with obesity or 
type 2 diabetes (Carvalho E,2001). 
 
Expanded adipose tissue can promote the development of type 2 diabetes by a 
number of mechanisms.  These are triggered by a change in adipocyte size. 
Large adipocytes, that occur in obesity, undergo changes in gene expression 
such  as  reduced  adiponectin,  and  tend  to  promote  insulin  resistance  (Yang 
X,2004) with increased intracellular lipid in non adipose tissue.  The presence of 
large adipocytes is also a predictor of type 2 diabetes and numbers inversely 
correlate with insulin sensitivity (Weyer C,2000), whilst in patients with type 2 
diabetes adipogenesis is impaired, decreasing the availability of new adipose 
cells and increasing average cell size (Yang X,2004). Large adipocytes have 
diverse functional abnormalities (Le Lay S,2001) with impairment of proliferation 
pathways  (β-catenin),  insulin  signalling  pathways  (GSK-3)  and  reduced 
adiponectin secretion (Yang X,2004). 
 
There  are  a  number  of  candidates  for  the  signal  from  adipose  tissue  that 
induces  insulin  resistance  in  liver  and  muscle.    Non-Esterified  Fatty  Acids 
[NEFA] are released in larger quantities by expanded adipose tissue (Ravussin 
E,2002) and are increased in the offspring of patients with type 2 diabetes even 
if glucose tolerance is normal (Perseghin G,1997).  Circulating levels of NEFA 
are inversely correlated with net glucose disposal (Baldeweg SE,2000).  The 
infusion  of  NEFA  inhibits  glucose  uptake  after  3-4  hours  (Fig  1.4),  (Boden 
G,1997) which with decreased glycogen synthesis (Krebs M,2001) means that 
there  is  a  reduction  in  the  effectiveness  of  insulin-driven  pathways.    NEFAs 
reduce PI(3)K activity (Dresner A,1999) possibly through activation of atypical 
PKC isoforms and Serine/Threonine phosphorylation of IRS proteins (Shulman 
GI,2000).   Increased delivery of NEFA alters membrane composition (Borkman   35 
M,1993) and has a direct effect on glucose transporters (Long SD,1996), which 
also  contributes  to  other  mechanisms  driving  insulin  resistance,  including 
intracellular lipid stores and inflammation. 
 
Adipose tissue forms over 10% of total body weight, but it is now clear that 
adipocytes have functions other than simple storage cells  (Shimada K,2004).  
The  most  significant  of  these  appears  to  be  the  secretory  capacity  of  the 
adipocyte.    The  adipocyte  secretes  a  number  of  peptides  that  have  been 
labelled adipocytokines or adipokines (Kadowaki T,2005).  Adipokines identified 
to  date  seem  to  function  as  modulators  of  metabolism,  such  as  Leptin  and 
Resistin,  or  of  inflammation,  such  as  Tumour  Necrosis  Factor-α  (TNF-α), 
Interleukin 6 [IL-6], adipsin (also known as complement factor D), acetylation-
stimulating  protein,  visfatin  (also  known  as  B-cell  colony-enhancing  factor), 
plasminogen-activator  inhibitor  type  1,  as  well  as  other  complement 
components and interleukins (Hug C,2005; Rajala MW,2003).   
 
The most abundantly secreted adipokine is adiponectin, making up 0.01% of 
circulating  protein,  with  serum  concentration  a  thousand  times  greater  than 
other  hormones  and  10
6  times  greater  than  other  inflammatory  cytokines 
(Shimada  K,2004). Studies  from  animal  models  and  human  subjects  confirm 
that adiponectin is an insulin-sensitising hormone, that is negatively regulated 
by  obesity  [Reviewed  in  Gable  D,  2006a].      A  significant  number  of  the 
metabolic  actions  of  adiponectin  are  dependent  on  the  activation  of  AMP-
dependent kinase (AMPK) (Tomas E,2002; Wong GW,2004; Yamauchi T,2002; 
Yamauchi  T,2003),  a  fuel-sensing  enzyme  (Wong  GW,2004).    AMPK 
dependent fuel-sensing systems have been identified in myocytes, hepatocytes, 
skeletal  muscle  and  parts  of  the  central  nervous  system  (Wong  GW,2004).  
AMPK is activated when ATP is required, and one of its main stimulators is the 
AMP/ATP ratio.  Activation increases glucose transport, glycogen accumulation 
and fatty acid oxidation, with the aim of increasing ATP production.  Adiponectin 
also  has  anti-inflammatory  actions.    The  increase  in  insulin  sensitivity 
associated with Leptin secretion is also through AMPK activation, although the 
secretion  of  anorexigenic  peptides  also  contributes  to  reduced  over-nutrition 
(Minokoshi Y,2002).     36 
Leptin is described as a “starvation signal” as its levels decline during fasting, 
but in obese individuals levels are often higher.  The mechanism of this Leptin 
resistance has yet to be elucidated (Ahima RS,1999).  TNF-α is also produced 
by adipose tissue and acts in an autocrine and paracrine way, increasing NEFA 
release  (Itani  SI,2002),  reducing  adiponectin  release  (Ruan  H,2002)  and 
reducing insulin signalling efficiency in adipocytes (Saltiel AR,2001).   
 
The possibility that inflammation was important in the development of insulin 
resistance was first suggested when it was noted that the lipid abnormalities in 
type  2  diabetes  were  similar  to  those  seen  in  the  acute  phase  response 
(Blackman JD,1993).  Further evidence of the link between inflammation and 
insulin  resistance  is  suggested  by  an  increase  in  levels  of  pro-inflammatory 
cytokines in the post prandial period (Carroll MF,2003), and the relationship of 
type  2  diabetes  and  obesity  with  low  grade  inflammation.    Low  grade 
inflammation  precedes  and  predicts  the  development  of  insulin  resistance.   
Insulin resistance is associated with higher levels of C-Reactive Protein (CRP), 
and  levels  of  this  acute  phase  protein,  as  well  as  others  such  as  IL-6, 
orosmuoid and sialic acid are associated with risk of type 2 diabetes  (Duncan 
BB,2003).    Obesity is also associated with non-specific markers of activation of 
the immune system including temperature, white cell count and total γ-globulin 
(Tataranni PA,2005). The acute phase response is part of the innate immune 
system and IL-6, of which up to 30% of the circulating levels are produced by 
adipose tissue (Mohamed-Ali V,1997), is one of the prime stimulators of acute 
phase proteins (Gabay C,1999).  IL-6 levels correlate with obesity and insulin 
resistance and predict the onset of type 2 diabetes (Bastard JP,2000).   Infusion 
of  IL-6  induces  insulin  resistance  (Tsigos  C,1997),  with  IL-6  having  a  direct 
effect on inactivating IRS function  via SOCS  (Rui L,2002).  One of the key 
transcription factors involved in the innate immune system activation is NF-κβ, 
which is maintained in its inactive state by binding with Iκβ.  NF-κβ is activated 
after Iκβ is released by the action of the kinase IKK.   Lipid infusion, which is 
associated with increased insulin resistance activates NF-κβ (Tripathy D,2003), 
while  blockade of IKK activity lowers blood glucose in rodents (Kim JK,2001) 
and in man (Hundal RS,2002).   The inflammatory response in obesity may be 
driven by changes in adipose tissue (Fig. 1.5), as a response to being unable to   37 
store  all  the  energy  delivered  (Wellen  KE,2003).    Adipose  tissue  and  the 
immune system are similar, with both functions performed by the fat body in 
Drosophila (Xu H,2003).  There are many shared pathways between T-cells, 
macrophages  and  adipocytes,  with  the  peroxisome  proliferator-activated 
receptors [PPAR] transcription factors, now known to regulate a large repertoire 
of  inflammatory  genes  as  well  as  their  well  known  metabolic  function  (Way 
JM,2001).  A  number  of  macrophage  and  inflammatory  genes  are  also 
upregulated in obesity (Xu H,2003). 
 
Skeletal muscle is responsible for 75% of post-prandial glucose disposal (Klip 
A,1990), and a defect in removal of glucose and glycogen by skeletal muscle is 
found in all insulin-resistant subjects (Shulman GI,1990).  Early investigations 
demonstrated  increased  lipid  in  the  skeletal  muscle  of  subjects  with  type  2 
diabetes  (Dagenais  GR,1976)  and  although  the  early  studies  required  prior 
removal of all extracellular lipid and were prone to error, they suggested that 
intramyocellular  lipid  (IMCL)  was  a  good  predictor  of  insulin  resistance 
(Machann  J,2004).    Advanced imaging techniques  (Simoneau  JA,1995), and 
more recently the use of magnetic resonance spectroscopy, has confirmed this 
association    (Thamer  C,2003).      However,  endurance  athletes  also  have 
elevated levels of IMCL but are very insulin sensitive (Goodpasture BH,2001).  
Fatty  acid  metabolites,  such  as  long  chain  acyl-CoA  (Ellis  BA,2000),  are 
correlated with level of insulin resistance and diacylglycerol, and can increase 
serine/threonine phosphorylation of the insulin signaling cascade, possibly by 
activating  atypical  PKC isoforms  or  through  pro-inflammatory  pathways  (Itani 
SI,2002).  However this relationship can be modified by the oxidative capacity of 
skeletal muscle (Thamer C,2003). 
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Fig 1.5. Inflammation in obese adipose issue 
 
Obese  adipose  tissue  is  characterized  by  inflammation  and  progressive  infiltration  by 
macrophages  as  obesity  develops.  Changes  in  adipocyte  and fat  pad  size lead to  physical 
changes in the surrounding area and modifications of the paracrine function of the adipocyte.  
For example, in obesity, adipocytes begin to secrete TNF- , which can stimulate preadipocytes 
to produce monocyte chemoattractant protein-1 (MCP-1). Increased secretion of leptin (and/or 
decreased  production  of  adiponectin)  by  adipocytes  may  also  contribute  to  macrophage 
accumulation  by  stimulating  transport  of  macrophages  to  adipose  tissue  and  promoting 
adhesion  of  macrophages  to  endothelial  cells,  respectively. Whatever  the  initial  stimulus  to 
recruit macrophages into adipose tissue, once these cells are present and active, they, along 
with adipocytes and other cell types, can perpetuate a vicious cycle of macrophage recruitment, 
production of inflammatory cytokines, and impairment of adipocyte function. (Wellen KE,2003). 
   
 
Mitochondria and insulin resistance 
 
Oxidative  capacity  is  determined  by  mitochondrial  function  and  there  is 
evidence of mitochondrial dysfunction in insulin resistance and type 2 diabetes.  
Mitochondria are also an important source of oxidative stress [see 1.3.4]. 
 
Mitochondria  have  their  own  genome,  and  mutations  in  the  mitochondrial 
genome are associated with diabetes.  The mitochondrial genome is maternally 
inherited, consists of 16.6kB and codes for 13 proteins that form part of the 
electron  transport  chain.    Mutations  have  been  associated  with  neurological   
disease and diabetes, and for the tRNA and rRNA involved in ribosomal protein 
synthesis within mitochondria (Wallace DC, 1999).  The most common causes   39 
of mitochondrial diabetes are the 3243A>G variant in the Leu,URR gene, a DNA 
encoded  tRNA  that  is  associated  with  low  BMI,  lipomas  and  hepatic  fat 
infiltration  suggesting  the  underlying  problem  is  aberrant  fat  storage.    The 
diabetes tends to occur around age 40 and is associated with significant β-cell 
damage.  A second gene [LARS2] has also been implicated in mitochondrial 
diabetes (Maassen JA, 2007). 
 
In mouse models there is reduced biogenesis of mitochondria (Choo HJ,2006) 
disease, while mitochondria in subjects with type 2 diabetes are smaller and 
have  reduced  activity  of  the  electron  transport  chain  (Kelley  DE,2002).      In 
subjects  with type 2 diabetes or insulin  resistance, gene expression profiling 
shows  reduced  electron  transport  chain  genes,  especially  in  visceral  fat 
(Dahlman I,2006), and also reduced copies of oxidative phosphorylation protein 
encoded  in  mitochondrial  DNA  (Bogacka  I,2005a).    PPAR-γ  co-activator  1 
(PGC-1α)  is  a  transcription  factor  that  drives  mitochondrial  biogenesis  (Wu 
Z,1999) and has a role in gluconeogenesis and fatty acid oxidation (Bogacka 
I,2005b).  PGC-1α expression is reduced in type 2 diabetes (Mootha VK,2003) 
and  also  in  insulin  resistant  offspring  of  subjects  with  type  2  diabetes  (Patti 
ME,2003).  The deterioration in mitochondria function that occurs with age leads 
to  reduced  oxidative  phosphorylation in the  elderly  which correlates  with the 
increase  in  insulin  resistance  seen  with  age  (Petersen  KF,2003)  and  the 
reduced  utilization  of  fatty  acids  in  those  with  insulin  resistance  (Kelley 
DE,2000).  Total  fasting  fat  oxidation  is  correlated  with  insulin  sensitivity 
(Wahrenberg H,2005).  Insulin sensitivity is also correlated with post-prandial 
thermogenesis (Robinson S,1992).  Women predisposed to obesity have lower 
24hr fat oxidation compared to controls (Raben A,1994), whilst in obese women 
relative post prandial fat oxidation is reduced (Blaak EE,2006).  The mechanism 
linking fat oxidation and insulin resistance is unclear.   ICML is important, as 
blocking fatty acid uptake molecules, such as CD36 (Hajri T,2002) and Fatty 
acid transporter-1, (Kim JK,2004) protects from insulin resistance.  In insulin-
sensitive individuals, insulin increases ATP synthesis and Respiratory Quotient, 
which does not occur in insulin-resistant states (Brehm A,2006).  Fat oxidation 
only adapts slowly to intake (Raben A,1994) and, combined with a diminished   40 
capacity to use fat as a fuel, it may be that mitochondrial dysfunction potentiates 
the problems of over-nutrition and abnormal adipose tissue biology. 
 
 
1.2.2b The development of pancreatic failure  
 
Although  insulin  secretion  in  type  2  diabetes  is  abnormal  in  response  to  a 
number of stimuli, including intravenous and oral glucose, arginine, β-agonists 
(isoproteronol),  and  sulphonylureas  (Kahn  SE,2003),  it  was  not  thought  that 
poor  insulin  secretion  contributed  to  the  early  aetiology  of  type  2  diabetes.  
Initial investigations demonstrating that subjects with type 2 diabetes continue 
to secrete insulin (Yalow RS,1960), and this taken with the evidence that insulin 
resistance appeared to be the first factor to appear, suggested that abnormal 
insulin  secretion  was  a  late  event  in  the  pathogenesis  of  type  2  diabetes.   
However,  these  studies  did  not  take  into  account  that    insulin  secretion  is 
modified by insulin resistance (Kahn SE,1993) and recent data suggests that β-
cell dysfunction occurs early, and is important in the pathogenesis of type 2 
diabetes  as  does  data  from  the  understanding  of  MODY  [discussed  below].    
Recently, genome wide association studies have also suggested an important 
role for insulin secretion as, to date, most of the replicated identified associated 
genetic variants seem to have more of a role in modulating pancreatic function 
rather than insulin resistance. 
 
 
Normal Insulin secretion (Fig 1.6) 
 
Insulin secretion occurs as the result of  uptake of glucose into the β-cell by 
GLUT-2,  a  low  affinity,  high  capacity  glucose  transporter.  Glucose  is 
“trapped“  in  the  cell  by  the  action  of  glucokinase  converting  the  glucose  to 
glucose-6-phosphate.   Further transformation to pyruvate via the tricarboxylic 
acid  cycle  and  the  mitochondrial  electron  transport  chain  to  ATP  follows.   
Alteration of the intracellular ADP:ATP ratio leads to closure of ATP-sensitive 
potassium  channels.    These  channels  include  in  their  structure  the 
sulphonylurea  receptors  (SUR1/SUR2)  and  the  subunits  Kir6.1,  Kir6.2  which   41 
have been implicated in the aetiology of neonatal diabetes and are closed in the 
presence of glucose.  This leads to a change in membrane electrical energy 
potential and opening of voltage-gated calcium channels (MacDonald PE,2005).  
 
Fig 1.6.  Normal Insulin secretion 
 
IAPP=islet  amyloid  polypeptide.  G-6-P=glucose-6-phosphate.  CoA=coenzyme  A. 
GLUT2=glucose transporter 2.(MacDonald PE,2005). 
 
Initially,  there  is  release  of  docked  and  readily  available  vesicles  and  then 
vesicle mobilization is stimulated.  Therefore, insulin release is biphasic (Del 
Prato S,2002) with an early peak (acute phase) followed by a more sustained 
plateau or second phase (Fig 1.7). 
 
Fig. 1.7.  Representation of the Biphasic insulin secretion 
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β-cell function in subjects at high risk of diabetes  
 
As described earlier, the presence of insulin resistance in those at risk of type 2 
diabetes will modify insulin secretion, which is often used as a marker of β-cell 
function.  This relationship is shown in Fig 1.8.   
 
Fig 1.8. Relationship between insulin sensitivity and β-cell function in 93 healthy 
individuals  (Kahn SE,1993). 
 
 
 
 
 
 
 
 
 
 
 
 
AIRglucose = acute insulin response to glucose.  Insulin sensitivity Index is derived from minimal 
model analysis of frequently sampled intravenous glucose tolerance testing.  5
th,25
th,50
th,75
th 
percentiles shown.
 
  
 
The development of insulin resistance must be associated with an increase in 
insulin secretion for normal glucose homeostasis to be maintained, a move to 
the right along the same centile.   When groups at increased risk of type  2 
diabetes are examined (Fig.1.9) they are indeed found to be insulin resistant but 
in addition β-cell dysfunction is also present as indicated by insulin secretion 
falling into the lower centiles (Kahn SE,1996). 
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Fig. 1.9.  Relationship between insulin sensitivity and β-cell function in groups 
at high risk of type 2 diabetes 
 
  
PCO= women with polycystic ovary syndrome 
GDM= Gestational Diabetes Mellitus   (Kahn SE,1996) 
 
The first defect in β-cell function that occurs, even in those with normal glucose 
tolerance, is the loss of the acute phase response  (Del Prato S,2002), even 
though  the  relationship  between  second  phase  and  insulin  sensitivity  is 
maintained.  During the development of worsening glucose tolerance the acute 
phase insulin release progressively worsens  (Weiss R,2005).   There is also 
evidence of abnormal insulin processing with increased release of pro-insulin, 
again  even in  those  at  high  risk  of  type  2 diabetes but  with  normal  glucose 
tolerance (Saad MF,1990).  The proportion of pro-insulin released is a predictor 
of  future  development  of  type  2  diabetes  (Kahn  SE,1995).    Insulin  is  co-
secreted with a 37 amino acid polypeptide, islet amyloid polypeptide (Cooper 
GJS,1987)  which  is  also  found  to  be  secreted  in  lower  amounts  in  type  2 
diabetes (Kahn SE,2003). 
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Mechanisms of β-cell dysfunction 
 
 
The investigation of monogenic Maturity Onset Diabetes Mellitus of the Young 
[MODY]  identified  the  causal  genes  as  a  number  of  transcription  factors 
(Barroso  I,2005).  Mutations  in  transcription  factors  have  a  different  clinical 
phenotype  of  progressive  beta-cell  failure  resulting  in  increasing 
hyperglycaemia  and  requirement  for  treatment 
(www.projects.ex.ac.uk/diabetesgenes/index).  Knockout  mouse  models 
generally have a reduced β-cell mass which can be compensated for in early 
life, but normal glucose levels cannot be maintained (Hattersley AT,2004).  In 
autopsy series, β-cell mass is reduced by 20-50%, however, this occurs many 
years after diagnosis and is consistent with the finding of increased apoptotic 
events  in  subjects  with  type  2  diabetes (Butler  AE,2003).    The  study  of  the 
pancreas in individuals  at  high  risk  of  diabetes  is  difficult,  but  differences in 
insulin secretion suggest the problem is not  simply reduced β-cell mass.   In 
dogs  with  65%  of  their  pancreas  removed,  acute  phase  insulin  secretion  is 
maintained, in part, by increasing the sensitivity of the existing β-cell mass to 
glucose  (Ward  WK,1988).    A  similar  compensation  occurs  early  in  Type1 
diabetes  as  β-cells  are  destroyed  by  the  autoimmune  process  (Johnston 
C,1987), but this compensation is not seen in type 2 diabetes suggesting other 
processes are also underway. 
 
There is a possibility that the increased circulating NEFA can also directly affect 
β-cell function.  NEFA increase insulin secretion for the first 24 hours but after 
this  inhibit  β-cell  function,  and  long  term  exposure  is  associated  with  β-cell 
dysfunction, as indicated by reduced insulin release  as well as reduced pro-
insulin processing (Zhou YP,1996).  NEFA are converted to long chain acyl-
CoA  in  the  cell,  which  can  counteract  ATP-induced  closure  of  potassium 
channels (Bränström R,2004).  They can also  modulate intracellullar calcium 
through the orphan G-protein coupled receptor GPR40 (Itoh Y,2003) and induce 
β-cell  apoptosis  through  increased  nitric  oxide  production  (McLean  N,1955).  
However,  circulating  fatty  acids  are  essential  for  glucose-stimulated  insulin 
secretion after prolonged fasting (Dobbins RL,1998), and long chain acyl CoA   45 
facilitates  the  fusion  of  secretory  granules  to  the  cell  membrane  (Deeney 
JT,2000).  The factors modulating the complex relationship between circulating 
fatty acids and insulin secretion are not fully understood.  The composition of 
free  fatty  acids  can  have  different  effects,  with  polyunsaturated  fatty  acids 
stimulating insulin secretion and short chain and saturated fatty acids inhibiting 
secretion (Haber EP,2002).  Glucose-stimulated insulin secretion depends on 
glucose oxidation, and there is a reciprocal relationship between glucose and 
fatty  acid  oxidation  (Zhou  YP,1996).    NEFA  reduce  glucose  uptake  and 
oxidation, which is more pronounced in insulin resistant states (Zhou YP,1995), 
and  feeding  rats  with  a  high  fat  diet  reduces  the  rate  of  glucose  oxidation 
(Carpinelli AR,1992).   Complex changes in the ratio of fat to glucose oxidation 
may explain the effects of NEFA on insulin secretion. 
 
The β-cell dysfunction progresses as glucose tolerance worsens, and the most 
severe insulin  deficiency is  seen after 10  years  of  type  2  diabetes  (Wallace 
TM,2002).    Glucose  toxicity  contributes  to  this  failure,  probably  through  a 
mechanism involving oxidative stress (see 1.3), increasing cytokine production  
(Maechler P,1999) and accelerating apoptosis (Butler AE,2003). 
 
Autopsy of subjects with type 2 diabetes reveals another potential mechanism 
of β-cell dysfunction.  Up to 90%, of subjects with type 2 diabetes have deposits 
of amyloid in the pancreas (Knowles NG,2002).  The protein is based on the 
islet  amyloid  polypeptide,  which  is  co-secreted  with  insulin  and  could 
accumulate with increased insulin demand.  These aggregates are toxic to islets 
in  culture  and  increase  β-cell  apoptosis  (Lorenzo  A,1994).    The  degree  of 
amyloid  replacement  predicts  the  need  for  insulin  therapy  (Kahn  SE,1998).  
Overexpression  of islet  amyloid  protein  in  animal  models  fed  a  high  fat  diet 
leads to higher glucose levels,  (Verchere CB,1996) which suggests that islet 
amyloid has a role in type 2 diabetes.  However, the fact there is no  increase in 
amyloid in impaired glucose tolerance states (Butler AE,2003) and that it is not 
present in all subjects with type 2 diabetes, means that its role has yet to be 
defined.  It may be a response to the underlying processes of β-cell dysfunction 
rather than driving it. 
   46 
1.3 Type 2 Diabetes and Oxidative Stress 
 
Redox  reactions  include  all  chemical  processes  in  which  atoms  have  their 
oxidation number (the charge that it would bear if all the ligands were removed 
along with the electron pairs that were shared with the central atom) changed. 
Oxidation is defined as an increase in oxidation number, and reduction  as a 
decrease in oxidation number.  In most cases oxidation occurs when a molecule 
transfers  electrons  to  another  molecule,  but  dehydrogenation  is  also  an 
alternative  method  of  oxidation.    Substances  that  have  the  ability  to  oxidize 
(remove  electrons  from)  other  substances  are  known  as  oxidizing  agents, 
oxidants or oxidizers, and are themselves reduced in the reaction. In biological 
systems normal metabolism results in the generation of a number of oxidants 
known  as  reactive  oxygen  species  [ROS]  if  based  on  oxygen,  or  reactive 
nitrogen  species  [RNS]  if  nitrogen  based,  although  they  are  often  described 
together as ROS.  These are generally very small molecules and are highly 
reactive due to the presence of unpaired valence shell electrons. To protect the 
structure of the organism from oxidation a number of cellular defences have 
developed.    Oxidative  stress  occurs  when  cellular  anti-oxidant  defences  are 
inadequate to inactivate generated ROS, and they are free to react with other 
cellular components (Stocker R,2004). 
 
 
1.3.1 Sources and effects of oxidative stress 
 
Oxidative  stress  can  result  from  exogenous  processes  such  as  radiation, 
pollution, smoking (Ghiselli A,2000) and toxins.  ROS generation is thought to 
be responsible for the cardiac side effects of anthracylines (Keizer HG,1990) 
and  the  hepatic  toxicity  of  some  antibiotics  (Orrenius  S,1985)  or  from 
endogenous metabolism.  ROS are continuously generated by the organism as 
a by-product of oxidative metabolism  (Gate L,1999) described in more detail 
later  (1.3.3c).    The  six  main  ROS  are  superoxide  [O
2-],  hydrogen  peroxide 
[H2O2],  peroxyl  radical  ROO
-,  Hydoxyl  radical  [OH
-],  singlet  oxygen  [O2]  and 
peroxynitrite  [NO
-]  (Huang  D,2005).    Cellular  damage  from  ROS  has  been 
implicated in a number of pathological conditions including atheroma (Heinecke   47 
JW,2003), Alzhiemer’s disease (Pratico D,2004), Parkinson’s disease (Giasson 
BI,2000),  Rheumatoid  arthritis  (Baskol  G,2005),  inflammatory  bowel  disease 
(Kruidenier L,2002), cancer (Brown NS,2001) and may even be responsible for 
the deterioration in function associated with ageing (Finkel T,2000).   ROS could 
be involved in pathology either through direct oxidative damage to biomolecules 
or through the cellular response such as apoptosis (Harrison DG,1997).    
 
Lipids are oxidised by ROS to aldehydes, of which the two most studied are 
malondialdehyde  (MDA)  and  4-hydroxyl-2-nonenal  (HNE).    Oxidised  lipid 
changes the biological properties of cell membranes, inactivating membrane-
bound  receptors  and  enzymes,  and  reducing  cell  junction  communication 
(Dalle-Donne  I,2006).    In  endothelial  cells,  oxidation  of  lipid  increases 
expression of cell adhesion molecules, activates matrix metallproteinases and 
induces proliferation of underlying vascular smooth muscle (Suzuki YJ,1997).  
These  induce thrombosis and endothelial dysfunction (Calingasan NY,1998), 
all changes associated with atheroma. A key part in the pathological process of 
atheroma  involves  oxidation  of  circulating  LDL  particles  (Ceconi  C,2003).  
These changes in function can lead to cell death, with evidence that MDA is 
cytotoxic (Uchida K,2003) and HNE can induce apoptosis (Esterbauer H,1991). 
 
Oxidation  of  protein  can  alter  its  structure  and  function,  and  for  example 
cataract  is  a  consequence  of  photo-oxidation  of  the  lens  proteins  (Taylor 
A,1993).  Modification of proteins  can generate new antigens and an immune 
response  (Rosen  A,1997),  and inhibit  enzyme  function  (Dalle-Donne  I,2006) 
which  can  cause  secondary  damage  if  repair  mechanisms  are  affected 
(Wiseman  H,1996).   The oxidised protein is  often poorly  degraded,  and  can 
form aggregates within the cell that can cause metabolic dysfunction and initiate 
apoptotic processes (Dean RT,1997).   
 
DNA  modification  will  have  a  broad  range  of  effects  on  cellular  function.  
Modified DNA contributes to risk of cancer (Block G,2006) and may contribute 
to  ageing  and  reduced  lifespan  (Hart  RW,1974)  as  urinary  excretion  of 
damaged  DNA  correlates  with  lifespan  across  a  broad  range  of  mammals 
(Foksinski M,2004).   48 
1.3.2 Anti-oxidant systems 
 
Anti-oxidants  are  substances  that  oppose  oxidation  or  inhibit  reactions 
promoted by oxygen or peroxides.  Living organisms have developed a complex 
anti-oxidant network to protect themselves from the damaging effects of ROS 
(Prior RL,1999).  There are essentially two main groups, the enzymatic anti-
oxidants  and  the  non-enzymatic  scavengers  that  break  down  radical  chain 
reactions and are in the process sacrificed and need to be regenerated  (see 
Fig.1.10)  (Huang  D,2005).    The  most  significant  circulating  anti-oxidant  is 
probably uric acid which is metabolised to allantoin (Grootveld M,1987). Anti-
oxidants  can  also  be  classified  by  their  lipid  solubility,  with  the  lipophilic 
carotenoids important in the protection of lipoproteins, while vitamin C is much 
more hydrophilic (Gate L,1999) and may have different roles. 
 
 
Fig 1.10.  Biological anti-oxidant systems 
•Enzymatic
Superoxide Dismutase
Catalase
Glutathione 
Peroxidase
•Non Enzymatic
Autooxidation factors [Se, Coenzyme 
Q10]
Oxidative enzyme inhibitors [Aspirin]
Transition Metal chelators [EDTA]
Radical Scavengers [Vitamin C & E]
 
(Huang D,2005) 
 
The function of i ntra-cellular anti-oxidants is  supported by the enzymatic  anti-
oxidants  superoxide dismutase , which  detoxifies  superoxide,  and catalase ,  
which breaks down hydrogen peroxide.   Anti-oxidant defences also depend on 
the action of glutathione, a low molecular weight thiol made from  glutamate, 
cysteine, and glycine.  Glutathione acts as a scavenger of ROS, and is oxidised 
to glutathione disulfide which protects the rest of the cell.  The glutathione is 
replenished by the action of glutathione reductase on glutathione disulfide  (Wu 
G,2004).  Anti-oxidants that can be obtained from the diet include vitamin C and 
E  (Ames BN,1995)   and the carotenoids eg lycopene in tomatoes  (Stahl 
W,1992).  Long-term anti-oxidant supplementation intervention trials have so far   49 
been disappointing in  the  prevention of  cancer  or  heart  disease  (2002;  Beta 
Carotene  Cancer  Prevention  Study  Group  The  Alpha-Tocopherol,1994; 
Hennekens CH,1996; Omenn GS,1996) despite epidemiological evidence that 
high vitamin C and E intake protects against degenerative disease (Enstrom 
JE,1992; Rimm EB,1993).  This may in part be due to the fact that life long 
exposure or genetic influences are more important and overwhelm the effect of 
short  time  (relative  to  total  lifespan)  supplementation.    Single  nucleotide 
polymorphisms  in  catalase  and  superoxide  dismutase  genes  have  been 
associated with differences in oxidative stress pathophysiology (Kohno S,1999; 
Liao F,1994; Sandstrom J,1992).  When a measure of total anti-oxidant status 
(see 1.3 for explanation) was examined in a family study, 37.8% of the variance 
was thought to be genetic.  The proportion increased when other factors such 
as  smoking  were  taken  into  consideration  so  that  in  smokers  42%  of  the 
variation was genetic in nature whilst in non-smokers it was only 26%.  This 
study  also  found  that diet  had little effect  on  total  anti-oxidant  status  (Wang 
XL,2001). 
 
 
1.3.3 Measuring the Oxidative Stress Burden 
 
The measurement of ROS is possible, but requires electron spin resonance or 
chemi-luminescence.  The first method is non-invasive but is expensive and as 
ROS are unstable, do not accumulate and are unsuitable for routine use (Dalle-
Donne  I,2006).    Hydrogen  peroxide  is  stable  in  body  fluids  and  can  be 
measured in urine (Varma SD,1990) and breath (Jobsis RQ,2001), but there are 
insufficient data at present to support its widespread use.  The accuracy of the 
electron spin resonance  method can be improved with the use of ROS “traps” 
such  as  1,1,3-trimethylisinordole-N-oxide  (Bottle  SE,2003),  but  their  safety in 
man has yet to be proved and they may also only “trap” a small proportion of 
ROS produced so their validity is also not yet certain (Halliwell B,2004).  The 
“trap”  concept  can  also  be  applied  to  molecules  for  which  an assay  already 
exists, this includes using salicylate which is non-enzymatically modified to 2-3 
dihydroxybenzoate  (Ingelman-Sundberg  M,1991)  or  endogenous  uric  acid 
excreted  as  allantoin  (Grootveld  M,1987).    These  will  suffer  from  the  same   50 
problems as the other “trap” methods, in so far as it is not possible to determine 
the percentage of generated ROS that is “trapped”. 
 
Due  to  the  difficulties  of  measuring  ROS  directly,  oxidative  stress  burden  is 
most commonly assessed through biomarkers.   A biomarker is used to assess 
the  generation  of  ROS  indirectly.    To  reflect  ROS  generation  accurately  a  
biomarker of oxidative stress must be 
 
  stable, as further oxidation products are often generated during sample 
handling  (Firuzi O,2006).   
  must accumulate to detectable concentrations.  
  be  non-invasive  and  represent  specific  oxidative  pathways  [ROS 
generation].    
  must correlate with disease severity (Dalle-Donne I,2006).   
 
The biomarkers of oxidative stress fall into three groups.   These are either the 
measurement of the oxidation of macromolecules, anti-oxidant concentration or 
the capacity of body fluids or tissue to interfere with in vitro redox reactions. 
 
1.3.3a Oxidation of Macromolecules 
 
Malondialdehyde  [MDA]  is  one  of  the  most  stable  of  the  lipid  peroxidation 
products.  It  can  be  detected  in  plasma  by  the  Thiobarbituric  acid  reactive 
substances assay [TBARS] (Buege JA,1978).  This is relatively non-specific and 
has  now  been  replaced  with  a  method  using  high  performance  liquid 
chromatography [HPLC] (Wong SH,1987).   However, MDA is only one of a 
number of products, and can be absorbed through the gut (Nelson GJ,1993).  
The oxidative modification of fatty acids to pentane and ethane gives products 
which can be detected in breath, but this method is problematic because of the 
difficulty in preventing contamination by airbourne sources (Knutson MD,2000).  
The most accurate method of measuring lipid peroxidation products is the assay 
of  F2-isoprostanes.    These  are  derived  from  the  non-enzymatic  oxidation  of 
arachidonic acid (Morrow JD,1990).  They can be measured in plasma using   51 
gas  chromatography-mass  spectroscopy  [GCMS].    This  method  has  high 
sensitivity and specificity and is not affected by passage across the gut (Blaak 
EE,2006).   However, F2 isoprostanes  are  only  a  minor  end  product  (Lawson 
JA,1999)  and  this  method  is  very  labour  intensive  and  requires  expensive 
equipment  (Milne  GL,2005).    An  immunoassay  is  now  available  (Morrow 
JD,2005) but there is limited information available regarding accuracy  (Dalle-
Donne I,2006), and GCMS remains the most common method used. 
 
The most useful assay of modified proteins is also a mass spectroscopy assay 
of nitro-chloro-orthtyrosine, however, this can be generated in sample handling 
(Halliwell B,2004).  An attempt to design simpler methods has not so far led to 
the development of an improved technique.  Antibodies to tyrosine derivatives 
have  not  been  specific  enough  (Duncan  MW,2003) and also  suffer  from  the 
same  problems  of  generation  during  sample  handling.    A  calorimetric  assay 
using  dinitrophenylhydrazine  has  been  developed  to  detect  the  more  stable 
carbonylated proteins that result from oxidation of side chains (Levine RL,1990).  
These are stable, even when stored frozen (Stadtman ER,2003) but the assay 
is not specific and is confounded by glycated proteins and protein oxidation that 
occurs during cooking (Halliwell B,2004). 
 
A huge range of base and sugar modification products are generated during 
DNA oxidation (Dizdaroglu M,2002).  The most widely measured is 8-oxo,7,8-
dihydro-2-deoxyguanasine  [8-OHdG]  which  can  be  measured  by  HPLC  or 
Enzyme Linked Immunosorbent Assay [ELISA] (Cooke MS,2000).  The assay is 
limited by low availability of tissue, as DNA is intracellular, and leucocytes are 
often used as a surrogate.  When 8-OHdG is measured in the urine as a marker 
it  can  be  confounded  by  variation  in  the  efficiency  of  the  DNA  repair 
mechanisms (Halliwell B,2002).   
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1.3.3b Anti-oxidant concentrations 
 
The concentration of a number of anti-oxidants is decreased by ROS attack, 
and  therefore,  may  function as  a  marker  of  oxidative  stress  (Rossi  R,2006).  
Vitamin C, carotenoids and glutathione/glutathione disulfide  [GSH/GSSG] can 
all be measured by HPLC (Craft NE,1992; Margolis SA,1996; Paolisso G,1992).  
These  methods  are  time  consuming, expensive, yield little  information  about 
combined effectiveness, and do not account for those that are undiscovered or 
difficult to measure (Maxwell SR,2006).  The measurement of lipid-soluble anti-
oxidants in plasma could also be misleading, and it has been reported that the 
risk of myocardial infarction correlates with adipose tissue levels of carotenoids 
but not plasma levels (Kohlmeier L,1997; Su LC,1998).  The measurement of 
anti-oxidants  is  further  confounded  by  degradation  during  sample  handling 
(Rossi R,2002). GSH/GSSG can be stabilised by the addition of Methyl-2-vinyl-
pyridium trifluoromethane sulfonate [M2VP] to the sample when it is taken.  The 
development of a colorimetric assay which is as accurate as the HPLC method 
(Floreani  M,1997)  has  helped  to  allow  the  simple  measurement  of  the 
GSH:GSSG ratio as a marker of intracellular redox status (Schafer FQ,2001).    
 
 
1.3.3c  Total anti-oxidant capacity assays 
 
 
The anti-oxidant function of plasma is a result of the interaction  between many 
different compounds, and often co-operation provides greater protection than 
each one alone,  as they regenerate and recycle each other (Packer JE,1979). 
Total anti-oxidant capacity assays [TAC] test all the multifunctional anti-oxidants 
present in the sample (Frankel EN,2000).  Although, this concept is attractive 
there are a number of disadvantages to the methods developed.  The redox 
reactions do not occur in a biological system, and the chain propagation that 
follows lipid peroxidation in vivo does not occur (Antunes F,1999).  The assays 
will all detect the anti-oxidant effect of uric acid, but this can be increased as a 
consequence  of  conditions  where  oxidative  stress  is  higher,  such  as  renal 
failure  (MacKinnon  KL,1999).  These  assays  are  also  only  able  to  detect   53 
scavenger  anti-oxidants  (Huang  D,2005),  and  can  only  look  at  either  the 
hydrophilic or hydrophobic phase at one time.  In vitro TAC depends on the 
distribution and interaction of anti-oxidants in the two phases (Huang SW,1996).  
The results also need to be interpreted with caution, as increased anti-oxidant 
levels may reflect an adaptive response to increased ROS generation, and low 
levels may just reflect low background ROS generation eg in low calorie feeding 
(Prior RL,1999). There are many versions of this assay but they can be divided 
into  two  main  groups.    Firstly,  where  plasma  is  used  to  interfere  with  an 
oxidation  reaction,  this  requires  an  oxidant  and  a  marker  that  undergoes 
oxidation.  Secondly, to drive a reducing reaction, which requires an oxidized 
marker that undergoes a reduction.   
 
Total Radical Trapping Anti-oxidant Parameter [TRAP] 
 
Method:   Inhibition of oxidation 
Oxidant:   2,2’-azobis(2-amidinopropane) [AAPH]  
Marker:  O2 production (oxygen electrode) (Wayner DD,1985) 
    Luminol (Alho H,1999) 
    Fluoroscein (Valkonen M,1997) 
Result:   Lag phase 
 
The result is calculated on the basis of the delay in the reaction seen as the 
anti-oxidants in the serum are consumed, and this is compared to the lag phase 
seen with the addition of a standard amount of the anti-oxidant Trolox (Fig 1.11).  
The  initial  method  was  modified  because  of  difficulties  in  maintaining  the 
oxygen electrode (Ghiselli A,2000).   
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Fig. 1.11  The use of lag phase to calculate TRAP result 
 
The kinetics of oxidation reaction in the presence of plasma after the addition of AAPH 
and trolox.  The result is calculated by comparing the two lag phases obtained. 
 
The  method  is  more  time-consuming  than  others  because  of  the  method  of 
calculating the result, and the method is also susceptible to error if the plasma 
is diluted, as this leads to significantly different values (DeLange RJ,1989).   
 
Oxygen Radical Absorbance Capacity [ORAC] 
 
Method:   Inhibition of oxidation 
Oxidant:   AAPH  
Marker:  Phycoerythin (Cao G,1998) 
    Fluoroscein (Naguib YM,2000) 
Result:  Area under the curve method 
 
This  method  is  similar  to  the  TRAP  method  but  the  result  is  calculated 
differently.  The oxidation reaction is allowed to proceed to completion and the 
result  is  calculated  from  the  area  under  the  curve  in  comparison  to  trolox 
standards  (Prior  RL,1999).    This  method  will  not  be  able  to  detect  slowly-
reacting  anti-oxidants  such  as  plasma  proteins,  which  may  react  with  ROS 
generated  at  a  rate  slower  than  the  marker  (DeLange  RJ,1989).    This  will 
change the slope of the oxidation curve and can alter the area under the curve 
(Cao G,1993). 
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Trolox Equivalent Anti-oxidant Capacity [TEAC] 
 
Method:   Inhibition of oxidation     Reduction 
Oxidant:  Ferrylmyoglobin*       persulphate used to generate  
    Hydrogen peroxide/     preformed ABTS
+ 
    Horseradish peroxidase^ 
Marker:  ABTS
+ Generation (Green)    ABTS Generation (Clear) 
Result:  Endpoint        Endpoint (Re R,1999) 
 
*  Commercialised  by  Randox  Laboratories  and  known  as  Total  anti-oxidant 
status  [TAS] (Miller NJ,1993). 
^  Known  as  Total  anti-oxidant  status  [TAOS]  (Sampson  MJ,2002).    This 
combination has also been used in a chemilumenescence assay with luminol as 
the marker (Maxwell SR,2006) 
ABTS= 2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) 
 
ABTS forms a clear solution, that when oxidised to ABTS
+ , undergoes a colour 
change which can be detected in a plate reader.  The assay is quick because of 
the use of an endpoint method to calculate the results.  The assay has also 
undergone significant commercial development, which enables it to be run at 
high  speed  on  multiple  samples  on  a  number  of  automatic  multi-channel 
analysis machines. 
 
Ferric ion Reducing Anti-oxidant Parameter [FRAP] 
 
Method:  Reduction 
Oxidant:  Fe
3+ 
Marker:  Fe
2+ generation 
Result:  Endpoint (Benzie IF,1996) 
 
The main disadvantage of this assay is that it is confounded by elevations in 
serum bilirubin (Huang D,2005), and, as with other reduction methods the anti-
oxidants present may not be able to reduce Fe
3+  with the same efficiency that 
they would achieve with ROS, especially as in vivo transition metal pro-oxidant   56 
states  tend  to  be  limited  by  chelators  not  scavenging  anti-oxidants  (Prior 
RL,1999).  A similar assay has been developed using copper instead of iron, 
total anti-oxidant potential (Zaporozhets OA,2004) or using the Folin-Ciocalteu 
regent which is misleading known as total phenol assay (Singleton VL,1999). 
 
Crocin Bleaching Assay 
 
Method:  Inhibition of oxidation 
Oxidant:  AAPH 
Marker:  Bleaching of crocin 
Result:  rate of bleaching 
 
Crocin is a natural pigment extracted from saffron and is subject to significant 
lot-to-lot variability.  The reaction rate of some anti-oxidants is very similar to 
blank controls, so the assay is prone to inaccuracy, and as the colour of crocin 
is very similar to some of the samples in which it is used to measure, this assay 
has found only limited applications (Huang D,2005).   
 
1.3.3d  Which Biomarker of oxidative stress? 
 
No  biomarker  has  yet  fulfilled  all  the  criteria  set  out  in  1.3.3  (Dalle-Donne 
I,2006).  This explains why the evidence for oxidative stress being involved in 
disease  in  humans  in  vivo  is  not  definitive  (Halliwell  B,2004).      The  poor 
correlation between the different methods is an indication of the high level of 
confounding that occurs when attempts are made to estimate oxidative stress 
burden.  Prior to assay, different biomarkers will appear under different time 
courses, so that at any one time, after an oxidative stress insult, products of 
lipid  oxidation  and  DNA  oxidation  will  correlate  poorly  (England  T,2000).  
Variation  in  sample  handling  is  also  a  source  of  error,  as  anti-oxidants  are 
unstable and degrade when exposed to air and light (Ghiselli A,2000), while any 
clotting  that  occurs  during  sampling  will  lead  to  the  release  of  ROS  from 
platelets (Leo R,1997).  DNA oxidation assays are more variable if performed 
on  isolated  DNA  than  on  urine,  suggesting  that  the  additional  handling 
introduces error, to the extent that there is currently no agreement on basal   57 
levels (Collins AR,2004).  When considering the TAC assays, they measure the 
chemical  activity  of  the  plasma  anti-oxidants  under  very  specific  conditions.  
The  affinity  of  different  anti-oxidants  with  the  radicals  generated  will  differ 
between assays, so that the anti-oxidant activity of vitamin C is low in TRAP 
[AAPH] but high in TAS [Ferrylmyoglobin] (Schlesier K,2002).  When different 
methods have been compared the correlation has been poor.  When FRAP was 
compared to  markers of lipid and protein oxidation, although correlation was 
described, it was found to be weak (r<0.5) (Firuzi O,2006).   
 
Three studies have compared TAC methods, no correlation was found between 
ORAC and TEAC, or FRAP and TEAC in one, with a weak correlation between 
ORAC and FRAP(r=0.35,p=0.019) only.  When the proportion of the TAC due to 
individual  anti-oxidants  was  calculated  the  proportions  were  significantly 
different, indicating that the assays have different affinities for the variety of anti-
oxidants found in plasma (Fig1.12) (Cao G,1998). A similar weak correlation 
was  found  when  a  luminol  method  was  used  comparing  ABTS  and  AAPH 
(r=0.37,p=0.03) (Waring WS,2003).   
 
Fig 1.12  The difference in the proportion of TAC due to individual anti-oxidants 
in different TAC methods (Cao G,1998) 
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When the anti-oxidant capacity of ten drinks was compared using five different 
methods  the  absolute  values  were  different,  although  the  drinks  that  ranked 
higher  tended  to  be  the  same  regardless  of  the  method  used  (table  1.3) 
(Schlesier K,2002).  This has led to the suggestion that investigators should 
report  two  replicate  biomarkers  when  reporting  associations  with  oxidative 
stress burden (Block G,2006; Schlesier K,2002).  This would overcome the two 
main confounding issues, firstly, the variability of the baseline between studies 
reflecting sampling artefact, and secondly, the variability in the substrate/ROS 
interaction, where different ROS have different affinity for different substrates 
(Mayne ST,2003). 
 
 
Table  1.3    The ranking by anti-oxidant capacity of different drinks using five 
different  TAC  methods.    See  paper  for  details  of  methods  used.  (Schlesier 
K,2002) 
 
   TEAC  DPPH  DMPD  FRAP  PCL 
Blackcurrant juice  1  1  1  2  1 
Blackcurrant Nectar  2  2  2  1  6 
Green Assam Tea  3  6  6  4  5 
Black Assam Tea  4  4  4  7  3 
Green Darjeeling Tea  5  3  3  6  4 
Black Darjeeling Tea  6  5  5  5  2 
Apple Juice 1  7  8  8  3  7 
Apple Juice 2  8  7  7  8  10 
Tomato Juice 1  9  10  10  10  9 
Tomato Juice 2  10  9  9  9  8 
 
 
1.3.4 Role of oxidative stress in type 2 diabetes 
 
There are a number of steps in the natural history of type 2 diabetes where 
oxidative  stress  may  play a  role.   These include  the  development  of insulin 
resistance, β-cell failure and end organ damage secondary to hyperglycaemia.   
States  that  predispose  to  the  development  of  type  2  diabetes  appear  to  be   59 
associated with increased oxidative stress.  ROS production increases with fat 
accumulation in humans, with higher levels of both TBARS (Furukawa S,2004) 
and isoprostanes (Keaney JF,2003) in obese subjects compared to controls.   
Reduced anti-oxidant expression has also been demonstrated in obese mice 
compared to controls (Furukawa S,2004).  Oxidative stress is also increased in 
the metabolic syndrome, with 3.7 times greater levels of isoprostanes and a 
41% reduction in the anti-oxidant activity of HDL in a AAPH system compared 
to controls (Hansel B,2004).  Diabetogenic cytokines such as TNFα are also 
associated  with  higher  levels  of  oxidative  stress  (Qi  C,2000).    If  ROS  are 
important in the development of type 2 diabetes then they should be associated 
with  over-nutrition.    Post-prandial  increases  in  lipid  and  carbohydrate  levels 
increase oxidative stress (Tsai WC,2004), in part, driven by increased rates of 
non-enzymatic  glycation  (Dandona  P,1996)  and  glucose  auto-oxidation 
(Mullarkey  CJ,1990)  seen  after  a  meal,  but  also  by  the  presence,  in  the 
circulation, of oxidized lipids, from a processed diet (Blaak EE,2006).  This may 
be more important in western societies where a significant part of the day is 
spent in the post-prandial state (Sies H,2005).    
 
This increase in ROS may act as a sensor of the nutrient environment (Nemoto 
S,2000).  This is because increased nutrient delivery will increase mitochondrial 
activity,  and  ROS  generation  is  an  obligatory  consequence  of  aerobic 
metabolism  (Bloch-Damti  A,2005).  Mitochondria  are  the  principle  source  of 
ROS in cells (Zhou YP,1995), and the primary factor determining the rate of 
production  is  the  redox  state  of  the  electron  transport  chain  (Skulachev 
VP,1996).   Glycolysis and the citric acid cycle generate NADPH and FADH, 
which donate electrons to the electron transport chain.  As electrons are moved 
along the four complexes, hydrogen ions are pumped out of the mitochondria 
and  an  electrochemical  gradient  is  established  (Nishikawa  T,2000a).    This 
gradient is dissipated through the ATP synthase complex, converting ADP to 
ATP  for use as an energy source in the cell (Fig 1.13).   
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Fig.1.13 A representation of the electron transport chain for the production of 
energy in the form of ATP from NADPH and FADH generated during oxidation 
 
(http://www.biologycorner.com/resources/electrontransport.jpg) 
The amplitude of this gradient regulates chain activity and increased nutrient 
delivery will increase this gradient  (Maddux BA,2001), which reduces activity 
and leads to the partial reduction of oxygen and the generation of ROS, whilst 
electrons  are  “held  up”  in  the  chain  (Nishikawa  T,2000b).      Reducing  the 
membrane  potential,  such  as  for  ATP  production,  reduces  ROS  generation 
(Fridlyand LE,2006). 
 
Mitochondrial DNA is in close proximity to the electron transport chain, and it is 
possible that mitochondrial DNA damage is the cause of the small dysfunctional 
mitochondria found in type 2 diabetes (Maassen JA,2004).  Significant oxidative 
stress leads to programmed death of mitochondria, reducing oxidative capacity 
further (Watson RT,2004).  Reducing the delivery of electrons to the electron 
transport chain would reduce oxidative stress.  The best way to achieve this is 
to  prevent  nutrient  entrance into  cells i.e. insulin resistance.    It  may  be  that 
insulin resistance is a protective mechanism when large amounts of ROS are 
being generated by the electron transport chain (Fridlyand LE,2006). 
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The generation of ROS has a number of deleterious effects on insulin secretion 
and  sensitivity.      A  transient  increase  in  ROS  enhances  insulin  signalling 
(Keaney JF,2003), possibly because insulin signalling itself may require ROS as 
a  second  messenger  (Kaneto  H,1999).    A  burst  of  ROS  is  triggered  with  a 
variety  of  ligands  including  Platelet  Derived  Growth  Factor  (Sundaresan 
M,1995),  Epidermal  Growth  Factor  (Bae  YS,1997)  and  Angiotensin  II 
(Griendling  KK,2000)  and  ROS  is  becoming  increasingly  recognised  as  an  
important intracellular signal (Goldstein BJ,2005).  However, chronic oxidative 
stress is damaging to insulin action (Furukawa S,2004) and may precede the 
development of type 2 diabetes (Salonen JT,1995).  Hydrogen peroxide impairs 
insulin  signalling  in  3T3-L1  adipocytes,  increases  serine/threonine 
phosphorylation  of  IRS  (Potashnik  R,2003),  reduces  PI3  kinase  and  Akt 
activation (Furukawa S,2004; Tirosh A,1999) and GLUT 4 translocation (Pessler 
D,2001; Rudich A,1998).  Hydrogen peroxide can also alter gene expression, 
reducing  the  expression  of  the  insulin  sensitisers  adiponectin  and  leptin 
(Kamigaki M,2006) 
 
ROS  also  stimulates  intracellular  processes  that  will  lead  to  secondary 
increases  in  insulin  resistance.    These  stimulate  a  number  of  transcription 
factors such as Mitogen Activated Protein Kinase, p38 kinase, protein kinase C 
isoforms and c-Jun kinases (Kaneto H,2005) and, hence, activate inflammatory 
pathways  which  regulate  gene  expression,  promoting  insulin  resistance  as 
described  earlier.    Exposure  to  oxidative  stress  therefore  promotes  insulin 
resistance by, firstly, impairment of insulin signalling and secondly, activation of 
cellular stress kinases (Pessler D,2001).   
 
The important role of oxidative stress is further supported by the effect of anti-
oxidants on insulin  sensitivity.   In  either  cell  (Benhamou  PY,1998)  or  animal 
(Kubisch HM,1997)  models of diabetes, genetic modifications of the oxidative 
stress  load  maintain  insulin  sensitivity,  and  the  anti-oxidant  α-lipoic  acid 
improves glucose utilisation in cell culture (Maddux BA,2001) and when given 
orally  (Konrad  T,1999).      Insulin  sensitivity  is  also  improved  by  the 
administration of the anti-oxidants vitamin C, E, N-Actylcysteine and Glutathione 
(Fridlyand LE,2006; Hildebrandt W,2004).   62 
 
Β-cell function and insulin secretion are also similarly affected by ROS.  ROS 
lowers glucose-induced insulin secretion as early as 30 minutes after exposure 
(Maechler P,1999), and in keeping with the functional abnormalities described 
in type 2 diabetes, hydrogen peroxide can suppress first phase insulin secretion 
(Sakai K,2003), while glucokinase, a crucial part of the glucose sensor, can be 
inactivated by ROS (Lenzen S,1988).  The pancreas is particularly vulnerable to 
oxidative stress as it has the lowest intrinsic  anti-oxidant capacity (Grankvist 
K,1981), and does not activate  anti-oxidant enzymes during times of cellular 
stress (Maechler P,1999). Β-cells are also susceptible to overfeeding as they 
are not dependant on insulin for glucose uptake (Ceriello A,2004).  Activation of 
stress signalling pathways is associated with reduced insulin gene expression 
and cell apoptosis (Kaneto H,2005), which may explain why the pancreas is 
unable  to  compensate  for  increased  insulin  resistance  and  type  2  diabetes 
develops (Pick A,1998).   These defects in β-cell function can also be reversed 
by anti-oxidant strategies, such as over-expression models of glutathione (Tran 
PO,2004)  or  C-Jun  inhibitors  (Duval  A,2000)  or  by  the  administration  of  N-
acetylcysteine (Tanaka Y,2002). 
 
Oxidative stress may also play a role in the progression of β-cell dysfunction, 
glucose intolerance and development of the complications of type 2 diabetes 
(Maritim AC,2003).  Development of hyperglycaemia in rats is associated with 
more severe defects in insulin secretion and sensitivity (Tanaka Y,1999).  The 
effect on β-cells is known as glucose toxicity (Robertson RP,2006).  In cultured 
human  islet  cells  high  levels  of  glucose  switch  on  expression  of  apoptosis 
genes Bad, Bid and Bik, while reducing expression of the anti-apoptosis gene 
Bcl-x1 (Federici M,2001).  This may explain the failure of β-cell mass to expand 
in order to counteract the effect of early glucose intolerance (Pick A,1998). 
 
Hyperglycaemia also appears to increase the oxidative stress burden.  TRAP is 
lower  (higher  oxidative  stress)  in  both  type  1  (Tsai  EC,1994)  and  type  2 
diabetes  (Ceriello  A,1997).    Markers  of  oxidative  stress,  including  salicylate 
hydroxylation (Ghiselli A,1992), F2-isprostanes (Gopaul NK,1995) and oxidised 
DNA (Rehman A,1999), are consistently elevated in type 2 diabetes, and this   63 
seems to be related to blood glucose levels as  F2-isprostane levels fall with 
improvements  in  diabetes  control  (Davi  G,1999).    Acute  rises    in  plasma 
glucose  (after  a  glucose  tolerance  test)  have  been  demonstrated  to  be 
associated with increased F2-isoprostanes (Sampson MJ,2002), reduced anti-
oxidant vitamins, uric acid and TRAP in subjects with type 2 diabetes (Ceriello 
A,1998), although similar findings in healthy volunteers were not replicated in a 
separate  study  measuring  anti-oxidant  vitamins,  FRAP  and  allantoin  (Ma 
SW,2005).  This may be because a higher blood glucose is needed as during a 
clamp  study  a  serum  glucose  of  15mmol/l  increased  nitrotyrosine  levels  in 
healthy volunteers (Marfella R,2001).  The role of oxidative stress in glucose 
toxicity is further supported by the reduction of severity of insulin resistance and 
β-cell dysfunction by the use of anti-oxidants in animal models, using the zucker 
diabetic rat (Tanaka Y,1999)and db/db mouse (Kaneto H,1999).    
 
The potential mechanisms  by which high glucose levels could increase ROS 
generation are shown in Fig 1.14.  Glucose can generate ROS through non-
enzymatic  pathways,  including  the  generation  of  ketoaldehydes  (Maritim 
AC,2003)  and  the  formation  of  Advanced  Glycation  End  products  [AGE].  
Glycation of proteins produces a Schiff base, which undergoes rearrangement 
to  form  amadori  products,  which  after  further  auto-oxidation  of  glucose  form 
AGE.  AGE can bind to specific receptors, triggering stress signalling through 
NF-κβ activation, as well as generating ROS (Yan SD,1994).  The upregulation 
of alternative metabolic pathways also increases ROS generation and stress 
signalling, and is responsible for the development of a number of complications 
of type 2 diabetes (Brownlee M,2001).   
 
The sorbitol pathway leads to the accumulation of fructose, which consumes 
intracellular  anti-oxidants  and  promotes  stress  signalling  (Brownlee  M,2001; 
Evans JL,2002).  The hexosamine pathway is also upregulated, and the end 
product  of  this  pathway,  UDP-N-acetylglucosamine,  is  the  substrate  for  the 
glycosylation  of  important  intracellular  factors  including  transcription  factors, 
particularily those involved in stress signalling  (Rolo AP,2006).   
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Fig1.14 The pathways leading to the generation of ROS during hyperglycemia.   
 
 
 
 
Six biochemical pathways along which glucose metabolism can form reactive oxygen 
species (ROS). Under physiological conditions, glucose primarily undergoes glycolysis 
and  oxidative  phosphorylation  (6).  Under  pathological  conditions  of  hyperglycemia, 
excessive  glucose  levels  can  overwhelm  the  glycolytic  process  and  inhibit 
glyceraldehyde  catabolism,  which  causes  glucose,  fructose  1:6-bis-P,  and 
glyceraldehyde  3-P  to  be  shunted  to  other  pathways:  (1)  enolization  and  α-
ketoaldehyde formation, (2) PKC activation, (3) dicarbonyl formation and glycation, (4) 
sorbitol metabolism, and (5) hexosamine metabolism (Robertson RP,2006). 
 
 
In hyperglycaemia, increased synthesis of diacylglycerol [DAG] activates up to 9 
isoforms  of  PKC,  which  can  also  activate  stress  signalling  and  lead  to  the 
generation  of  ROS  (Brownlee  M,2001).    The  deleterious  effects  of  these 
pathways  are  not  all  dependent  on  ROS,  but  oxidative  stress  from 
hyperglycemia-induced  overproduction  of  superoxide  by  mitochondria  is  the 
trigger that drives each of these pathways (Rolo AP,2006) (Fig1.15).   
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Fig 1.15.  The stimulation of pathological pathways by hyperglycemia-induced 
ROS generation 
 
 
(___,  direct  role;  -----,  indirect  role).  GlcNac,  O-linked  N-acetylglucosamine;  PAI, 
plasminogen activator inhibitor; TGF-β, transforming growth factor-β. (Rolo AP,2006) 
 
 
 
The effect of NEFA on the induction of insulin resistance and β-cell function 
may  also  in  part  be  modified  by  generation  of  ROS.    In  healthy  volunteers 
infusion of NEFA increases levels of MDA, reduces intracellular GSH (Paolisso 
G,1996)  and  activates  NF-κβ  (Evans  JL,2003).    The  long  chain  fatty  acid 
sodium palmitate increases ROS generation in isolated rat β-cells, in parallel 
with decreases in glucose-stimulated insulin secretion, indicating ROS may also 
play a part in NEFA-induced β-cell dysfunction. 
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Therefore, despite significant difficulties in the assessment of oxidative stress 
there is considerable evidence that the development of insulin resistance and β-
cell dysfunction are driven by oxidative stress-dependent mechanisms and that 
once established, glucose tolerance is perpetuated by increased generation of 
ROS.    The  mitochondria,  and  more  specifically  the  rate  of  mitochondrial 
oxidation and the mitochondrial membrane, appear to be key components of 
this process. 
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1.4   Mitochondrial Uncoupling Proteins 
 
The  uncoupling  proteins  2  and  3  (UCP2/UCP3)  are  part  of  a  mitochondrial 
carrier superfamily that are membrane proteins of around 300 amino acids with 
six transmembrane domains (Bross O,2000).   Their description as uncoupling 
proteins is based on their homology to uncoupling protein 1 (UCP1), the first of 
the family to be described.   
 
The generation of a proton gradient across the mitochondrial membrane during 
fuel substrate oxidation is described earlier in this chapter.  However, isolated 
mitochondria can continue to respire in the absence of ATP (Brand MD,1994).  
This  is  due  to  leak  of  the  protons  back  across  the  membrane  rather  than 
through  ATP  synthase.    The  stored  energy  is  released  as  heat,  and  fuel 
substrate metabolism is said to be “uncoupled” from ATP production (Fig. 1.16).  
Proton  leaks  are  a  feature  of  all  living  cells  (Schrauwen  P,2002a)  but  the 
mechanism of these leaks was not previously understood.   
 
Fig  1.16 The dissipation of the mitochondrial proton gradient to provide ATP 
synthesis (coupled) or with energy wasting (uncoupled) (Schrauwen P,2002a) 
 
 
 
 
In rodents, body temperature is maintained by uncoupling (Nicholls DG,1999), 
and is mediated primarily by brown adipose tissue (BAT) (Rothwell NJ,1979).    68 
This  led  to  the  identification  of  a  uniquely  expressed  protein,  UCP  1  (Lin 
CS,1980)  which  was  responsible  for  the  thermogenic  proton  leak.    UCP  1 
expression increases with cold stress (Silva JE,1997), and the UCP1 knockout 
mice were more likely to develop hypothermia in cold conditions than wild-type  
mice (Enerback S,1997). 
 
However, uncoupling was not unique to BAT (Rolfe DF,1996) with proton leaks  
responsible for 26-50% of resting energy expenditure (Rolfe DF,1996).  This led 
to the identification of UCP2 and UCP3,  which show 55% and 57% homology 
with UCP1 respectively and 71% homology with each other (Vidal-Puig A,1997).  
These two UCPs are both located in a gene cluster on chromosome 11q13, 
within  8kb  of  each  other,  and  share  similar  genomic  structures  (Pecqueur 
C,1999).  Two central nervous system UCPs have also been identified, known 
as  UCP4  (Mao  W,1999)  and  UCP5  or  Brain  Mitochondrial  carrier  protein-1 
(Sanchis D,1998), although the homology of these two proteins with UCP1 is 
low (<40%) (Dalgaard LT,2001a).  UCP-like proteins have also been identified 
in plants and birds, indicating that they are an ancient, well-conserved family 
likely to be important physiologically (Rousset S,2004). 
 
 
1.4.1. Physiology of Uncoupling Protein 2 
 
UCP 2 was discovered in 1997 (Fleury C,1997; Gimeno RE,1997).  The protein 
is expressed widely in spleen, lung, stomach, skeletal muscle, pancreas, heart, 
liver, kidney and macrophages (Fleury C,1997; Gimeno RE,1997; Millet L,1997; 
Pecqueur  C,2001),with  high  homology among  species  e.g. 95%  between  rat 
and  human  (Matsuda  J,1997).     The  ability  of  UCP1  to  dissipate  the  proton 
gradient without the generation of ATP (Nicholls DG,1984) identifies its function 
as  an  uncoupler  of  metabolism,  although  the  exact  mechanism  of  proton 
transfer is still unclear (Esteves TC,2005).  The similarity in structure suggests 
that  UCP2  should  also  function  as  an  uncoupling  protein.    A  number  of 
experimental  systems  suggest  UCP2  does  possess  uncoupling  properties, 
including  E.  coli  inclusion  bodies  (Jaburek  M,1999)  or  liposomes  (Echtay 
KS,2001), overexpression in yeast systems (Fleury C,1997; Gimeno RE,1997;   69 
Rial E,1999), and cell culture systems [Hela cells (Mills EH,2002), INSE-1 cells 
(Hong  Y,2001),  Human  thymus  (Krauss  S,2002),  Ob/Ob  mice  hepatocytes 
(Chavin  KD,1999)and  Zucker  diabetic  rat  islet  cells  (Cortez-Pinto  H,1999)].  
However, there is not a close link between tissue proton leak and UCP2 levels 
(Dalgaard LT,2001a), and some of these systems such as liver cells and yeast 
mitochondria can exhibit a proton leak in the absence of UCPs (Porter RK,1995; 
Stuart  JA,1999a).    The  yeast  system  also  has  other  potential  confounding 
features that may apply to the other systems.  When UCP2 is expressed in 
yeast  it  is  misfolded  and  only  poorly  incorporated  into  the  membrane.  
Replication at low levels of expression did not demonstrate a proton leak, and it 
is thought that the earlier results could be due to an over-expression artefact 
(Stuart JA,2001). The structure of UCP2 also lacks a histidine pair thought to be 
essential  for  UCP1  function  (Masaki  T,1997).    Therefore,  the  evidence  that 
UCP2 functions as an uncoupler of mitochondrial metabolism is not conclusive.  
There is  no  change  in  proton  conductance in  the  UCP2  mouse  under  basal 
conditions,  although  this  does  change  under  certain  conditions  such  as 
activation  by  ROS  or  free  fatty  acids  (Esteves  TC,2005).      These  results 
suggest that UCP2 has a novel function that may be dependent on conventional 
uncoupling, or may act through a non-uncoupling mechanism. 
 
1.4.1a UCP2 and Metabolism 
 
Despite  there  being  little  BAT  in  adult  humans  (Garruti  G,1992)  there  is  no 
evidence  to  suggest  that  UCP2  has  a  role  in  thermogenesis.    The  UCP1 
knockout mouse remains cold-sensitive despite increased expression of UCP2 
(Enerback  S,1997),  while  the  UCP2  knockout  mouse  is  not  cold  sensitive 
(Arsenijevic  D,2003).    The  expression  of  UCP2  in  ectothermic  fish,  which 
remain the temperature of the surrounding water, also suggests that UCP2 has 
no role in the regulation of body temperature (Stuart JA,1999b).   
 
The ability to waste energy derived from substrate utilisation would make UCP2 
an  attractive  molecule  for  a  role  in  the  adaptive  response  to  over-nutrition.   
Resting  metabolic  rate  is  dependent  on  thyroid  and  steroid  hormone  levels, 
sympathetic nervous system activity and ratio of fat to fat-free mass (Toubro   70 
S,1996).   Energy expenditure over 24hrs is in part genetic, with a heritability of 
between  0.26-0.70  (Dalgaard  LT,2001a),  and  lower  expenditure  is  more 
predictive of future weight gain than increased nutrient intake (Roberts SB,1988) 
with  only  very  small  differences  increasing  the  risk  of  obesity  significantly 
(Leibel RL,1997).  UCP2 expression is increased in obese mouse models, the 
Ob/Ob  and db/db mouse (Chavin KD,1999; Gimeno RE,1997), and the obesity 
prone C57b/6 mouse fails to upregulate UCP2 when fed a high fat diet (Fleury 
C,1997).  In man, abdominal muscle tissue  mRNA  was 28% lower in obese 
subjects  compared  to  those  without  obesity  (Nordfors  L,1998)  and  muscle 
mRNA levels correlated with percentage body fat and BMI (Bao S,1998).  Low 
expression was also found in intraperitoneal fat tissue taken at surgery, which 
persisted even when the subjects lost weight (Oberkofler H,1998).   However, 
most of this evidence is circumstantial, and UCP2 expression could be following 
other obesity-induced metabolic changes.  The UCP2 knockout mouse does not 
gain weight on a high fat diet (Arsenijevic D,2003), UCP2 levels do not change 
after  weight  loss  in  man  (Vidal-Puig  A,1999)  and  groups  with  lower  UCP2 
expression, such as first degree relatives of those with type 2 diabetes, do not 
have lower energy expenditure.  This suggests either that UCP2 does not have 
a major role in energy balance, or that there is significant overlap in energy 
control mechanisms (Erlanson-Albertsson C,2003).  The data, so far, does not 
support a critical role for UCP2 in energy balance.  This is confirmed by the 
upregulation of UCP2 by fasting, a state of reduced energy expenditure and 
reduction in body temperature.   
 
The upregulation of UCP2 by fasting has been consistently demonstrated in rats 
(Boss O,1997a; Cadenas S,1999; Memon RA,2000; Samec S,1998a; Samec 
S,1998b;  Teshima  Y,2003;  Xiao  H,2004),  mice  (Kersten  S,1999;  Samec 
S,1999a)  and  humans  (Millet  L,1997).    Interestingly,  these  studies 
demonstrated a reduction in mRNA expression with re-feeding, although not if 
re-fed  with  a  high  fat  diet  (Samec  S,1999a;  Teshima  Y,2003;  Xiao  H,2004).   
The  fasting  state  and  the  re-fed  high  fat  diet  state  are  both  associated  with 
elevations  in  free  fatty  acids,  and  abolishing  this  increase  with  intervention 
prevents the induction of UCP2 expression (Dulloo AG,2001).  The observation 
that  free  fatty acids  uncouple  mitochondrial  metabolism  (Challoner  DR,1966)   71 
raises  the  possibility  that  this  is  due  to  UCP2,  which  has  a  function  in  fuel 
substrate switching or protection of the high rate of oxidation associated with 
fatty acid delivery.  The changes seen with fasting were more pronounced in 
muscle  that  is  usually  glucose  dependent  (fast  twitch-gastrocnemius)  than 
muscle groups with high rates of basal fat oxidation (slow twitch-soleus) (Samec 
S,1998a).  Free  fatty  acids  appear  to  be  key  regulators  of  UCP2  mRNA 
expression.  The higher fatty acid levels associated with a high fat diet (Aubert 
J,1997;  Chan  CB,2001;  Fleury  C,1997;  Gong  DW,1999;  Joseph  JW,2002; 
Matsuda  J,1997;  Surwit  RS,1998;  Tsuboyama-Kasaoka  N,1999),  chemically 
induced  diabetes  (Hidaka  S,2000;  Kageyama  H,1998)  and  acute  exercise 
(Thompson MP,2004)  all increase UCP2 mRNA levels in a number of rodent 
models  and  tissues, including  in  hepatocytes  which  do  not  normally express 
UCP2  (Cortez-Pinto  H,1999).    The  transition  from  glucose  to  free  fatty  acid 
metabolism in cardiomyocytes at birth is associated with a five times increase in 
levels of UCP2 mRNA in rats (Van Dere Lee KAJM,2000).  Interventions such 
as fibrates (Tsuboyama-Kasaoka N,1999) and nicotinic acid (Samec S,1998a), 
which  lower  free  fatty  acid  levels,  also  lower  UCP2  mRNA  in  rodents.    In 
humans, lipid infusion increased mRNA expression in subcutaneous fat (Nisoli 
E,2000)  although  no  change  was  found  in  skeletal  muscle  in  another  study 
(Khalfallah  Y,2000).    Cell  culture  experiments  confirm  these  studies  with 
palmitate,  α-bromopalmitate,  oleic  acid  and  linoleic  acid  all increasing  UCP2 
mRNA in a variety of cell lines, including rat cardiomyocytes and hepatocytes, 
3T3-L1, INS-1, H9c2 and L6-myotubules (Armstrong MB,2001; Aubert J,1997; 
Camirand A,1998; Lameloise N,2001; Medvedev AV,2002; Reilly JM,2000; Van 
Dere  Lee  KAJM,2000;  Viguerie-Bascands  N,1999).      In  rat  islet  cells  the 
increase in mRNA expression paralleled the increase in fat oxidation and was 
inhibited by high glucose levels, which lowers fat oxidation (Medvedev AV,2002).   
 
A role in fatty acid metabolism is also suggested by the regulation of the gene 
by the key metabolic transcription factors of the PPAR group (Masaki T,1997), 
as well as other regulators that modify fatty acid metabolism, including thyroid 
hormones  (Nagase  I,2001),  catecholamines  (Masaki  T,1997)  and  the  sterol 
regulatory element binding protein-1 (Medvedev AV,2002).  The result of this is 
that changes in UCP2 mRNA parallel changes in other genes in fat oxidation   72 
such as carnitine palmitoyltransferase, acylcoA dehydrogenase and long chain 
CoA dehydrogenase (Samec S,2001). 
 
Overexpression  of  uncoupling  proteins  in  mice  induced  resistance  to  weight 
gain, even on a high fat diet with higher oxygen metabolism (Li B,2000).  The 
widespread expression would  make UCP2 an attractive candidate for energy 
balance control.  The expression of UCP2 suggests an important role in fatty 
acid metabolism but does not support the hypothesis that this role is in energy 
balance.  The ability of fatty acids to uncouple is probably not dependent on 
UCP2 (Hirabara SM,2006), and may just be a reflection of the fatty acid content 
of  cell  membranes  (Porter  RK,2001).    Therefore,  despite  a  large  body  of 
evidence  that  UCP2  is  an  important  component  of  fatty  acid  metabolism  its 
physiological role is unclear.  From an evolutionary standpoint the development 
of a mechanism to waste energy, when food seeking and energy conservation 
is given high priority, is surprising (Erlanson-Albertsson C,2003).  The earlier 
sections of this chapter describe an important difference between glucose and 
fat oxidation, documenting the higher levels of ROS production by the electron 
transport  chain  during  fat  metabolism.      Non-thermogenic  uncoupling  does, 
however,  reduce  ROS  generation  (Vidal-Puig  AJ,2000).    The  possibility  that 
UCP2 is a modulator of ROS production is examined in more detail in 1.4.1c, 
but if this is the case then the involvement in fatty acid metabolism  may be 
purely a feature of the higher levels of ROS generated therein.  
 
 
1.4.1b UCP2 and Islet Cell Function 
 
The  dependence  of  insulin  secretion  on  ATP  production  makes  it  likely  that 
expression  of  UCP2  in  the  pancreas  will  have  a  modifying  effect  on  β-cell 
function.  A small study described 80% higher skeletal muscle  UCP2 mRNA 
levels in type 2 diabetes, although the small number of subjects in the study 
meant that this difference was not statistically significant (p=0.09)(Bao S,1998).  
However,  UCP2 mRNA levels in skeletal muscle correlate with fasting blood 
glucose  in  subjects  with  obesity/type  2  diabetes  (Bao  S,1998).    The  UCP2 
knockout mouse has increased β-cell ATP levels, and higher glucose-stimulated   73 
insulin secretion, leading to 18% lower blood glucose levels (Zhang C-Y,2001), 
as well as higher β-cell mass and insulin content even on a high fat diet (Joseph 
JW,2002).  If UCP2 is knocked out in the Ob/Ob mouse, then first phase insulin 
secretion is restored and higher insulin levels and lower blood glucose levels 
are observed, with no changes to insulin sensitivity (Zhang C-Y,2001) Although 
one  early  dissenting  report  suggested  the  opposite  (Wang  MY,1999),  UCP2 
over-expression models have now shown consistently lower insulin secretion in 
rat  islet  cells  (Chan  CB,1999),  human  insulinoma  cells  (Hong  Y,2001)  and 
mouse  and  human  islet  cells.    The  defect  in  insulin  secretion  is  isolated  to 
glucose, with no difference in response to direct stimulators of ATP-dependent 
K channels (Chan CB,2001) .  
 
Studies  on  the  UCP2  knockout  mouse  have  suggested  UCP2  may  be  an 
important modulator of insulin secretion.   The reduction of β-cell function, and 
increase in UCP2 mRNA, seen with free fatty acids, may in part explain their 
diabetogenic effect.  The exposure of the UCP2 knockout mouse to palmitate 
does not cause the lower glucose-stimulated insulin secretion that is normally 
seen in response to free fatty acids.  Isolated islet cells have higher ATP levels, 
and  the  mitochondrial  membrane  is  hyperpolarized  faster  and  to  a  greater 
extent (Joseph JW,2004).  Superoxide can also have a negative effect on β-cell 
function, which is absent in the UCP2 knockout mouse (Krauss S,2003).   
 
Thus UCP2 appears to be a critical modulator of insulin secretion, but once 
again it is not clear if that is the primary function of the protein, or if it is simply a 
side effect of UCP2 being activated by fatty acid-derived ROS.  This means that 
potentially enhanced UCP2 function would be associated with protection from 
obesity but increased risk of type 2 diabetes, an “Adiposity Angel and Diabetes 
Devil” (O'Rahilly S,2001).  This effect also raises the possibility that UCP2 could 
be  a  therapeutic  target  for  the  treatment  of  type  2  diabetes.    In  mice,  a 
pharmacological inhibitor of UCP2-determined proton leak did reverse obesity-
induced β-cell dysfunction through higher levels of ATP production, although it 
is not clear how long this effect persists (Zhang CY,2006). 
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1.4.1c  UCP2 and oxidative stress. 
 
In most cells the majority of ROS is generated by the electron transport chain, 
so  that  a  protein  that  can  modulate  mitochondrial  function  would  be  a  good 
candidate  for  being  part  of  the  cellular  defense  against  ROS  (Skulachev 
VP,1996).   Mitochondrial production of superoxide is inversely correlated with 
the  amount  of  uncoupling  (Gimeno  RE,1997),  and  mitochondrial  ROS 
generation  can  be  modulated  by  UCP2  activation  (Negre-Salvayre  A,1997), 
whilst inactivation using an antisense RNA method increases ROS generation 
in a mouse endothelial cell line (Duval C,2002).  The immune system is also a 
high  producer  of  ROS,  and  oxidative  stress.  The  regulation  of  UCP2  with 
immune function further suggests that it may have a role in the modulation of 
oxidative stress.  UCP2 mRNA expression is activated by superoxide (Echtay 
KS,2001; Echtay KS,2002a), hydroxynonenal (Echtay KS,2003), AAPH (Murphy 
MP,2003),  lipopolysaccharide  [LPS]  (Faggioni  R,1998;  Viguerie-Bascands 
N,1999)  and  TNF  α  (Cortez-Pinto  H,1998;  Viguerie-Bascands  N,1999)  and 
levels  become  high  in  macrophages  as  they  differentiate  into  functioning 
phagocytes (Nishio K,2005).   The induction of UCP2 expression by LPS can be 
blocked by the administration of the anti-oxidant n-acetylcysteine, indicating the 
role of ROS generation in UCP2 expression regulation (Alves-Guerra MC,2003).  
UCP2  expression  is  also  increased  in  pathological  situations  where  ROS  is 
thought to be important, such as ischaemia (de Bilbao F,2004), ischaemic pre-
conditioning  (McLeod  CJ,2005),  irradiation  (Voehringer  DW,2000),  left 
ventricular  dilatation  and  failure  (Guo  P,2005)  and  inflammatory  conditions 
(Rousset S,2004).  The findings of increased ROS in UCP2 knockout models 
(Bai Y,2005; Joseph JW,2004), and decreased ROS in over-expression models 
(Kizaki T,2003), confirms the finding that ROS is a modulator of UCP2 function, 
and that changes to UCP2 function can modulate ROS production. 
 
The first study to demonstrate that this may be of physiological importance was 
a study on the immune function of the UCP2 knockout mouse.  Pathogen killing 
is  dependent  on  the  generation  of  superoxide  by    macrophages  (Babior   75 
BM,2000).  The UCP2 knockout mouse had a higher bactericidal activity against 
Salmonella  typhimurium,  and  was  able  to  clear  Toxoplasma  gondii infection, 
which remains a chronic infection in wildtype mice (Arsenijevic D,2003).   The 
activation of the immune system by LPS is also higher with higher levels of 
inflammatory  cytokines,  NF-κβ  activation  and  hydrogen  peroxide  generation 
during bacterial killing compared to wildtype  mice  (Bai Y,2005).  The role of 
UCP2  modulation  of  ROS  has  also  been  studied  in  a  number  of  models  of 
neuroprotection.  UCP2 over-expression reduces the toxicity of 1,2,3,6-methyl-
phenyl-tetrahydropyridine  [a  toxin  used  to  induce  an  animal  model  of 
Parkinsons  disease]  on  isolated  neurones  (Conti  B,2005),  and  injury  size  in 
stroke and  traumatic  brain  injury  models  (Mattiasson  G,2003).   In  a  mouse 
model of Multiple Sclerosis the knock out of UCP2 led to higher disease scores 
and  increased  T-cell  activity  and  cytokine  production  (Vogler  S,2006).    The 
response to toxins that induce ROS-dependent disease is also higher in UCP2 
knockout  mice,  including  tumour  development  to  azooxymethane  (Derdak 
Z,2006) and cell damage to mendione in hepatocytes (Collins P,2005), while 
hepatic regeneration after injury is also delayed as ROS interferes with the cell 
cycle (Horimoto M,2004) . 
 
ROS are thought to play an important part in the generation of cardiovascular 
disease.   LDL oxidation is one of the first steps of atheroma.  The LDL-receptor 
knockout  mouse  is  a  model  of  cardiovascular  disease,  and  when  the  UCP2 
gene was also knocked out in this mouse the plaque area was increased by 
42% compared to the LDL-receptor knock out “wildtype” (Blanc J,2003).  The 
plaques in the UCP2/LDL receptor knockout mouse were strongly positive for 
nitrotyrosine staining [a marker of peroxynitrite generation form superoxide and, 
thus, oxidative damage] while the UCP2 wildtype/LDL receptor knockout mouse 
nitrotyrosine staining was barely detectable (Blanc J,2003). In  human vascular 
smooth  muscle  cells  overexpression  of  UCP2  lowered  the  toxic  effects  of 
glucose and angiotensin II (Park JY,2005) .   
 
Cell  death  pathways  including  apoptosis  can  be  stimulated  by  ROS  or 
mitochondrial  dysfunction.    The  early  steps  often  include  changes  to 
mitochondrial  membrane  potential,  mitochondrial  calcium  entry  and  ROS   76 
generation.        UCP2  can  protect  mitochondrial  function  by  modulating 
membrane  potential.    Cell  survival  after  exposure  to  hydrogen  peroxide  is 
higher  with  UCP2  over-expression  in  β-cell  (Li  LX,2001),  cardiomyocytes 
(Teshima Y,2003; Zackova M,2003) and endocrine cell models (Diano S,2003).  
In human aortic endothelial cells UCP2 over expression inhibited all the steps of 
mitochondrial  dysfunction  and  cell  death  that  occurred  with  administration  of 
lysophophatidylcholine [LPC].  This effect appears to be physiologically relevant 
as LPC induces impaired endothelial function, an effect not seen in isolated rat 
aorta infected with an UCP2 over-expression vector (Lee KU,2005). 
 
Summary 
 
The  function  of  UCP2  is  still  not  fully  understood.    The  protein  may  be  a 
conventional uncoupler, but there is no evidence of a role in thermogenesis or 
obesity/energy balance.  Expression studies indicate a potential role in fatty acid 
metabolism,  or  protection  from  the  redox  pressure  on  the  electron  transport 
chain from the higher ATP production associated with fatty acid metabolism.  
The modulation of ATP production means that UCP2 clearly modulates insulin 
secretion,  although it is  not  clear  if  this  is a  primary  function.    The immune 
system is a large generator of ROS and patterns of expression, such as in the 
liver where it is located in the phagocytic Kuppfer cells only (Larrouy D,1997), 
suggests that protection from immune system ROS is a potential function, while 
a modulator of immune function or even inflammation-induced pyrexia (Faggioni 
R,1998)  are  potential  functions.      The  possibility  that  the  mRNA  expression 
observed  in  other  tissues is  due  to  the  presence  of entrapped  circulating  or 
tissue  immune  cells  has  yet  to  be  examined.    However,  expression  studies 
need  to  be  interpreted  with  caution,  as  UCP2  mRNA  undergoes  significant 
translational modification  and  regulation,  and  a  number  of  tissues  may  have 
mRNA  identified  in  them  but  not  UCP2  protein  (Pecqueur  C,2001).    The 
absence of a specific antibody further impedes the understanding of the role of 
UCP2. 
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1.4.2  Physiology of Uncoupling Protein 3 
 
UCP3 was also identified by cDNA library screening (Boss O,1997b; Vidal-Puig 
A,1997)  and  mapped  to  chromosome  11q13  in  man,  adjacent  to  UCP2 
(Solanes  G,1997).    UCP3  mRNA  was  identified  in  two  forms,  UCP3L  and 
UCP3S,  the  second  form  lacking  the  sixth  transmembrane  domain  and  the 
nucleotide binding site (Boss O,1997b).  However, levels of the two forms are 
highly correlated, indicating regulation by a common mechanism (Bao S,1998).   
UCP3  also  shows  high  homology  between  species,  mouse  UCP3  is  88% 
identical and rat 86% to humans, and both also express a UCP3S mRNA also 
lacking a transmembrane domain (Solanes G,1997) and a purine binding site 
(Bouillaud  F,1994).      The  tissue  distribution  of  UCP2  and  UCP3  are  very 
different, with UCP3 being located predominantly in skeletal muscle, with weak 
signals seen in the heart, thyroid and bone marrow, and in rodents, in brown 
adipose tissue (Boss O,1997b; Vidal-Puig A,1997). 
 
1.4.2a UCP3 thermogenesis and uncoupling 
 
The  tissue-specific  distribution  in  skeletal  muscle  makes  UCP3  an  attractive 
candidate for a role in energy balance in man.  Skeletal muscle is responsible 
for roughly 80% of resting energy expenditure (Ravussin E,1992) and 40% of 
adrenaline-induced  thermogenesis  (Simonsen  L,1993).  Skeletal  muscle 
metabolism is also uncoupled, with up to 50% of resting metabolic rate due to 
proton  leaks  (Rolfe  DF,1996).      UCP3  uncouples  metabolism  in  yeast  over-
expression  systems  (Gong  DW,1997;  Hagen  T,1999;  Hinz  W,1999;  Zhang 
CY,1999), insulinoma cells (Hong Y,2001), MCF7 cells (Stock MJ,1999), 293T 
cells  (Mao  W,1999),  E.  Coli  (Echtay  KS,2001;  Jaburek  M,1999),  C2C12 
myoblasts (Boss O,1998a) and L6 myocytes (Guerini D,2002).  However, most 
of these systems are susceptible to overexpression artefact, and the proton leak 
is not regulated by purine nucleotides in a physiological manner  (Schrauwen 
P,2006a).  Like UCP2, UCP3 lacks the histidine pair thought to be required for 
conventional uncoupling activity (Masaki T,1997).   
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Evidence from whole organisms is also unclear.  Mice UCP-3 over-expression 
models  have  smaller  adipose  tissue  depots,  are  resistant  to  obesity  and  do 
demonstrate increased energy expenditure, fat oxidation, oxygen consumption 
and a decline in mitochondrial membrane potential (Clapham JC,2000), but the 
proton leak is again not regulated in a physiological manner, indicating that this 
may be an artefact (Cadenas S,2002).  The UCP3 knockout mouse is not obese 
and  has normal  energy  expenditure  even  though  the  mitochondria  are  more 
coupled.    There  appears  to  be  no  effect  on  bodyweight  or  temperature 
regulation  phenotype  (Cline  GW,2001;  Gong  DW,2000;  Vidal-Puig  AJ,2000).   
Temperature maintenance in hibernating squirrels is not dependent on UCP3 
even at temperatures as low as -10C (Barger JL,2006). In Pima Indians mRNA 
levels  are  associated  with  24hr  energy  expenditure  and  adjusted  metabolic 
rates and inversely correlated with BMI and percentage body fat (Schrauwen 
P,1999).  Women who successfully lost weight were more uncoupled and had 
higher UCP3 mRNA levels than women who were unable to lose weight in a 
simple  trial  of  dietary  advice  (Harper  ME,2002).      When  UCP3  protein  is 
measured directly no such relationship with BMI (Schrauwen P,2001a), sleeping 
metabolic rate or 24 hour energy expenditure (Schrauwen P,2002a) could be 
detected.    In  rodents,  although  free  fatty  acids  uncouple  mitochondrial 
metabolism, this does not occur in conjunction with changes in UCP3 mRNA 
levels  (Hirabara  SM,2006).    Acute  exposure  to  cold  does  upregulate  UCP3, 
mRNA which later falls on chronic exposure (Lin B,1998), but again this does 
not correspond to the time course of non-shivering heat production (Schrauwen 
P,2002a), while in humans mild cold exposure has no effect on UCP3 mRNA or 
protein levels (Schrauwen P,2002b).   Although UCP3 expression is regulated 
by  thyroid  hormone,  and  in  pathological  thyroid  states  changes  in  energy 
metabolism may be in part due to altered UCP3 levels (Hesselink MK,2005), 
there is no evidence that the primary role of UCP3 is mitochondrial uncoupling 
and regulation of energy expenditure. This data, combined with similar evidence 
reviewed  later,  shows  that  UCP3  is  regulated  by  skeletal  muscle  fatty  acid 
tissue delivery regardless of body temperature or energy balance, which makes 
it unlikely that the primary function of UCP3 is the regulation of either of these 
parameters. 
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1.4.2b UCP3 and fatty acid metabolism 
 
The paradoxical increase in UCP3 mRNA with fasting again led to a number of 
studies that suggest that UCP3 has an important role in fatty acid metabolism.   
UCP3 mRNA levels correlate with free fatty acids (Boss O,1998a; Vidal H,1999) 
and  in  most  cases,  physiological  or  pharmacological  increases  in  free  fatty 
acids  and  their  metabolism  increase  UCP3  mRNA  levels  or  protein.    This 
includes in the rat, fasting (Boss O,1998c; Cadenas S,1999; Gong DW,1997; 
Samec  S,1999b;  Samec  S,1998b;  Weigle  DS,1998),  sepsis  (Sun  X,2003), 
acute exercise (Cortright RN,1999), high fat feeding and lipid infusion (Weigle 
DS,1998) in skeletal muscle; fasting (Gong DW,1997; Samec S,1998b; Sivitz 
WI,1999), high fat feeding  (Matsuda J,1997) in brown and white adipose tissue 
and fasting in the heart (Hidaka S,1999).  In mice, fasting, high fat feeding , and 
acute exercise have similar effects in both adipose tissue and skeletal muscle  
(Gong  DW,1999;  Hwang  CS,1999;  Schrauwen  P,2003;  Tsuboyama-Kasaoka 
N,1998; Tsuboyama-Kasaoka N,1999).  At the beginning of suckling, levels of 
free fatty acids rise over a couple of weeks in mice, and this is accompanied by 
a  rise in  UCP3  mRNA  over  the  exact  same  time  course  (Brun  S,1999).    In 
humans,  UCP3  is  upregulated  by  fasting  (Millet  L,1997;  Vidal  H,1999),  lipid 
infusion (Khalfallah Y,2000; Nisoli E,2000), acute exercise (Noland RC,2003; 
Schrauwen P,2002a) and by a high fat diet (Hesselink MKC,2003).  The switch 
to fat metabolism in the failing heart is also associated with higher UCP3 mRNA 
levels (Murray AJ,2004).  The effect of fatty acids persists at thermoneutrality 
(Boss  O,1998a)  and  is  more  pronounced  in  glycolytic  muscle  fibres  (Samec 
S,1998a).  It does not occur if levels of free fatty acids are suppressed (Samec 
S,1998a) or if fatty acid oxidation is suppressed  (Schrauwen P,2002a).  The 
reversal of these changes, such as by refeeding, also reverses the effect on 
UCP3.   Cell systems also demonstrate increased UCP3 mRNA levels, with free 
fatty acids in C2C12 cells (Cabrero A,2000; Hwang CS,1999), human myocytes 
(Sbraccia P,2002), L6 myocytes (Costello A,2003; Nagase I,1999; Son C,2001) 
and rat myocytes (Hoeks J,2003). 
 
Fasting  is  not  accompanied  by  a  change  in  proton  conductance  (Cadenas 
S,1999),  and  changes  in  proton  gradient  with  any  of  these  stimuli  follow  a   80 
different time course to the changes in UCP3 (Bevilacqua L,2005), so it is likely 
that  the  role  of  UCP3  is  related  to  fatty  acid  oxidation  rather  than  energy 
balance  or  conventional  uncoupling.      A  number  of  studies  support  this 
hypothesis;  during lipid infusion in humans the lipid oxidation rates correlate 
with  UCP3  mRNA  and  free  fatty  acid  levels  (Khalfallah  Y,2000),  and  the 
regulation of UCP3 expression occurs in parallel to other fatty acid oxidation 
genes  (Samec  S,2001).    The  PPAR  family  are  also  important  regulators  of 
UCP3  expression    (Cabrero  A,2000;  Nagase  I,1999;  Son  C,2001)  and  both 
PPAR α (Silvestri E,2006) and γ (Brunmair B,2004; Hwang CS,1999) agonists 
increase UCP3 mRNA, while levels are lower in the PPARγ knockout mouse 
(Murray AJ,2005).  However there are a number of situations when fatty acid 
metabolism is not associated with an increase in UCP3 mRNA or protein levels.   
UCP3 mRNA levels are higher in muscle groups with a higher proportion of fast 
twitch glycolytic fibres and lower fat oxidation (Schrauwen P,2001b).  Exercise 
training  (Boss  O,1998b;  Russell  AP,2003;  Schrauwen  P,2005;  Tsuboyama-
Kasaoka  N,1998)  and  weight  reduction  (Esterbauer  H,1999;  Schrauwen 
P.,2000;  Vidal-Puig  A,1999),  which  increase  fat  oxidation  capacity,  are  also 
associated with lower levels of UCP3 mRNA or protein.  The pharmacological 
inhibition of fatty acid oxidation is also associated with an increase in UCP3 
mRNA (Cabrero A,2001; Samec S,1999b).  In all these conditions UCP3 levels 
do not appear to correlate with the rate of fat oxidation, however, the muscles 
with  low  oxidative  capacity  tend  to  accumulate  excess  free  fatty  acids 
(Schrauwen P,2004), and it appears that UCP3 expression may be regulated by 
intracellular    fatty  acid  surplus,  which  has  led  to  the  hypothesis  that  UCP3 
functions in mitochondrial fatty acid transport.  
 
1.4.2c UCP3 and fatty acid transport 
 
Although thought to be the classical uncoupling protein the actual mechanism of 
mitochondrial uncoupling by UCP1 is unclear and it is possible that rather than 
directly transporting protons the protein transports fatty acid anions (Schrauwen 
P,2002a).  The function of UCP3 is dependent on the availability of free fatty 
acids, and the mRNA is specifically upregulated by the oversupply of long chain 
but not medium chain fatty acids (Schrauwen P,2003).  There is an important   81 
difference in the handling of these two types of fatty acid by mitochondria.  Fatty 
acids are taken up into the mitochondrial matrix by CPT1, with carnitine as a co-
factor,  where  they  are  converted  to  fatty  acylCoA.    The  inner  mitochondrial 
membrane is impermeable to fatty acylCoA, so fatty acids are transported by 
conversion to fatty acyl carnitine by CPT1 and then back to fatty acylCoA in the 
inner  mitochondrial  matrix  by  CPT2.    This  is  then  available  for  oxidation 
(Schrauwen P,2006a).  Fatty acids can accumulate within the matrix by either 
removal  of  the  acylCoA  by  thioesterases,  releasing  the  CoA  for  immediate 
oxidation in the citric acid cycle, or by passive transport of neutral fatty acids, 
when fatty acid supply overwhelms the ability to incorporate them into fatty acid 
acylCoA.  Within the inner mitochondrial matrix medium chain fatty acids can be 
readily oxidised without modification, whilst this is not the case for long chain 
fatty acids.  These are deprotonated into fatty acid anions (Hamilton JA,1999), 
which  become  trapped  within  the  mitochondria,  as  the  membrane  is 
impermeable to fatty acid anions (Ho JK,2002).   The accumulation of fatty acid 
anions  near  the  respiratory  chain  are  prone  to  oxidation  by  lipid  peroxides, 
which are highly reactive (Yagi K,1987), and will have the capacity to further 
damage  important  metabolic  enzymes  as  well  as  mitochondrial  DNA  (Goglia 
F,2003).   The impairment of mitochondrial function has been linked to insulin 
resistance and ageing as described earlier.   
 
Thus there are a number of potential mechanisms by which UCP3 may protect 
the mitochondria from fatty acid anion and lipid peroxide accumulation (see Fig 
1.18) and there are a number of studies supporting this as the primary function 
of UCP3.  Medium chain fatty acids are less susceptible to oxidative damage, 
and, as discussed above, are not linked to regulation of UCP3 expression.  In 
mouse  models  UCP3  mRNA  is  regulated  in  parallel  with  mRNA  levels  of 
thioesterases (Moore GBT,2001).  UCP3 over-expression increases fatty acid 
oxidation,  CPT1  levels,  and  reduces  lipid  accumulation  in  skeletal  muscle 
(Bezaire  V,2005),  without  any  effect  on  glucose  oxidation  or  convention 
uncoupling  (MacLellan  JD,2005).  Fat  oxidation  is  reduced  in  the  UCP3 
knockout  mouse  (Bezaire  V,2001),  which  also  demonstrates  higher levels  of 
ROS  production  (Vidal-Puig  AJ,2000),  intramuscular  lipid  peroxides  (Hoeks 
J,2006)  and  oxidative  damage  to  protein  lipids  and  DNA  (Brand  MD,2002;   82 
Echtay  KS,2003).    Aconitase  function,  inactivated  by  superoxide,  is  reduced 
both by purine inhibition of UCP3 function and in the UCP3 knockout mouse 
(Talbot DA,2005).  The effects in the knockout mouse are influenced by diet, 
with  a  decrease in lipid  peroxide formation on  a  high  fat  diet,  because of  a 
decrease in intracellular fat storage by a mechanism as yet unknown (Echtay 
KS,2003).  Therefore, these results must be interpreted with caution, in case 
they are confounded by a compensatory mechanism.   83 
Fig 1.17 Hypothesized mechanisms by which UCP3 may protect from fatty acid accumulation and peroxidation (MacLellan JD,2005) 
 
1)UCP3  removes  long-chain  fatty  acids  (LCFA) 
produced  by  MTE1;  the  latter  liberates  mitochondrial 
matrix CoASH, a rate-limiting coenzyme for ß-oxidation 
and the Krebs cycle. Long-chain fatty acids are exported 
from  the  matrix  by  UCP3 for  reactivation by  acyl-CoA 
synthase in the intermembrane space. Thus, MTE1 and 
UCP3 are proposed  to function  in tandem to facilitate 
fatty acid oxidation (Himms-Hagen J,1990).  
2)  UCP3  removes  excess  long-chain  fatty  acids  that 
have entered the mitochondrial matrix independently of 
the CPT system. This would serve to remove potentially 
damaging fatty acid anions from the matrix (Schrauwen 
P,2003). 
 3) UCP3 translocates lipid peroxide anions, generated 
from the interaction of matrix ROS with unsaturated fatty 
acids  of  the  inner  leaflet,  from  the  inner  to  the  outer 
leaflets  of  the  mitochondrial  inner  membrane  (Goglia 
FERN,2003).  This  would  remove  fatty  acid  peroxides 
and prevent damage of mitochondrial DNA, aconitase, 
and other matrix components.  
4)  4-hydroxynonenal  (HNE),  a  lipid  by-product  of 
mitochondrial superoxide (SOD) production, is proposed 
to  activate  a  UCP3-mediated  proton  leak  (Echtay 
KS,2003).  It  is  proposed  that  this    decreases 
mitochondrial membrane potential and hence decreases 
ROS production.    84 
If the function of UCP3 is to control lipid accumulation and peroxidation then 
UCP3  expression  should  be induced by  ROS  or  oxidative  damage.    Muscle 
contraction releases ROS and increases UCP3 mRNA, which is blocked by the 
administration  of  anti-oxidants  (Silveira  LR,2006),  as  does  ROS  induced  by 
hypoxia  in  C2C12  cells  (Flandin  P,2005)  and  in  peri-infarct  cardiomyocytes 
(Almsherqi ZA,2006).   The increase in mitochondrial proton conductance seen 
with the administration of hydrogen peroxide is dependent on free fatty acids 
and is not seen in the UCP3 knockout mouse, indicating the role of UCP3 in 
protection  from  ROS  (Echtay  KS,2002b).    Interestingly,  superoxide  does  not 
appear to regulate UCP3 expression  directly (Mozo J,2006) but 4-hydroxy-2-
nonenol one of the major products of lipid peroxidation does have this function 
(Echtay KS,2003).  Where higher UCP3 mRNA levels have been attributed to 
higher  ROS  generation,  such  as  the  models  above,  it  may  be  the  higher 
generation  of  mitochondrial  peroxides  by  the  generated  ROS  that  increases 
UCP3 mRNA levels.   However, ROS generation per se does not seem to be 
the main stimulus of UCP3  expression.  Metabolic changes in ischaemic pre-
conditioning  are  only  partly  dependent  on  UCP3  (McLeod  CJ,2005)  and 
although UCP3 levels increase after administration of LPS this is thought to be 
due  to  fatty  acid  changes  rather  than  higher  levels  of  ROS  (Yu  XX,2000).  
UCP3 function will, as an added feature of its suggested function, lower the 
mitochondrial membrane potential and reduce  metabolic ROS generation, so 
protecting the cells where it is found (Vincent AM,2004). 
 
In  summary,  the  putative  function  of  UCP3  is,  firstly,  the  protection  of 
mitochondria from fatty acid anion accumulation and peroxidation.  Secondly, it 
also  has  a  role  in  the  protection  of  mitochondrial  function  against  further 
oxidative damage from these lipid oxidation products. 
 
1.4.2d UCP3 and type 2 diabetes 
 
The  possibility  that  insulin  resistance  is  a  disorder  of  fat  oxidation  or 
mitochondrial function, as discussed earlier, suggests that UCP3 may have an 
important role in protection from the development of insulin resistance, and that 
aberrant  UCP3  function  might  be  associated  with  type  2  diabetes.    UCP3   85 
mRNA  levels are correlated with glucose tolerance (Samec S,1999b).  Studies 
of UCP3 mRNA in subjects with type 2 diabetes have had differing results, with 
studies  showing  higher  (Bao  S,1998;  Vidal  H,1999)  and  lower  levels  (Krook 
A,1998) associated with disease.  Lower levels were also reported in rats with 
diabetes (Vincent AM,2004).  The level in subjects at risk of type 2 diabetes is 
also  variable,  with  no  difference  reported  in  those  with  first  degree  relatives 
(Pedersen SB,2005), but lower levels seen in subjects with impaired glucose 
tolerance  which  were  corrected  by  treatment  with  the  insulin  sensitizer 
rosiglitazone  (Schrauwen P,2006b).   UCP3 protein was 50% lower in subjects 
with type 2 diabetes (Schrauwen P,2001a), and UCP3 gene expression is not 
upregulated  in  fasting  subjects  with  type  2  diabetes  (Vidal  H,1999).  
Experimental models also support a role for aberrant UCP3 function in insulin 
resistance.  UCP3 over-expression in mice is associated with improved glucose 
tolerance  (Clapham  JC,2000;  Vincent  AM,2004;  Wang  S,2003),  while  over 
expression in L6 myocytes increases GLUT4 levels, glucose uptake and insulin 
signalling (Huppertz C,2001; Hwang CS,1999).  The increase in UCP3 mRNA 
levels  after  acute  exercise  is  mirrored  by  an  increase  in  GLUT4  mRNA 
(Tsuboyama-Kasaoka N,1998) leading to increased glucose uptake.  The UCP3 
knockout  mouse  is  not  diabetic  (Brand  MD,2002),  but  this  may  be  because 
other compensatory mechanisms are limiting the delivery of free fatty acids to 
mitochondria  (Schrauwen  P,2006a).      Lipid  peroxidation  and  mitochondrial 
dysfunction  are  features  of  type  2  diabetes,  and,  through  its  effects  on lipid 
oxidation, UCP3 appears to play a protective role against insulin resistance.   
 
1.5  Variation in the uncoupling Protein Genes 2 and 3 
 
The  genes  for  UCP2  and  UCP3  are,  as  described  earlier,  located  on 
chromosome  11q13  within  8Kb  of  each  other  (Pecqueur  C,1999).      UCP2 
consists of eight exons while UCP3 consists of seven.  The gene structures are 
represented  in  Fig  1.17.  The  region  including  these  two  genes  or  their 
equivalent has been associated, by linkage analysis, with obesity and diabetes 
in the  mouse (Seldin  MF,1994; Taylor  BA,1996; Warden  CH,1995).    In  man 
11q13  has  been  linked  to  resting  metabolic  rate  and  percentage  fat  mass 
(Bouchard  C,1997),  type  1  (Hashimoto  L,1994)  and  type  2  diabetes  (Ghosh   86 
S,1996; Watanabe RM,2000), all in caucasian samples.  However, replication 
has been poor, with a number of studies failing to find linkage with obesity or 
type  2  diabetes  in  Caucasians  or  Mexican  Americans  (Comuzzie  AG,2000; 
Elbein SC,1997; Hager J,1998; Lee JH,1999).  However, this does suggest that 
this area of the genome may be important in determining risk of obesity and 
diabetes.  
 
Fig 1.18. The structure of the UCP2 and UCP3 gene on chromosome 11 
 
 
 
1.5.1 Uncoupling Protein 2 
 
The human UCP2 gene consists of 8 exons, of which exons 1 and 2 are non-
coding (Pecqueur et al. 2001).  Exon 2 contains a short open reading fragment 
that is, like the protein amino acid sequence, highly conserved among species 
(Jastroch M,2004), and seems to act as an inhibitor of translation although the 
functional  significance  of  this is  unclear  at present  (Pecqueur  C,2001).   The 
transcription  site  is  preceded  by  a  region  that  contains  a  strong  cis-acting 
positive  regulatory  element  (-141  to  -65)  which  may  underlie  the  ubiquitous 
expression  of  UCP2.    In  keeping  with  the changes in  expression  described, 
several consensus sequences exist for transcription control elements, such as 
C/EBP- , CREB-1 (cAMP response binding protein 1), two PPAR  responsive 
elements, two TREs (thyroid hormone response elements), and NF -B. 
 
The  first  UCP2  variants  to  be identified  were  in  exon  4,  a  +164C>T  variant 
which results in an amino acid change of alanine to valine (A55V) and a 45bp 
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insertion/ deletion in exon 8 (3‟UTR).  Although the +164C>T variant was not 
associated with obesity or diabetes markers in a Danish population (Urhammer 
SA,1997),  in  Pima  Indians  these  two  variants  were  associated  with  either 
sleeping metabolic rate (+164C>T) or 24 hour energy expenditure (45bp I/D).  
The 3‟UTR variant had no effect on mRNA levels in this study (Walder K,1998).   
The 3‟UTR was associated with BMI in South Indian women living in the UK but 
not in  a  Caucasian  sample, and  was  not  associated  with  type  2  diabetes in 
either a family study or a case control study  (Cassell PC,1999).  Thus early 
studies suggested that UCP2 was not important in the susceptibility to either 
obesity or type 2 diabetes. 
 
Interest  in  UCP2  as  a  candidate  gene  for  type  2  diabetes  and  obesity  was 
renewed by the discovery of five new variants, -2723T>A, -1957G>A,-866G>A, 
-371G>C and a 13bp insertion deletion in exon 1.  Esterbauer et al showed two 
of  these  were  associated  with  mRNA  levels  in  intraperitoneal  fat  tissue,  the        
-2723T>A and -866G>A.  The UCP2 promoter consists of two main blocks, with 
most of the activity in the first 1200bp with a second inhibitory block from -1200 
to -1600bp (Dalgaard LT,2003). The -866G>A variant is at a junction between a 
negative and positive cis-acting DNA region, and within a region that contains 
binding sites for hypoxia, aromatic hydrocarbons, inflammatory cytokines and 
the important β-cell transcription factor PAX-6.  This variant is in 100% LD with 
the -2723T>A promoter variant, strong LD (97%) with the A55V and moderate 
(75%) LD with the 3‟UTR.  The -866G>A variant has been reported to account 
for  71%  of  the  variation  in  mRNA  transcript  ratio  of  the  3‟UTR  variant, 
regardless of the nucleotide at -2723 indicating that the -866G>A may be more 
important in the LD block.  The higher activity of the variant promoter, confirmed 
in  expression  studies  in  Paz-6  cells  (derived  from  brown  fat  cells),  was 
associated with a lower risk of obesity in two separate case-control studies in 
Caucasians  from  the  Salzburg  area  of  Austria.    In  the  second  cohort  the 
population  attributable  fraction  associated  with  this  variant  for  obesity  was 
14.7% (Esterbauer H,2001).  In a similar case-control study from Austria the -
866A was associated with risk of type 2 diabetes.  The over activity of the -866A 
promoter  was  confirmed  in  INSE-1  cells  (a β-cell  line)  when  stimulated  with 
PAX-6.  Interestingly, the same stimulus was associated with lower activity from   88 
the -866A promoter in COS-7, cells suggesting that regulation of UCP2 is tissue 
specific  (Krempler  F,2002).    This  was  confirmed  using  electromobility  shift 
assays  which  showed  that  different  complex  patterns  formed  with  THP-1 
(macrophages)  and HUVEC (endothelium) cells compared to INSE-1 and Paz-
6 cells, indicating differences in transcription factor binding.  Baseline mRNA 
levels in THP-1 and HUVECS are higher for the wildtype promoter and these 
differences  in  activity  appeared  to  be  in  response  to  an  aryl  hydrocarbon 
receptor/  nuclear  translocator  [AhR/ARNT],  and  Hypoxia  inducible  factor-
1α/ARNT complex binding (Oberkofler H,2005).   These transcription factors are 
involved in cell stress responses to either environmental pollution (Park H,1999) 
or  hypoxia  (Semenza  GL,2001),  and  could explain  why  the  -866A  variant is 
associated with higher F2-isoprostanes, lower TOAS, higher prospective risk of 
coronary  artery  disease  in  Caucasian  men  (Dhamrait  SS,2004)  and  more 
extensive  carotid  atheroma  in  women  (Oberkofler  H,2005),  all  of  which  are 
associated with increased oxidative stress,  and would be expected if  UCP2 
function (i.e. mRNA and protein levels) were lower in carriers of -866A. 
 
Overall,  cross-sectional  studies  have  been  consistent  in  demonstrating 
associations between UCP2-866G>A and markers of obesity, oxidative stress-
related disease and type 2 diabetes.  In other ethnic groups the relationship has 
been less consistent, with the -866G associated with type 2 diabetes in a mixed 
race  sample  from  the  USA  (Wang  H,2004),  and  the  -866AA  genotype 
associated with higher waist hip ratio and risk of metabolic syndrome in Chinese 
and South Asians (Shen H,2006).  This indicates that the effect may be race-
specific  or  that  UCP2  variation  has  only  a  modest  effect,  confounded  by 
environmental  differences,  such  as  diet,  between  ethnic  groups.    The  gene 
association studies for UCP2 are summarized in table 1.4.   
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Table 1.4a The associations of the A55V variant in the UCP2 gene and obesity 
and diabetes markers. 
 
Phenotype  Population  Assoc^n  Risk 
Allele 
Reference 
 
 
Obesity 
 
       
Sleeping MR  Pima Indians  Y  AV↑  (Walder K,1998) 
Exercise Eff↑  Denmark  Y  V  (Buemann B,2001) 
24hrEE ↓  Denmark  Y  V  (Astrup A,1999) 
↓Fat Oxid  Denmark  Y  V  (Astrup A,1999) 
Weight loss ↓  USA –overfed*  Y  V  (Ukkola O,2001) 
Morbid Obesity  Taiwan  Y  V  (Chen HH, 2007) 
Weight Loss post 
Surgery 
Taiwan  Y  V  (Chen HH, 2007) 
Obesity  Taiwan  Y  V  (Wang TN, 2007) 
Weight Loss  Korea  Y  A  (Yoon, Y,2007) 
24hr EE  Pima Indians  N    (Walder K,1998) 
Juvenile cc  Denmark  N    (Urhammer SA,1997) 
BMI  Utah  N    (Wang H,2004) 
Obesity cc  Italy  N    (Mancini FP,2003) 
Obesity cc  Japan  N    (Kubota T,1998) 
Juvenile cc  USA-mixed  N    (Yanovski JA,2000) 
Resting MR  USA- 
baseline/overfed* 
N    (Ukkola O,2001) 
Weight gain  USA-
baseline/overfed* 
N    (Ukkola O,2001) 
BMI,%Fat  Korea  N    (Yoon, Y,2007) 
 
Diabetes 
 
       
Type 2  Pima Indians  Y  V  (Walder K,1998) 
Type 2  Utah  Y  V  (Wang H,2004) 
Type 2  USA-Mixed 
[obese] 
Y  V  (Yu X,2005) 
Type 2  Pima Indians  N    (Walder K,1998) 
Type 2  Denmark  N    (Urhammer SA,1997) 
Glucose/Insulin  Italy  N    (Mancini FP,2003) 
Type 2  Pima Indians  N    (Kovacs P,2005) 
Type 2  Japan  N    (Kubota T,1998) 
 
Other 
 
       
Multiple Sclerosis  Basque  Y  A  (Otaegui D,2007) 
HDL Cholesterol  Korea  Y  V  (Cha MH, 2007) 
Plasma Leptin  Scotland  Y  V  (Rance KA,2007)   90 
Key for Table 1.4a-c 
*Volunteers partook in an controlled overfeeding protocol 
[ ] indicated in this sub group only (F= female), EE= energy expenditure, MR= 
metabolic rate, cc=case control study. 
 
Table  1.4b  The associations of the 45bp 3UTR insertion/deletion [I/D] in the 
UCP2 gene with mRNA levels and obesity and diabetes markers. 
 
Phenotype  Population  Associ^n  Risk 
Allele 
Reference 
 
 
mRNA 
 
       
Half life  Paz-6 cells  Y  D  (Esterbauer H,2001) 
Levels  Muscle biopsy  N    (Walder K,1998) 
 
Obesity 
 
       
Sleeping MR  Pima Indians  Y  I/D ↑  (Walder K,1998) 
24hr EE  Pima Indians  Y  D  (Walder K,1998) 
BMI  South Indian [F]  Y  D  (Cassell PC,1999) 
BMI  Utah  Y  D  (Wang H,2004) 
24hr EE  Pima Indians  Y  D↓  (Kovacs P,2005) 
Obesity  Germany  Y  D  (Evans D,2001) 
Juvenile Obesity  USA-Mixed  Y  D  (Yanovski JA,2000) 
Fat Mass [Dialysis]  Sweden  Y  D  (Wang X, 2006) 
Obesity  Spain  Y  D  (Ochoa MC,2007) 
Weight gain  USA-
baseline/overfed* 
N    (Ukkola O,2001) 
Obesity cc  Denmark  N    (Dalgaard LT,1999) 
BMI  England  N    (Cassell PC,1999) 
24hr EE  Pima Indians  N    (Kovacs P,2005) 
10 yr wt gain  Denmark  N    (Berentzen T,2005) 
Adiposity [Dexa]  Scotland  N    (Rance KA,2007) 
Plasma Leptin  Scotland  N    (Rance KA,2007) 
Weight Loss  Korea  N    (Yoon, Y,2007) 
BMI,%Fat  Korea  N    (Yoon, Y,2007) 
 
Diabetes 
 
       
Type 2  Pima Indians  Y  D  (Walder K,1998) 
Type 2  Utah  Y  D  (Wang H,2004) 
Insulin Resistance  Spain  Y  D  (Ochoa MC,2007) 
Type 2  Pima Indians  N    (Walder K,1998) 
Type 2  South Indians  N    (Cassell PC,1999) 
Type 2  Pima Indians  N    (Kovacs P,2005)   91 
 
Table  1.4c  The  association  the  -866  variant  in  the  UCP2  gene  with  mRNA 
levels and obesity and diabetes markers. 
Phenotype  Population  Assoc^n  Ris
k  
Reference 
 
mRNA 
(Low activity) 
       
Promoter activity  Paz-6 cells  Y  G  (Esterbauer H,2001) 
Promoter activity  INSE-1 cells  Y  G  (Krempler F,2002) 
Promoter activity  COS-7 cells  Y  A  (Krempler F,2002) 
Promoter activity  THP/HUVEC cells   Y  A  (Oberkofler H,2005) 
Levels  SC Fat (mixed)  Y  A  (Wang H,2004) 
Promoter Activity  INSE-1 cells  Y  G  (Sasahara M,2004) 
Levels  Blood (cauc)  Y  G  (Vogler S,2005) 
Promoter activity  Jukhat (T-cell) 
U9377 (Mphage) 
Y  G  (Vogler S,2005) 
Obesity         
BMI  Austria  Y  G  (Esterbauer H,2001) 
Fat:Glc OX  Europe  Y  G  (Le Fur S,2004) 
24hr EE  Pima Indians  Y  G  (Kovacs P,2005) 
WHR  Indian/Chinese  Y  A  (Shen H,2006) 
Weight Loss  Korea  Y  A  (Yoon, Y,2007) 
Obesity  Spain  Y  G  (Ochoa MC,2007) 
BMI,%Fat  Korea  N    (Yoon, Y,2007) 
BMI,%FAT  Denmark  N    (Dalgaard LT,2003) 
Juvenile onset  Europe  N    (Le Fur S,2004) 
Obesity cc  Japan T2  N    (Sasahara M,2004) 
BMI  France T2  N    (Reis AF,2004) 
BMI  Japan  N    (Ji Q,2004) 
Morbid Obesity  Taiwan  N    (Chen HH, 2007) 
Weight Loss post 
Surgery 
Taiwan  N    (Chen HH, 2007) 
Obesity  Taiwan  N    (Wang TN, 2007) 
Body Adiposity 
[Dexa] 
Scotland  N    (Rance KA,2007) 
Diabetes         
Type 2  Austria  Y  A  (Krempler F,2002) 
GSIS  Italy  Y  A  (Sesti G,2003) 
Type 2  Utah  Y  G  (Wang H,2004) 
Type 2   Italy [F]  Y  A  (D'Adamo M,2004) 
Insulin therapy  Japan  Y  A  (Sasahara M,2004) 
Type 2   Italy  Y  G  (Bulotta A,2005) 
Glucose/Insulin  Italy  N    (Mancini FP,2003) 
NEFA/Insulin 
Relationship 
Hungary  Y  Lost 
in A 
(Bokor S, 2007) 
Type 2 Diabetes  North India  Y  G  (Rai E, 2007) 
Insulin Resistance  Spain  Y  G  (Ochoa MC,2007) 
Glucose/Insulin  Denmark  N    (Dalgaard LT,2003) 
Glucose/Insulin  France  N    (Reis AF,2004) 
HOMA-R  Japan  N    (Ji Q,2004) 
Type 2  Pima Indians  N    (Kovacs P,2005)   92 
Oxidative Stress 
 
       
Multiple Sclerosis  Germany  Y  G  (Vogler S,2005) 
TOAS  England  Y  A  (Dhamrait SS,2004) 
CAD  England  Y  A  (Dhamrait SS,2004) 
Carotid Atheroma  Austria [F]  Y  A  (Oberkofler H,2005) 
Neuropathy  Japan Type 2  Y  A  (Yamasaki H,2006) 
Neuropathy  USA- Europe/Type   Y  G  (Rudofsky G,2006) 
TOAS [Smokers]  England  Y  A  (Stephens J, 2007) 
Other 
 
       
Triglycerides  France T2  Y  A  (Reis AF,2004) 
Hypertension  Japan  Y  A  (Ji Q,2004) 
Triglycerides  Indian/Chinese  Y  A  (Shen H,2006) 
Long Chain FA  Hungary  Y  A  (Bokor S, 2007) 
HDL Cholesterol  Iran  Y  A  (Akrami SM, 2007) 
HDL Cholesterol  Korea  Y  A  (Cha MH, 2007) 
Plasma Leptin  Scotland  N    (Rance KA,2007) 
 
1.5.2 Uncoupling Protein 3    
 
The  UCP3  gene  has  7  exons  and  the  presence  of  binding  sites  for  muscle 
dependent transcription factors CCAC and E box, Mefz and MyoD explains how 
UCP3  expression  is  targeted  to  skeletal  muscle  cells  (Acin  A,1999).  The 
promoter has several other binding sites, and is regulated by other important 
metabolic  signals  including  retinoic  acid  (Solanes  G,2000),  PPAR,  thyroid 
hormone  (Acin  A,1999),  leptin,  steroids  and  β3  (Gong  DW,1997)  and  β2 
receptors (Masaki T,1997).  The activity of the metabolic response elements in 
most cases is also dependent on activation of muscle-dependent transcription 
factors ensuring metabolic response is  also targeted to skeletal muscle cells 
(Solanes G,2000) 
 
Sequencing  and  gene  association  studies  involving  UCP3  have  been  less 
successful  in  identifying  important  variants  with  consistent  effects.    The 
discovery  of  significant  mutations  in  obese  African  Americans  with  type  2 
diabetes  suggested  that  UCP3  may  be  important.    One  of  these  sites,  a 
mutation  at  the  splice  site  of  exon  6,  was associated  with  a  significant  50% 
reduction in fat oxidation (Argyropoulos G,1998).    
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A number of variants have been identified throughout the gene (see table 1.5) 
but only one of these has been associated with differences in mRNA levels.  
The -55C>T was originally located near a TATA box (6bp) although a recent 
report  (Acin  A,1999)  places  the  variant  in  the  „5UTR  near  (4bp)  a  PPAR 
responsive element, which also suggests it could modify regulation of  UCP3 
expression.  The variant allele was associated with higher levels of mRNA but 
not with obesity (Schrauwen P,1999). This variant is also near a DR1 retinoic 
acid response element (6bp) and an area responsible for MyoD activity (61bp) 
(Solanes G,2000), so may affect the action of other important factors as well. 
 
Phenotype association studies have been very inconsistent, and often in conflict 
with the association with mRNA levels.  The T allele was associated with higher 
BMI  or  WHR,  consistent  with  decreased  function,  in  French  and  German 
Caucasians, South Asian Indian parent-offspring trios, South Asian Indians and 
the  British  Diabetic  Association  Warren  2  trios  collection  (Cassell  PG,2000; 
Halsall  DJ,2001;  Herrmann  SM,2003;  Otabe  S,2000).    However,  one  study 
showed  a  lower  BMI  in  TT  subjects  in  a  United  Kingdom  sample  (Halsall 
DJ,2001),  and  increased  function  is  also  suggested  with  the  association  of 
protection  from  diabetic  neuropathy  (Rudofsky  G,2006).  In  these  studies 
association with T2DM was examined only once and a relationship not found.  
The  variant  allele  was  found  to  be  protective  against  T2DM  in  two  French 
cohorts,  suggesting  increased  function,  although  also  associated  with  an 
atherogenic lipid profile (Meirhaeghe A,2000).  These studies are summarized 
in table 1.6.  The results in both tables are not well replicated.  The frequency of 
a number of the variants is different across ethnic groups (Kimm SY,2002; Liu 
YJ,2005), so differences could be seen depending on the origin of the sample.  
The effect of variation in UCP3 on obesity is likely to be small, estimated at 2-
3% of total variation in one study (Liu YJ,2005), which means that not all the 
studies will be adequately powered to detect a difference.  There is strong LD 
between the variants in both genes (Walder K,1998) and some signal from a 
functional variant is likely to be detected in studies of several “non-functional” 
variants across the cluster. 
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Table  1.5    A  summary  of  association  studies  for  variants  within    UCP3 
excluding  the  -55C>T polymorphism. [The variants are described as the appear 
most commonly in the literature.] 
Variant  Phenotype  population  Risk   Reference 
Promoter         
-155C>T  Obesity  France  No  (Otabe S,2000) 
-439Del A  Obesity  France  No  “ 
Exon 1         
+5 G>A  Obesity  France  No  (Otabe S,2000) 
Exon 2         
Val9Met  Obesity  France  No  (Otabe S,1999) 
  Growth/O2 use  Yeast  No  (Hagen T,1999) 
Intron 2         
+521G>C  BMI/Weight loss  Korea  No  (Cha MH,2006) 
Exon 3          
Arg70Trp  Growth/O2 use  Yeast  Variant 
↓  
(Brown AM,1999) 
Ala83Ala  Obesity/DM  France  No  (Otabe S,1999) 
Gly84Ser  Juvenile Obesity  Denmark  No  (Urhammer 
SA,1998) 
Tyr99Tyr  Obesity/DM  France  CC ↑BMI  (Otabe S,1999) 
  Juvenile Obesity  Denmark  No  (Urhammer 
SA,1998) 
  Weight Loss  Canada [F]  No  (Harper ME,2002) 
  Resting EE  USA-mixed  No  (Kimm SY,2002) 
  BMI  USA- Cauc  No  (Liu YJ,2005) 
  Met R./Obesity  Pima  No  (Walder K,1998) 
  TSH r TRH  USA  ↓ CC  (Ukkola O,2001) 
  Weight loss after 
overfeeding 
USA   ↓ CC  (Ukkola O,2001) 
  RQ Baseline + 
after overfeeding 
USA  ↓ CC  (Ukkola O,2001) 
  BMI/Weight loss  Korea  No  (Cha MH,2006) 
  BMI/Weight loss  Korea  No  (Yoon Y, 2007) 
Val109Ile  Resting EE  USA-mixed  No  (Cha MH,2006) 
  Growth/O2 use  Yeast  No  (Brown AM,1999; 
Hagen T,1999) 
  Obesity  Tiawan  No  (Wang TN, 2007) 
Intron 3         
-46A>T  Juvenile Obesity  Denmark  No  (Urhammer 
SA,1998) 
-47A>G  Juvenile  Obesity  Denmark  No  “ 
  BMI/Weight loss  Korea  No  (Cha MH,2006) 
-96C>T  Juvenile Obesity  Denmark  No  “ 
-143A>G  Juvenile Obesity  Denmark  No  “ 
Intron 4         
+36C>T  Obesity/DM  France  TT↑DM  (Otabe S,1999) 
+1811C>T  BMI/Weight loss  Korea  No  (Cha MH,2006) 
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EE = Energy Expenditure, RQ = Respiratory Quotient, DM = Diabetes Mellitus, Met R 
=Metabolic rate, [ ] = in this subgroup only, F= females.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Variant  Phenotype  population  Risk   Reference 
Exon 5          
Tyr210Tyr  Obesity/DM  France  TT↑DM  (Otabe S,1999) 
  Juvenile Obesity  Denmark  No  (Urhammer SA,1998) 
  Fat/Lean mass  USA women  TT↑  
(↓intake) 
(Damcott CM,2004) 
  BMI/fat mass  Canada-
mixed 
↑ T  (Lanouette CM,2002) 
  BMI  USA  No  (Liu YJ,2005) 
  Weight loss  Canada [F]  No  (Harper ME,2002) 
  Resting EE  USA- mixed  ↑ T 
[Black] 
(Kimm SY,2002) 
  BMI/Weight loss  Korea  No  (Cha MH,2006) 
  HDL Cholesterol  Korea  Y  (Cha MH, 2007) 
  BMI/Weight loss  Korea  No  (Yoon Y, 2007) 
Exon 6         
Splice site 
Mutation 
Fat oxidation  Black USA  Yes  (Argyropoulos 
G,1998) 
  Growth/ O2 use  YEAST  No  (Brown AM,1999) 
  BMI/Fat mass  USA Black  No  (Chung WK,1999) 
  UCP3mRNA  USA Black  UCP3S 
only 
(Chung WK,1999) 
Intron 6         
GAIVS6 
(microsatellite) 
BMI/skin fold  Canada 
[Cauc] 
↑
wildtype 
(Lanouette CM,2002) 
Exon 7         
Arg308Trp  Obesity DM  France  No  (Otabe S,1999)   96 
 
Table 1.6   The association of the -55C>T variant in UCP3 with Obesity and 
Diabetes phenotypes.  
 
EE= Energy Expenditure, DM = Subjects with diabetes mellitus, [ ] = in this subgroup 
only, F= females 
 
Phenotype   Population  Association  Risk   Reference 
mRNA         
Decreased  PIMA  Y  C  (Schrauwen P,1999) 
Obesity         
WHR  Germany  Y  TT↑  (Herrmann SM,2003) 
Obesity  Spain  Y  T  (Ochoa MC,2007) 
WHR  South 
Indian[F] 
Y  T↑  (Cassell PG,2000) 
WHR  UK White[F]  Y  T↑  “ 
Obesity  France   Y  TT ↑BMI  (Otabe S,2000) 
BMI  USA 
Caucasians 
Y  C ↑  (Liu YJ,2005) 
Juvenile 
Obesity 
UK  Y  C ↑ BMI  (Halsall DJ,2001) 
% Fat/VO max  UK  N    “ 
Obesity/ 
weight gain 
Denmark  N    (Dalgaard LT,2001b) 
Weight loss  Canada [F]  N    (Harper ME,2002) 
Resting EE  USA mixed  N    (Kimm SY,2002) 
BMI  France DM  N    (Meirhaeghe A,2000) 
Weight Gain  Denmark   N    (Berentzen T,2005) 
Obesity  Korea  N    (Cha MH,2006) 
Obesity  Taiwan  N    (Wang TN, 2007) 
Obesity  PIMA  N    (Schrauwen P,1999) 
T2DM         
Family study  South Indian  N    (Cassell PG,2000) 
Case-control  South Indian  N    “ 
Family study  UK  N    “ 
Case-control  France  Y  C↑DM  (Meirhaeghe A,2000) 
Insulin 
resistance 
Spain  Y  T  (Ochoa MC,2007) 
Misc         
Cholesterol  France DM  Y  ↑TT  (Meirhaeghe A,2000) 
Neuropathy  Germany DM  Y  ↑ CC  (Rudofsky G,2006)   97 
1.6  Study Aims 
 
The aim of this study was to use a genetic approach to determine the role of the 
Uncoupling Proteins 2 and 3 in the development of type 2 diabetes mellitus.    
 
 
Hypothesis: 
 
Uncoupling  Proteins  2  and  3  influence  the  risk  of  development  of  type  2 
diabetes through the modulation of oxidative stress. 
 
 
Specific Aims 
 
1)  Confirmation  that  identified  genetic  variants  in  the  UCP2-UCP3  gene 
cluster  are associated  with  type  2  diabetes  using  a prospective  study 
design. 
 
 
2)  Examining the association of common variants in the UCP2-UCP3 gene 
cluster traits with markers of oxidative stress. 
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2.1 Study Samples 
 
2.1a Japanese American Family Study (JAM) 
The JAM Study was organised by the Department of Epidemiology, University of 
Washington.  The study was designed to investigate risk factors for coronary heart 
disease,  diabetes,  and  the  insulin  resistance  syndrome  in  Japanese  American 
families (Austin MA,2004a).  The study had full Institutional Review Board approval 
from The University of Washington.  
Probands  were  Nisei  (2
nd  generation)  participants  in  the  Japanese  American 
Community Diabetes Study (JACDS) who had a spouse of Japanese descent and 
children, and who were non-diabetic at the time of the first community-wide survey 
conducted  in  1983.  Members  of  the  Nisei  generation  now  range  in  age  from 
approximately  65  to  75  years.  Because  most  Nisei  married  other  Japanese 
Americans, the Sansei (3
rd generation) is predominately of Japanese descent, with 
ages now ranging from about 30 to 55 years.  Probands were contacted by letter 
and those interested were asked to give permission to contact family members. 
Eligible family members included parents, spouses and offspring of the proband, 
siblings,  spouses  of  siblings,  and  nieces  and  nephews  of  the  proband,  age  18 
years and over, residing anywhere in the United States, who were not pregnant 
and not too ill to participate.   Thus, the study sample consists primarily of two-
generation extended Nisei and Sansei kindreds. Each proband and relative was 
contacted individually by letter and phone, and asked to participate by providing a 
fasting blood sample and medical history questionnaire. For relatives living outside 
of the Seattle metropolitan area, blood samples were shipped by overnight mail to 
the University of Washington.   Type 2 diabetes was defined as fasting glucose 
>125 mg/dl, taking
 known medication for diabetes, self-reported diabetes, and self-
report
 of taking insulin or oral antidiabetic pills by questionnaire (Austin MA,2004a) 
The study participants all provided written, informed consent.  I would like to thank 
Mellissa Austin, principal Investigator, for the use of JAM samples.   101 
2.1b The Second Northwick Park Heart Study Cohort (NPHSII) 
 
The Second Northwick Park Heart Study (NPHSII) was recruited by the Medical 
Research  Council  Cardiovascular  group  at The Wolfson  centre  for  Preventative 
Medicine.  In brief, 3012 unrelated healthy Caucasian middle-aged male subjects 
(mean  age  56.1+3.5  years)  recruited  from  nine  UK  general  practices,  detailed 
elsewhere were prospectively followed for up to 15 years (Gable DR,2006b).  The 
study  was  approved  by  the  institutional  ethics  committees  and  performed  in 
accordance  with the  declaration  of  Helsinki.    All  subjects  gave  written informed 
consent. 
 
Baseline characteristics were ascertained by means of a questionnaire at entry into 
the study.  Exclusion criteria at baseline were a history of myocardial infarction, 
cerebrovascular  disease,  life-threatening  malignancy  or  regular  medication  with 
aspirin or anticoagulants.  At entry, a 5ml EDTA blood sample was obtained, from 
which genomic leukocyte DNA was extracted. Time to first CHD event (defined as 
sudden cardiac death, symptomatic/silent MI (the appearance of a new major Q 
wave on the follow up ECG, using Minnesota codes 11,12.1 to 12.7, 12.8 plus 51 or 52, 
or  coronary  revascularisation)  was  recorded,  yielding  only  one  event/subject.  
Cases of Type 2 Diabetes at baseline were identified by self report.  Exclusion 
criteria precluded subjects requiring insulin or oral hypoglycaemics from entry into 
NPHS  II.    New  cases  were  identified  by  practice  note  search  for  physician 
diagnosed and treated T2DM according to current national guidelines.  To date, 
288 coronary heart disease events have occurred in 2775 of the subjects with DNA 
available for analysis.  There were 76 cases of Type 2 Diabetes at baseline and by 
15 years a further 169 cases had been identified.  
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2.1c  Hypercoagulability  and  Impaired  Fibrinolytic  Function  Mechanisms  Study 
(HIFMECH) 
 
The  HIFMECH  study  was  designed  to  study  genetic  and  environmental 
mechanisms contributing to the higher cardiovascular risk in Northern compared to 
southern Europe (Juhan-Vague I,2002).  The study samples of Caucasian male 
first myocardial infarction survivors below 60 years of age were recruited from four 
European  centres  (Northern  European-Stockholm,  London;  Southern  European-
Marseille,  San  Giovani  Rotondo)  (n=598).  Subjects  with  familial 
hypercholesterolemia and insulin-dependent diabetes
 mellitus were excluded.  A 
selection of randomly-selected age-matched healthy controls were also recruited 
from each catchment area (n=653).  The study was performed in accordance with 
the  guidelines  in  The  Declaration  of  Helsinki  and  approved  by  local  ethics 
committees. Written informed consent was obtained from all subjects.  The patients 
and  control  subjects  were  examined
  in  parallel  in  the  early  morning  after  an 
overnight  fast,  and  a  blood  sample  was  also  obtained.    Post-infarction  patients 
were investigated 3 to 6 months after
 the acute event.  
 
2.1d UCL Diabetes and Cardiovascular Disease Study (UDACS) 
 
The  UDACS  is  a  cross-sectional  sample  of  subjects  designed  to  study  the 
association  between  common  variants  in  inflammatory/metabolic  genes  and 
biochemical risk factors implicated in CHD in patients with diabetes.  The subjects 
were  recruited  by  Dr  Jeffrey  Stephens  (Cardiovascular  Genetics,  UCL  and 
Diabetes and Endocrinology, University College London Hospitals NHS Foundation 
Trust)  between  December  2001  and  January  2003  from  the  diabetes  clinic  at 
University College London Hospitals NHS Trust (UCLH).  Clinical information was 
gathered  from  the  computerised  clinic  database,  which  was  first  established  in 
1983.  The  database  contains  demographic  and  clinical  information  on  patients 
attending the diabetes clinic and clinic measurements of blood pressure (supine 
and  lying),  weight  and  height  were  measured  on  all  subjects  and  routine  clinic   103 
biochemistry  was  also  recorded.  All  patients  had  diabetes  according  to  WHO 
criteria  current  at  the  time  of  diagnosis.  Patients  were  categorised  by  the 
presence/absence of clinically manifest CHD.  The presence of CHD was recorded 
if  any  patient  had  positive  coronary  angiography/angioplasty,  coronary  artery 
bypass,  cardiac  thallium  scan,  exercise  tolerance  test,  myocardial  infarction  or 
symptomatic/treated angina. Any individual who was asymptomatic or had negative 
investigations was categorised as „no CHD‟.   Ethical approval was obtained from 
UCL/UCLH Ethics Committee and the project was registered with the Department 
of Research and Development at UCLH.  All subjects completed a self-assessment 
questionnaire and gave written consent before being recruited in the study.  All 
subjects were free from acute illnesses at the time of recruitment. 
 
2.2 Genotype Determination  
 
 
Leukocyte DNA for genotyping had previously been extracted for all studies from 
whole blood using the “salting out” method (Miller SA,1988). Briefly, the cell lysis  is 
achieved  with  a  sugar  lysis  buffer  followed  by  nuclear  lysis  using  the  defined 
nuclear lysis buffer.  De-proteinisation is performed with sodium perchlorate.  The 
DNA  was  extracted  using  chloroform  and  then  precipitated  from  the  aqueous 
phase using ethanol.  The extracted DNA was dissolved and stored in TE Buffer.    
All  samples  were  carefully  logged  and  entered  into  a  database  with  a  unique 
identifier in order to preserve the anonymity of individuals in the study. This stock 
DNA is used to prepare working 96 well arrays for genotyping. 
 
Working DNA was standardized to a concentration of 15ng/ l.  This was achieved 
by calculating the volume of DNA required to be added to 750 l of dH2O to achieve 
this concentration on the basis of the absorbance of a 10 l sample of stock DNA.  
Stock arrays were created in labelled 96-well Beckman‟s array.  These were stored 
at -20
oC. To create working arrays, 100 l of each sample was removed from the 
stock array, and transferred to another labelled 96-well array.   104 
2.2a Polymerase chain reaction & Restriction Digest (RFLP) 
 
The technique of Polymerase chain reaction (PCR) relies on double stranded DNA 
being  denatured  into  single  strands  by  heat,  consequently  annealing  with 
oligonucleotides, and with the addition of DNA polymerase and nucleotide bases, 
the  synthesis  of  a  double  strand  on  cooling.  This  process  leads  to  binary 
replication, generating large quantities of DNA in a short period of time. The first 
step is therefore a short period of high temperature to denature or „melt‟ the DNA. 
This  is  followed  by  cooling  in  the  presence  of  oligonucleotides  that  are 
complementary  to  the  DNA  either  side  of  the  sequence  to  be  studied.  These 
oligonucleotides anneal, and a DNA polymerase adds nucleotides base by base, 
thus  replicating  the  DNA  (Fig.  2.2).  The  polymerase  used  is  derived  from  the 
bacterium Thermus aquaticus (Taq) and is heat stable. Therefore, it does not need 
to be replenished after each cycle of heating and cooling.  
 
Fig. 2.1: Schematic representation of the polymerase chain reaction (PCR). Denaturation 
of double stranded DNA occurs at 95°c (melting). Annealing of oligonucleotides varies 
according  to  the  relative  amounts  of  the  four  bases  present.  Polymerisation  with  Taq 
usually occurs at 72°c (polymerisation). 
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Sample Preparation for Polymerase Chain Reaction  
 
The DNA samples were prepared for PCR by centrifuging the DNA working-array 
at 200g for one minute to ensure that all the DNA dilutions were at the bottom of 
their respective wells, reducing the possibility of cross-well contamination when the 
array  lid  was  removed.  The  appropriate  amount  of  DNA  (see  2.2c)  was  then 
removed from each array and transferred into a standard 96-well PCR plate from 
Corning Inc. (Hemel Hempstead, UK) using a multichannel dispenser.  Life Positive 
and negative controls were utilised to ensure accuracy. Extreme care was taken to 
ensure  that  samples  were  placed  in  the  identical  orientation  as  in  the  original 
arrays.  
 
A bulk mix of reagents was made up for each PCR, allowing adequate volume for 
the planned number of reactions, with an additional 10% added to ensure that the 
mix would not run short. PCR oligonucleotides and Taq polymerase were kept on 
ice  and  added  just  before  the  commencement  of  the  reaction.  PCRs  were 
performed in a total volume of 20 l made up with distilled water. Each reaction 
contained  1x  concentration  of  appropriate  polmix,  MgCl2,  8pmol  of  each 
oligonucleotide and 0.4U of Taq polymerase. 
 
The  PCR  mix  was  added  to  each  well  of  the  PCR  plate  using  an  automatic 
repeating dispenser. Each sample was overlaid with 20 l of mineral oil to prevent 
evaporation. The microtitre plate was then sealed with a clear sticky plastic lid and 
carefully  labelled.  Plates  were  centrifuged  at  200g  for  thirty  seconds  to  ensure 
good  mixing  of  the  reaction  components  in  each  well.  PCR  amplification  was 
performed  on  an  MJ  Tetrad  DNA  Engine  Thermocycler.    A  description  of  the 
individual primers and conditions for each variant can be found in section 2.2c. 
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Detection of DNA (Agarose gels) 
 
In order to check the successful amplification and size of PCR products, agarose 
gels were utilised.  For a 2% gel, 2 grams of agarose  was mixed with 100ml of 
1×TBE solution containing 10µL of Ethidium bromide (10µg/µL). A microwave oven 
was used to heat the mixture and dissolve the agarose. The melted agarose was 
poured into a plastic gel tray (10 × 14cm) and a comb inserted. Solid gels were 
placed into an electrophoresis tank containing 750ml of 1xTBE buffer solution. 2 l 
of MADGE loading dye was added to 5µL PCR product and the entire volume was 
mixed thoroughly and placed in the separate, submerged wells of the gel. 2µl of a 
1Kb ladder (Invitrogen, Paisley UK) was pipetted into the central well in order to 
size relevant products. All agarose gels were run at 100 volts (v) for a minimum of 
30 minutes. 
 
Restriction digestion 
 
Restriction enzymes are derived from bacteria, and cleave double stranded DNA at 
a particular sequence. The enzyme translocates along the DNA until a particular 
recognition  site  is  reached,  where  the  DNA  is  cut.  The  restriction  enzyme  is 
sensitive even to a single base change in the recognition sequence, and thus can 
be used to detect point mutations and single base polymorphisms. A single base 
change can either eliminate or create a cutting site for a particular enzyme. 
 
A restriction enzyme digest mix with the recommended buffer system was made up 
in a 1ml Eppendorf tube on each occasion, containing sufficient enzyme to digest 
the PCR products in each well of the PCR plate.  5 l of digestion mix was then 
added to 8 l of each reaction product using a repeater pipette as for the PCR mix. 
Each omniplate was then centrifuged at 200g for thirty seconds to ensure that the 
PCR product and restriction enzyme were mixed well. The PCR/digestion mix was 
then incubated overnight at the recommended temperature. The specific conditions 
and possible product sizes for each genotyping assay are detailed in section 2.2c.   107 
Microtitre Array Diagonal Gel Electrophoresis (MADGE) 
 
The  DNA  fragments  produced  by  restriction  enzyme  digest  were  separated  by 
electrophoresis  on  a  non-denaturing  polyacrylamide  gel,  using  Microtitre  Array 
Diagonal  Gel  Electrophoresis  (MADGE)(Day  IN,1995).  This  technique  makes  it 
possible to electrophorese all the 96 wells of a standard PCR plate on a single gel, 
by allowing the samples to run diagonally. Use of MADGE allowed the 96 well DNA 
array format to be retained throughout the screening process.  
 
MADGE consists of an open arrangement of 8x12 wells each 2mm deep. The wells 
are arranged at an angle of 71.2
o to the short axis of the array, but perpendicular to 
the long-axis of the Perspex formers used (Fig. 2.2A).   Before making the mix, 
glass plates of appropriate size (160 x 100 x 2mm) were rigorously cleaned and 
hand dried. 5 drops of  -methacryloxypropyltrimethoxysilane („sticky‟ silane) were 
spread across the plates and left to air-dry. Polymerisation of the MADGE mix was 
initiated by the addition of ammonium persulphate and the solution was mixed and 
quickly poured into the three-dimensional former. A glass plate was then gently 
placed over the mould (silane side facing downwards) taking care not to trap any 
air bubbles. This was then left for fifteen minutes to set, using a small weight to 
ensure  that  the  glass  did  not  slip  whilst  the  gel  was  setting.  Excess  gel  was 
trimmed from the edges of the MADGE former before the glass plate and attached 
gel were then prised away from the plastic former.  
 
Gel staining and loading 
 
Prior  to  loading  a  gel  with  digested  PCR  product,  each  gel  was  stained  with 
Ethidium  Bromide  (EtBr).  This  was  achieved  by  placing  them  individually  in  a 
Stuart box, shielded from direct light, containing 100ml of 1x TBE and 10 l EtBr for 
20 minutes.   MADGE loading dye (2 l) was added to each well of a new, round-
bottomed, loading tray, followed by 5 l of each digested sample, using a multi-
channel  pipette  to  pick  up  the  samples  from  under  the  oil  in  the  plates.  The   108 
digested  samples  were  gently  mixed,  by  aspirating  the  formamide  dye–digest 
mixture up and down several times into the pipette, before dispensing them on the 
digest plate.  
 
After placing the stained MADGE gel into an electrophoresis tank containing 750ml 
of 1xTBE buffer solution, a multi-channel pipette was used to transfer 5 l of this 
digest/dye mixture to the wells of the gel. At all times the samples were kept in the 
same  layout  as  on  the  PCR  tray,  allowing  each  sample  to  be  easily  identified 
without being re-labelled. The gel was electrophoresed at 150v for a minimum of 
30 minutes. 
 
Following electrophoresis, the gel was viewed and photographed under ultraviolet 
light using the UVP Gel Documentation System. Care was once  more taken to 
ensure the correct orientation of the MADGE under UV.  Figure 2.2B illustrates a  
typical pattern obtained for the polymorphisms genotyped. 
 
All genotyping was performed in a double blind fashion using both positive and 
negative controls. The results were rechecked by two individuals at the time of 
MADGE imaging and during data entry into the computer database. Any apparent 
genotype differences were resolved by repeat PCR. Overall there was excellent 
reproducibility with >95% consistency between observers. 
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Fig. 2.2: Perspex former (A) and visualised MADGE gel (B) for the UCP2-866G>A and 
UCP3 -55C>T gene variants.  
 
   
 
Perspex former is used to create angled Indentations in 
the gel.  
 
 
 
 
 
 
 
 
 
 
B 
 
Both  wild  type 
genotypes  were  cut  by 
their  respective 
enzymes.  Arrow  at  the 
bottom  of  the  gel 
represents  the  direction 
of electrophoresis. 
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2.2b Taqman® genotyping 
 
The principle behind the Taqman® reaction is described in Fig. 2.4. The method 
involves the inclusion of two fluorescent, dye-labelled probes for each allele of a 
specific variant.  The allele specific probes each contain a short sequence of DNA, 
a reporter dye (Labelled VIC™ or FAM™ depending upon the allele) at the 5‟ end, 
and a non-fluorescent quencher (NFQ) dye at the 3‟ end. During the PCR process, 
forward/reverse oligonucleotides as well as the labelled probes, anneal to the DNA 
of interest (Fig. 2.4.A). Amplitaq Gold® DNA polymerase is able to replicate the 
single strand of DNA until it reaches the labelled probe. Any non-specific binding 
results  in  a  weakened  interaction  of  the  labelled  probe  with  the  DNA  and 
displacement  of  the  intact  probe  (no  cleavage  of  the  dye  from  the  quencher) 
(Fig.2.4.B). If the probe is entirely complementary (hence allele specific probes) to 
the  annealed  DNA  sequence,  the  5‟  to  3‟  exonuclease  activity  of  the  enzyme 
results in the cleavage of the 5‟ dye from the rest of the probe (Fig. 2.4.C). The 
close  proximity  of  the  dye  to  the  quencher  usually  prevents  any  significant 
fluorescent emission. However, once the dye is cleaved, fluorescence increases 
with  each  round  of  DNA  replication  (Fig.2.4.D).  A  7900HT  Sequence  Detection 
machine  (Applied  Biosystems,  California  USA)  is  then  able  to  determine  the 
relative  levels  of  either  the  VIC  or  FAM  dyes,  thereby  determining  the  specific 
genotype. 
 
Preparing the DNA 
 
In  contrast  to  traditional  PCR  and  MADGE  based  technology,  the  Taqman® 
system enables high throughput genotyping in a 384 well format. In order to use 
this system, DNA was first standardised to an optimal concentration of 1.25ng/µL 
using  the  same  methodology  described  in  section  2.2.  A  Biomek  2000  robot 
(Beckman-Coulter, High Wycombe UK) was used to aliquot 4µL of standardised 
DNA from a 96 well stock array into a 384 well plate (5ng total) with 16 wells left 
blank  to  act  as  negative  controls.  A  data  sheet  was  also  compiled  in  order  to   111 
identify  each  well  to  patient  ID  number.  The  plates  were  dried  out  overnight at 
room temperature in sterile paper bags and stored until use.  
 
 
Fig. 2.3: Schematic of the Taqman® assay system. A. represents the annealing of the 
fluorescent probes and oligonucleotides. B. If the fluorescent probe is not identical to the 
DNA sequence, the probe is displaced by the Taq. C. Successful annealing leads to 5‟-3‟ 
exonuclease of the probe. D. The VIC™ and FAM™ labels fluoresce and are picked up by 
the Taqman® machine.  
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Taqman master mix  
 
Forward/reverse  oligonucleotides  and  labelled  probes  were  ordered  using  the 
„Assay  by  demand‟  service  available  on  the  Applied  Biosystems  website 
(www.appliedbiosystems.com).    Section  2.2c  lists  all  the  assays  successfully 
designed by Applied Biosystems for this thesis.  For each 384 well plate, a master 
mix  was  made  of  the  ABgene  QPCR  Rox  mix,  the  individual  assay  mix,  and 
distilled sigma water.  4µL of mix was then applied to each well of the 384 plate 
using a manual Eppendorf 300, 8 channel multi-dispensing pipette and centrifuged 
(Sigma 4-15) at 200g for thirty seconds. A clear plastic lid (ABgene, Surrey UK) 
was applied to seal the plate. 
 
Fig. 2.4: Screen shot of a typical allelic discrimination plot. The three different coloured dots 
represent each individual genotype: Blue and red represent homozygotes with the green 
dots representing heterozygotes. Light blue crosses show the negative controls. Those 
dots which were not tightly clustered (circled in the figure) to a particular group were re-
genotyped. 
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Reading and entering of genotypes 
 
A standard two step heat cycle program on a Thermohybaid (Basingstoke, UK) 384 
well, heated block was used to initiate the PCR reaction (95°C for ten minutes, 
followed by 40 cycles of 95°C for 15s and 60°C for 1min), and all plates were then 
read  on  a  7900HT  Sequence  Detection  machine  (Applied  Biosystems).  The 
7900HT Taqman® machine uses SDS software 2.1 (Applied Biosystems) in order 
to  differentiate  the  different  genotypes  (Fig.  2.6).  SDS  2.1  produces  an  allelic 
discrimination plot as well as assigning genotypes automatically to an excel file 
containing patient ID numbers according to array position. To ensure no incorrect 
inputting of data, a second researcher validated all the genotypes before the data 
was finally entered into the analysis database.  
 
 
2.2c Specific Gene variants 
 
UCP2 -866G>A; rs659366 and UCP3 -55C>T; rs1800849 
 
 
These variants were genotyped in NPHSII using the RFLP method with the help of 
Dr Jeff Stephens and by using Taqman® genotyping in HIFMECH and JAM with 
the help of Kah Wah Li.  Dr Jeff Stephens kindly provided the RFLP conditions.  
The details of the Oligonucleotides and PCR and digest conditions can be found in 
table 2.1a and 2.1b repectively.  The Taqman oligonucleotides and probes can be 
found in table 2.1c. 
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Table 2.1a PCR conditions for genotyping by RFLP 
Variant   Oligonulceotides 
DNA ( l) 
POLMIX 
BSA 
MG(mmol) 
Conditions 
(
OC) 
Fragment 
Length 
(bp) 
UCP2 -866 
CACGCTGCTTCTGCCAGGAC 
AGGCGTCAGGAGATGGACCG 
1.5 
NH4 
YES 
1.5 
4 MINS @ 95 
45s @ 90 
30s @ 60  
60s @ 72 
(30 CYCLES) 
5 MINS @ 72 
360 
UCP3 -55 
GGATAAGGTTTCAGGTCAGGC 
AAGGGATGAGGGAGGAGAAA 
1.5 
NH4 
YES 
1.5 
4 MINS „ 95 
40s @ 95 
55s @ 30 
60s @ 72 
(30 CYCLES) 
5 MINS @ 72 
194 
 
 
 
Table 2.1b The digest conditions for genotyping by RFLP 
 
Variant   Allele  Enzyme  
Buffer 
BSA 
Incubation 
(
OC)  
Fragment 
Length (bp) 
UCP2 
G 
A 
Mlu1 
NEB Buffer 2 
NO 
37 
290 + 70 
360 
UCP3 
C 
T 
HaeII 
NEB Buffer 2 
NO 
37 
110 + 64 + 20 
110 + 84  
All enzymes and buffers were supplied by New England Biolabs. 
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Table 2.2 Taqman assays design for all variants  
 
Variant 
 
Primers 
 
Probes 
 
 
UCP 2 
 
GCCAGAGGGCCCAATTGTT 
GGGCCTGGTTCGCTTTAATT 
 
 
VIC-CACGCGTCAGTTAC-NFQ 
FAM-TTCACGCATCAGTTAC-NFQ 
 
UCP3 
 
GCTGTCAACCAACTTCTCTAGGATA 
ACTGTTGTCTCTGCTGCTTCTG 
 
VIC-TCTTATACACACGGGCTGA-NFQ 
FAM-TCTTATACACACAGGCTGA-NFQ 
 
 
 
2.3 Biochemical assays 
For  all  biochemical  assays  blood  was  collected  in  EDTA-containing  tubes  and 
centrifuged  immediately  (unless  specified).   The  plasma  was  aliquoted  into 
microtubes and placed into dry ice.  The samples were stored at -80
0C until use.  
All assays were performed on plasma not previously thawed.  All the assays were 
performed by myself with the help of Jasmin Matin in the JAM study.  The Plasma 
F2-isoprostanes were measured by myself in the laboratories of Professor Kevin 
Moore in the Centre for Hepatology at the Royal Free campus of UCL. 
2.3a Total Antioxidant Status (in House) (TAOS) 
Plasma TAOS was measured by a photometric microassay previously described 
by Sampson et al (Sampson MJ,2002). The TAOS of plasma was determined by 
its  capacity  to  inhibit  the  peroxidase-mediated  formation  of  the  2,2-azino-bis-3-
ethylbensthiazoline-6-sulfonic  acid  (ABTS
+)  radical.  In  the  assay,  the  relative 
inhibition  of  ABTS
+  formation  in  the  presence  of  plasma  is  proportional  to  the 
antioxidant capacity of the sample.  There are two arms to the assay (Figure 2.5),   116 
the test arm and a control arm with phosphate buffered saline (PBS) instead of 
plasma.      Plasma  TAOS  is  therefore  inversely  proportional  to  the  degree  of 
oxidative stress in the sample.  
 
Fig 2.5 Measurement of plasma TAOS 
ABTS
ABTS+
Fluorescence at 405nm
H2O2
+ve
ABTS
ABTS+
H2O2
Fluorescence at 405nm
Plasma
+ve -ve
PBS
% Inhibition of  reaction (TAOS) = Control Abs-Test Abs x 100%
Control Abs
Control Arm Test Arm
 
Method 
 
Plasma (2.5 l) was placed in duplicate into 90 wells of a 96 well Nunc Immuno 
Maxisorp 96 well-plate.  2.5 l of PBS was added to 2 wells, an internal control 
sample  to  2  wells  and  2  wells  were  also  left  empty  (as  blank  controls).  The 
following solutions were subsequently added to each well:- 
 
-20 l of ABTS (20mmol/l). 
-20 l of HRP (30mU/ml). 
-40 l PBS (pH 7.4). 
 
The reaction was then initiated by the addition of 20 l of H2O2 (final concentration 
0.1 mmol/l). At the end of ten minutes the absorbance due to the accumulation of 
ABTS
+ in the test sample was read, along with the control (containing 2.5 l of PBS 
instead  of  plasma).    This  was  performed  using  a  Tecan  GENios  plate  reader 
(TGPR) utilising the Magellan 3 software package. The difference in absorbance   117 
(control  absorbance  minus  test  absorbance)  divided  by  the  control  absorbance 
(expressed as a percentage) was used to represent the percentage inhibition of the 
reaction.  
 
2.2b Total Antioxidant Status (Randox, Ireland) (TAS) 
 
Plasma  TAS  is  based  on  a  similar  principle  to  TOAS,  in  that  the  sample  anti-
oxidant capacity is derived from the ability of the sample to inhibit the peroxidase-
mediated  formation  of  the  ABTS
+radical.    The  TAS  kit  uses  the  peroxidase 
metmyoglobin rather than horseradish peroxidase which gives a radical cation that 
is measured by the measurement of absorbance at 600nm (Fig 2.6).   The assay is 
calibrated  using  a  6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic  acid 
standard (Randox Ireland) and a PBS blank.  Quality control is possible by the 
inclusion of a control human serum sample of known TAS.   
 
 
 
Fig 2.6 The creation of the ABTS radical in the Plasma TAS kit  
HX-Fe+++  + H2O2 X-[Fe++++ =0] +  H2O
ABTS® + X-[Fe++++ =0] ABTS®+  + HX-Fe+++
HX + Fe +++  = Metmyoglobin
X-[Fe++++ =0] = Ferrylmyoglobin
ABTS®= 2,2‟-Azino-di-[3-ethylbenzthiazoline sulphonate]
ABTS®is a registered trademark of Boehringer Mannheim
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Method. 
 
1. Cuvette method 
 
20 l  of  sample,  standard  or  control is  added  to  the  cuvette followed  by  1ml  of 
“chromagen”.  The absorbance is read at 600nm (A1) and 200 l of “substrate” was 
added and incubated at 37
0C for 3 minutes.  Absorbance was read a second time 
(A2). All experiments were completed in duplicate. 
 
2. Microplate Method  
 
2.0 l of sample standard or control was placed in duplicate into 90 wells of a 96 
well Nunc Immuno Maxisorp 96 well-plate.  Using an automatic Biohit repeating 
dispenser, 100 l of “chromagen was added to each well.  The TGPR was used to 
read  absorbance  (A1)  and  then  20 l  of  “substrate”  was  added  and  the  plate 
maintained  at  37
0C  for  3  minutes  within  the  TGPR.    After  3  minutes  the 
absorbance was read again (A2). 
 
The results were exported to an Excel spreadsheet.  Sample Absorbance (ΔA) was 
calculated A2-A1.  For each set of solutions a factor was derived from which the 
TAS could be calculated (Fig 2.7) 
 
 
Fig 2.7 The calculation of TAS 
Total Antioxidant Status:
Factor =       conc of standard   
[ΔA blank – ΔA Standard]
mmol/l = Factor x [ΔA blank – ΔA Sample]
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2.3c Bioxytech® AOP-490
TM (Oxis International Inc, USA) 
 
The AOP-490
TM assay measures the combined antioxidant action of the sample by 
assaying  its  ability  to reduce  the  Cu
++  to  Cu
+.    The  chromogenic  reagent  (2,9-
dimethyl-4,7-diphenyl-1,10-phenanthroline)  forms  a  2:1  complex  with  Cu
+  which 
has a maximum absorbance at 490nm.   The assay is calibrated using a standard 
curve derived from 5 uric acid standards and a deionized water control. 
 
Method 
 
The standard was prepared by adding 1.5ml of water to the “standard vial” and 
then performing four further dilutions of 500 l of standard to 500 l of water.  The 
samples or standard were diluted by adding 15 l to 585 l “R1” which contained the 
chromagen.  200 l of this solution was then added, in duplicate, to a well in the 
provided microplate.  The absorbance was measured at 490nm in the TGPR (A1) 
and 50 l of “R2” (containing the copper ions) was added to each well using an 
automatic  Biohit  repeating  dispenser.    The  plate  was  incubated  at  room 
temperature for 3 minutes and the 50 l of stop solution was added to each well 
and  repeat  absorbance  measured  (A2).    The  absorbance  of  the  sample  was 
calculated as A2-A1.  The absorbance of a sample was derived from a standard 
curve and the calculation of a linear regression equation (SPSS 12.0) and the anti-
oxidant action reported as mM uric acid equivalents (Fig 2.8). 
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Fig 2.8 A typical standard curve for the AOP-490
 TM assay 
 
Determine the Uric acid equivalents for each sample from the curve and sample net absorbance by 
solving for “x”. 
[Example provide in technical specifications AOP-490
 TM ] 
 
2.3d Glutathione/ Reduced Glutathione Ratio (Calbiochem,UK) 
 
Reduced  glutathione  (GSH)  is  a  major  antioxidant  in  human  tissues,  becoming 
oxidized  (GSSG)  during  the  conversion  of  hydrogen  peroxide  or  lipid 
hydroperoxides to water and the respective alcohol.  When exposed to oxidative 
stress  the  ratio  of  GSH/GSSG  will  decrease  as  a  consequence  of  GSSG 
accumulation, which makes this a useful indicator of oxidative stress.  Accurate 
measurement of GSSG requires the prevention of further oxidation of GSH.  This is 
achieved by the addition to the sample, before storage, of 1-methyl-2-vinylpyridium 
trifluoromethane-sulfonate  (M2VP),  a  thiol  scavenger  reagent  that  leaves  only 
GSSG.  A second sample is stored  without M2VP to assay GSH + GSSG.  The 
detectable product is derived from the reaction of Ellman‟s reagent (5,5‟-dithiobis-
2-nitrobenzoic  acid  [DTNB])  with  GSH  (Fig  2.9).    The  GSSG  in  the  sample  is 
converted to GSH by the action of Nicotinamide adenine dinucleotide phosphate 
(NADPH) catalyzed by Glutathione reductase (GR). 
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Fig 2.9 The measurement of GSH/GSSG (see text for explanation of abbreviations) 
A) GSSG          B) Total GSH 
 
Each GSSG molecule is equivalent to 2 GSH molecules. 
 
Method  
 
The samples and reagents were prepared as follows 
 
1.  Blood for GSH - 50 l of whole blood collected in an EDTA containing tube 
was placed in a microtube in dry ice and then stored at -80
0C until use. 
2.  Blood for GSSG - 100 l of whole blood collected in an EDTA containing 
tube  was  placed  in  a  microtube  containing  10 l  of  provided  M2VP  and 
frozen in dry ice and then stored at -80
0C until use. 
3.  GSH buffer – The provided vial was reconstituted in 650mls of deionized 
water. 
4.  NADPH – The provided vial was reconstituted in 7.5mls of assay buffer on 
the day of use and discarded after 24 hours 
5.  5% Metaphosphoric acid (MPA) was prepared daily. 
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1. GSSG assay 
 
The sample was prepared by mixing the thawed sample with 290 l of ice cold MPA 
followed by centrifuge at 1000x g for 10 minutes.  The extract was diluted in the 
GSSG assay buffer provided (50 l extract + 700 l buffer) and stored on ice until 
use.    The  low  concentration  standards  were  used  for  GSSG  measurement 
(0,0.1,0.25,0.50  M GSH). 
 
2. GSH assay 
 
The sample was prepared by mixing the thawed sample with 350 l of ice cold MPA 
followed by centrifuge at 1000x g for 10 minutes.  The extract was diluted in the 
GSH assay buffer as above (50 l extract + 3ml buffer) and stored on ice until use.  
The high concentration standards were used for GSH measurement (0,0, 1.5,3.0 
M GSH). 
 
The reagents were then added, in duplicate, to the  Nunc Immuno Maxisorp 96 
well-plate in an identical method for both the GSH and the GSSG assay. 
 
1.  50 l of sample, standard or blank 
2.  50 l of chromagen (Ellaman‟s reagent) 
3.  50 l of Enzyme (GR) 
4.  Mix and incubate at room temperature for 5 minutes 
5.  50 l of NADPH 
6.  Record the change of absorbance at 412nm for 3 mins 
 
Calculation 
 
The TGPR automatically calculated the gradient of the accumulation of chromagen 
based  on  5  absorbance  readings  over  the  3  minutes.      Standard  curves  were   123 
generated for the standards based on these reaction rates in a similar way to the 
AOP-490
TM kit (Fig 2.8).  The actual concentrations were calculated allowing for 
dilution by multiplying the total GSH by a dilution factor of 488 and the GSSG by a 
factor of 30.  Once the calculations of the concentration of total GSH and GSSG 
are made the ratio can be calculated.  GSH is calculated by total GSH – GSSG(x2) 
and the ratio GSH/GSSG can then be calculated. 
 
2.3e  Plasma F2-isoprostanes 
 
Measurement  of  isoprostane  was  performed  by  Gas  Chromatography  Mass 
Spectroscopy (GC-MS) after extraction, purification and derivitisation.  The ability 
of  the  sample  to  withstand  oxidative  stress  was  also  assessed  by  the 
measurement  of  isoprostanes  in  a  200 l  sample  of  plasma  incubated  with  3-
Morpolinosyndomimime chloride (SIN-1) at 37
0C for six hours (Ferraro B,2003).  
SIN-1  is  a  peroxynitrate  releasing  compound  generating  superoxide  and  nitric 
oxide.     The final concentration of SIN-1 was 11mmol (100 l of 2.2mg/ml added). 
 
Extraction  
 
Prior to extraction the phospholipids underwent alkaline hydrolysis.  To either 800 l 
of sample or the 200 l SIN-1 sample 10 l of 10mg BHT in 1ml methanol and 40 l  
of 8.8mg Trolox in 1 ml methanol was added.  An equal volume of 25% Potassium 
hydroxide was then added with D4-PGF2   standard.  This was then incubated at 
37
0C for 45 minutes.  The sample was adjusted to pH 3 using 1M HCL. 
 
Initial  extraction  of  the  prostaglandin-like  compound  was  performed  using  tC18 
columns.  Solid  phase  cartridges  were  used  to  remove  water  soluble  and 
uncharged  organic  components,  taking  advantage  of  the  lipid  nature  of  the 
molecule combined with the polar –OH and –COOH groups.  These samples were 
prepared by washing with 6ml methanol, followed by 6ml of pH 3.0 water. The 
sample was then loaded onto the column using a pastette and washed with 6ml of   124 
pH 3.0 water to remove water soluble compounds. At this pH, isoprostanes remain 
relatively  uncharged  and  are  bound  to  the  solid  phase.  The  column  was  then 
washed with 6ml of heptane to elute completely hydrophobic lipids. Isoprostane 
was then eluted into polypropylene tubes with 6ml of heptane, ethyl acetate and 
methanol (40:50:10), and dried under nitrogen. 
 
Derivatization- Step 1. Preparation of pentaflourbenzyl ester  
 
The pentafourobenzyl ester was prepared by the addition of 20 l 10% DIPEA (N,N-
di-isopropylethylamine  in  acetonitile  (AcN)  and  40 l  10%  PFBR 
(pentaflourobenzylbromide) in AcN to each sample in the fume hood. This was left 
at room temperature for thirty minutes and dried under nitrogen. 
 
Purification 
 
The  samples  then  underwent  an  additional  purification  with  thin  layer 
chromatography (TLC). TLC plates (Whatman 60A, Linear K6D, 5x20cm, 250 m 
thick) were pre-run in 100ml methanol for sixty minutes and subsequently dried. A 
TLC tank  was  prepared  with  100ml  of  chloroform  and  ethanol  (93ml:  7ml)  and 
allowed  to  equilibrate  for  sixty  minutes.  Samples  were  resuspended  in  40 l  of 
methanol  and  chloroform  (1:2),  loaded  onto  the  plates  and  run  along  with  a 
separate plate loaded with 5ng of the methyl ester of PGF2 , which was run as a 
standard.  The  solvent  front  was  run  to  13cm  above  the  application  zone.  The 
plates  were  then  dried  and  the  position  of  the  standard  visualised  with  2% 
phosphomolybolic acid. The sample plates were then scraped 1.5cm above and 
1.2cm below the solvent front of the standard, and the PFBR esters extracted in 
1ml of ethyl acetate and methanol (1:1). The samples were then vortexed for two 
minutes and centrifuged for two minutes. The supernatant was then removed and 
dried under nitrogen.  
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Derivatization-Step 2. trimethylsilyl derivative 
 
Final  esterification  was  achieved  by  adding  10 l  of  anhydrous  DMF 
(dimethylformamide) and 20 l BSTFA (bis-siylyltrimethylfluoroacetamide) for thirty 
minutes.  Samples  were  dried  under  nitrogen  and  subsequently  resuspended  in 
20 l  of  undecane,  transferred  to  a  conical  autosampler  vial  using  a  Hamilton 
syringe and sealed. 
 
 Gas Chromatography-Mass Spectroscopy 
 
Four  microlitres  of  each  sample  was  then  delivered  to  the  GC-MS  apparatus 
(Fissons GC 8000 series coupled to a Fissons Trio 1000 MS). After injection the 
isomers were separated by gas chromatography with the 8-iso-PGF2  appearing 
first. 
 
Negative ion chemical ionization with ammonia was used to determine the mass 
spectrum. Selective ion monitoring at 569m/z and 573m/z was performed, as these 
were  the  masses  of  the  predominant  fragments  of  the  undeuterated  and 
deuterated forms of the isomers respectively. The concentration of F2-isoprostane 
in  the  sample  was  then  calculated  by  dividing  the  measure  from  the  unknown 
sample by the standard and multiplying by concentration of the standard. Plasma 
F2-isoprostane  results  were  expressed  as  pg/ml.  The  inter  assay  CV  is  7% 
(Personal Communication, Dr Ali Reza, Department of Hepatology, UCL). 
 
2.3f  Plasma Non-Esterified Fatty Acids 
 
Plasma Non-esterified fatty acids (NEFA) were measured by an in vitro enzymatic 
colormetric assay (Wako Chemicals GmBH, Neuss, Germany).   The test utilizes 
three  steps.   Firstly, the generation  of  Acyl-Coa  from  NEFA  using the enzymre 
Acyl-CoA  Synthase.    Secondly  the  generation  of  Hydrogen  peroxide  by  the 
addition of Acyl-CoA oxidase.  Thirdly, the generation of colour from the reaction   126 
between  4-aminophanazone  and  the  hydrogen  peroxide.    Oleic acid (282mol/L) 
was used as the standard and distilled water as negative control. 
 
Method 
 
The assay was performed, in duplicate, in a Nunc Immuno Maxisorp 96 well-plate 
as follows. 
 
1.  5µl sample, standard or control 
2.  100µl Reagent A (dissolved in solvent A) 
3.  Mix well and leave for 10 minutes @ 37
oC 
4.  200µl Reagent B (dissolved in solvent B) 
5.  Mix well and leave for 10 minutes @ 37
oC 
6.  Read in the Tecan Plate reader @ 550nm. 
 
The result is calculated as follows 
 
                  Concentration of  
                  standard (mg/dL)* 
Free fatty acids (mg/dL*) = Absorbance of sample x  --------------------------------------
                  Absorbance of  
                  Standard 
*concersion factor: mg/dL x0.035=mmol/L 
 
 
2.4 Clinical Protocols 
 
The clinical protocols were all recruited and performed by myself.   All the studies 
have  been  approved  by  committee  alpha,  Combined  UCL/UCLH  local  ethics 
committee and for the fatty meal a site-specific assessment was also approved for 
the Institute of Child Health, UCL.   Healthy subjects were recruited from laboratory   127 
and clinic staff while subjects with diabetes were recruited from the UDACS study. 
Excluded were those with clinically manifest CVD, smokers, those with connective 
tissue or other inflammatory disease and those with malignancy or other terminal 
illness.  Those on anti-inflammatory medications such as steroids or NSAID‟s were 
also excluded. Medication was omitted on the day of the study but patients were 
encouraged to take any medication after the study was completed. Written consent 
was  obtained  and  all  subjects  were    given  an  information  leaflet  regarding  the 
study.  A letter was sent to the General Practitioner of each consenting patient to 
inform them of the patient‟s participation in the study.  A small snack was provided 
for all patients before they left. 
 
2.4a Oral Glucose tolerance test 
 
The subjects attended after an overnight fast.  Blood was drawn from a cannula 
placed in the left ante-cubital vein and collected at ten minute intervals in relation to 
the  ingestion  of  a  standard  75g  oral  glucose  load  (394ml  Original  Lucozade, 
Glaxosmithkline (GlaxoSmithKline,2005)). Glucose was collected in oxalate tubes 
(grey top) and assayed on a YSI 2000 glucose analyzer (CV 0.9%).   Blood was 
also collected into EDTA-containing tubes and prepared for the measurement of 
TAOS.  
 
2.5b Meal rich in used cooking oil  
 
The subjects attended after an overnight fast.  Blood was drawn from a cannula 
placed in the left ante-cubital vein for assessment of lipid profile, renal function and 
glycated  haemoglobin,  and  analysed  using  routine  methods  by  Chemical 
Pathology Department, Middlesex Hospital.  Blood was also taken for glucose and 
oxidative stress markers as above. The subject was then given a prepared meal 
rich in used cooking oil.  Blood was taken for glucose and oxidative stress markers 
every hour for four hours. 
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Used cooking oil meal 
The meal consisted of 100g of vanilla ice cream (Tesco value soft serve), 200ml of 
skimmed milk, 50ml evaporated milk, 10g Yoghurt (Onken Natural), 50g of tinned 
apricots (no syrup), one egg and 46g of used cooking oil obtained from a local 
commercial restaurant (Potion Bar and Restaurant). The cooking oil was always 
obtained  at  the  same  time  every  week,  on  a  Friday  afternoon.    The  oil  was 
changed by the restaurant on Saturday morning so had been used for one week. 
The  fat  was  stored  at  -20
0C  and  protected  from  light  until  use.  The  meal  was 
blended and presented as a milkshake with chocolate syrup added as flavour if 
required.  This provided 64.4g of fat of which 30g was saturated.  The meal also 
contained 62.5g of carbohydrate and 20.5 g of protein (Williams MJA,1999).  The 
subjects were requested to drink the meal over a period of 15 minutes and the 
meal was well tolerated. 
2.5 Statistical Analysis 
Statistical analysis was performed using SPSS (version 12.1, SPSS Inc., Chicago) 
or  „Intercooled STATA‟ package (version 7.0, STATA Corporation, Texas).  The 
analysis was performed by Jackie Cooper, Fotios Drenios and myself.  For gene 
association analysis, data are reported for those individuals amongst whom high-
throughput genotyping was successful. 
Deviations  from  Hardy-Weinberg  equilibrium  were  considered  using  chi-squared 
tests. Hardy-Weinberg equilibrium gives the expected genotype distribution based 
on  the  observed  frequency  of  the  rare  allele  (q)  and  common  allele  (p)  as 
p
2+2pq+q
2, where p
2 is the predicted frequency for homozygosity of the common 
allele, q
2 is the predicted frequency for homozygosity of the rare allele and 2pq, the 
heterozygotes. These frequencies are expected provided the sample is drawn from 
a population with random mating and no strong selection. 
Specific details are include in the relevant section but in general, allele frequencies 
are shown with the 95% confidence interval.  Analysis of variance (ANOVA) was   129 
used to assess the association between genotypes and baseline characteristics on 
normally distributed data, or on other data after appropriate transformation.  Chi-
squared  tests  were  used  to  compare  differences  in  categorical  variables  by 
genotype. 
No  adjustment  was  made  for  multiplicity  of  testing.    However,  analysis  always 
followed an a-priori hypothesis or design.  In all cases a P value of less than 0.05 
was considered statistically significant.   
 
In NPHSII, survival analysis with respect to the prospective risk of cardiovascular 
disease or type 2 diabetes was carried out using Cox proportional hazards model, 
„failure‟ being the first CHD event or diagnosis of type 2 diabetes.  Results are 
presented as hazard ratios (HR) with their corresponding 95% confidence interval 
(CI).  To allow for differences in baseline data according to age and practice, age 
was included as a covariate in the model and data stratified by practice.   
 
2.6  Reagents and commonly used stock solutions and equipment 
 
Reagents 
 
Plasma  Total  antioxidant  status:  2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic  acid 
(ABTS),  Horseradish Peroxidase (HRP) and Hydrogen Peroxide (H2O2). All supplied by 
Sigma (Poole, UK).  
 
Plasma F2-isoprostane: D4-PGF2  standards supplied by Cayman Chemical (MI, USA). 
tC18 (-Si-C18-H37: tc18 Sep-Pak) columns (Waters, MA, USA). N,N-di-isopropylethylamine 
Pentaflourobenzylbromide,  dimethylformamide  (DMF)  and  bis-
siylyltrimethylfluoroacetamide  (BSFTA)  and  TLC  plates  (Whatman  60A,  Linear  K6D, 
5x20cm, 250 m thick). All other reagents were supplied by Sigma-Aldrich (Poole, UK).  
 
DNA Extraction: All reagents were supplied by Sigma (Poole, UK).  
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Polymerase  chain  reaction  (PCR):  PCR  oligonucleotides  and  Taq  polymerase  were 
supplied by Invitrogen Ltd (Paisley, UK). 50mM MgCl2 supplied by Bioline (London, UK). 
All  necessary  restriction  enzymes  were  supplied  by  New  England  Biolabs  Inc 
(Hertfordshire,  UK)  or  Roche  Diagnostics  (Lewes,  UK).  dNTPs  were  supplied  by 
Pharmacia Biosystems Ltd (Milton Keynes, UK). 96 well PCR plates were obtained from 
Corning Inc. (Hemel Hempstead, UK). All other reagents supplied by Sigma-Aldrich Ltd. 
(Poole, UK).  
 
Gels: 19:1 30% acrylamide:N,N‟-methylenebenebisacrylamide was supplied by Protogel, 
National Diagnostics (Hull, UK). TEMED (NNN‟,N‟-tertramethylethylethylenediamine and 
Ammonium persulphate (APS) were supplied by BDH (Leicestershire, UK). Agarose was 
supplied by Helena Biosciences (Sunderland, UK) and 10× Tris Borate EDTA (TBE) was 
supplied  by  Severn  Biotech  Ltd  (Worcestershire,  UK).  1kb  ladder  was  supplied  by 
Invitrogen Ltd (Paisley, UK). 
 
Taqman assays: All Taqman assays were obtained from Applied Biosystems (California, 
USA). Taqman Absolute QPCR Rox mix and 384 well plates were supplied by ABgene 
(Surrey, UK).  
 
 
Commonly used stock solutions 
 
Ammonium persulphate solution (APS): 0.25g APS dissolved in 1ml distilled water.  
MADGE Loading Dye: 0.0015% bromophenol blue; 0.015% xylene cyanol; 10% glycerol; 
10mM EDTA 
 
NH4  polmix buffer:  16mM  [NH4]2  SO4; 67mM  Tris-HCL  pH8.4;  0.01%  Tween 20;  2mM 
dATP; 2mM dTTP; 2mM dGTP; 2mM dCTP 
 
Sticky  Silane:  0.5%  v/v glacial acetic acid; 0.5%  v/v  γ  methacryloxy-propyl-trimethoxy-
silane 
 
TBE buffer: 0.04M Tris-borate; 1mM EDTA pH7.4 
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Reagent A (sucrose lysis buffer): 0.32M sucrose; 5mM MgCl2; 10mM Tris-HCl ph7.5; 1% 
Triton-X-100 
 
Reagent B (nuclei lysis buffer): 10mM Tris-HCl pH8.2; 0.4M NaCl; 2mM Na2EDTA pH 8.0 
TE Buffer: 10mM Tris-HCl; 1mM EDTA pH 7.6 
 
Equipment 
 
Automatic pipettes 
 
Manual Eppendorf 300, 8 channel pipette (Eppendorf, Hamburg, Germany). 
Eppendorf multipette Pro repeating dispenser (Eppendorf, Hamburg, Germany). 
Finnipipette multichannel dispenser (Life Sciences, Basingstoke, Hants, UK). 
Automatic Biohit repeating dispenser (Alpha Laboratories, UK) 
 
Plate Reader 
Tecan GENios (Tecan Group Ltd, Switzerland) 
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2.7 Declaration of activity 
 
Chapter 3 NPHSII 
 
Standardised DNA was available to me.  Genotyping was performed by a mixture 
of RFLP and Taqman.  I performed this with the help of Dr J. Stephens, Miss J. 
Matin and Ka-Wah Li.  Statistical analysis was directed by me with the help of Ms 
J. Cooper. 
 
Chapter 4 HIFMECH 
 
Standardised DNA was available to me.   I performed genotyping by Taqman with 
the help of Miss Ka-Wah Li.  Statistical analysis was directed by me with the help 
of Ms J Cooper and Ms E. Dawe. 
 
 
Chapter 5 
 
Markers of Oxidative stress in JAM 
 
I performed the selection and assessment of different assays to measure plasma 
markers of oxidative stress.  I performed the assays on the samples from the JAM 
study with the help of Miss J. Matin.  I directed the statistical analysis with the help 
of Dr Brendan Pearce (University of Washington). 
  
JAM 
 
Standardised DNA was available to me.  I performed genotyping using Taqman 
with the help of Miss Ka-Wah Li.  Statistical analysis was directed by me with the   133 
help  of  Dr  Brendan  Pearce  (University  of  Washington)  who  performed  the 
hereditability calculations. 
 
Chapter 7 Clinical Studies 
 
The  patients  and  normal  volunteers  were  recruited  by  me.    I  prepared  and 
administered the glucose drink and test meal.  Venous sampling, plasma glucose 
assay,  oxidative  stress  marker  and  NEFA  assays  were  performed  by  me.  I 
measured  plasma  F2-isoprostanes  in  the  Department  of  Hepatology,  UCL 
[Professor  K.  Moore]  with  the  help  of  Dr  Ali  Reza.  Statistical  analysis  was 
performed by me with the help of Dr F. Drenos. 
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3.1 Prospective Risk of Type 2 Diabetes in NPHSII 
 
3.1.1 Introduction 
 
As described in chapter 1, the rate of mitochondrial oxidative metabolism appears 
to be important in the development of T2DM.  UCP2 and UCP3, as part of the 
mitochondrial carrier protein superfamily are, therefore, good candidates for having 
a role in the pathogenesis of T2DM.  The UCP2 and UCP3 genes are located in a 
cluster within 8kb of each other on chromosome 11q13.  A variant associated with 
altered  mRNA  levels  has  been  identified  in  both  these  genes  (UCP2-866G>A; 
UCP3-55C>T).   
 
As seen in chapter 1, these variants have been associated with both obesity and 
T2DM  traits  which  suggest  that  they  are important in  their pathogenesis (Table 
1.4c and 1.6).  The UCP2-866A is associated with higher mRNA levels and was 
associated with reduced insulin secretion or T2DM in Austrian (Krempler F,2002), 
Italian (D'Adamom M,2004) and Japanese samples (Sasahara M,2004), however, 
the  -866A  allele  was  also  associated  with  lower  subcutaneous  adipose  tissue 
mRNA, but not with T2DM in a mixed race sample from the USA (Wang MY,1999).   
Although  50%  lower  UCP3  protein  has  been  described  in  subjects  with  T2DM 
(Schrauwen P,2001a), the UCP3-55C>T variant, which is associated with altered 
UCP3  mRNA  levels  (Schrauwen  P,1999),  has  not  consistently  been  associated 
with  T2DM.    The  UCP3-55T  allele  was  associated  with  reduced  risk  of  T2DM 
(Meirhaeghe  A,2000),  but  this  was  not  replicated  in  other  studies  (Cassell 
PG,2000; Halsall DJ,2001) . 
  
3.1.2 Aims 
 
The purpose of this research was to clarify the inconsistencies identified in cross- 
sectional gene association studies, and to further elucidate the role of identified 
genetic variation in the UCP2-UCP3 gene cluster in the development of T2DM.   137 
3.1.3 Methods 
 
The  Second  Northwick  Park  Heart  Study  is  a  prospective  study  of  over  three 
thousand men who have now been followed for 15 years.  The men were healthy 
at  recruitment,  based  on  a  definition  that  excluded  men  with  cardiovascular 
disease,  malignancy  or  taking  regular  medication.      Therefore,  men  with  diet 
controlled T2DM, were not excluded from the study.  Analysis excludes these men 
unless stated otherwise.  New cases were identified by practice note search for 
physician diagnosed and treated T2DM according to current national guidelines.   
Obesity was defined as BMI over 30kg/m
2.  Population attributable fraction (PAF) 
represents the impact of the variant on the sample in question, and is a composite 
of the exposure to the risk and the magnitude of the risk and is estimated as pd * 
(Hazard ratio -1/ Hazard ratio), where pd is the proportion of cases exposed to the 
risk factor (Greenland S,1993). 
 
3.2.  Baseline Characteristics Predicting the Development of Type 2 
Diabetes 
 
The NPHSII contains a total of 3012 eligible men.  There were a total of 76 (2.5%) 
of  men  with  T2DM  at  baseline.    At  10  years  86  (2.9%)  new  cases  had  been 
recorded  and  at  15  years  169  (5.6%)  new  cases  were  recorded.    The  total 
incidence at ten years was 5.4% and 8.1% at 15 years. 
 
The baseline characteristics associated with the development of T2DM are shown 
in table 3.1a including baseline subjects with diabetes, and in table 3.1b excluding 
baseline subjects with diabetes.  The factors associated with diabetes are similar in 
both analyses [blood pressure, lipid parameters and CRP], with age being only 
significantly associated with diabetes if baseline subjects with T2DM are included. 
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Table 3.1a Baseline characteristics and their association with the development of 
T2DM over 15 years-including baseline subjects with T2DM 
 
 
 
 
No diabetes 
N=2767 
With 
diabetes  
N=245 
HR* (95% CI)  P value 
Age (years)  56.0 (3.5)  56.7 (3.4)  1.31 (1.08-1.58)  .005 
SBP
†(mmHG)  136.3 (18.7)  142.3 (18.8)  1.32 (1.16-1.51)  <0.0001 
DBP(mmHG)  84.4 (11.4)  85.6 (11.1)  1.08 (0.94-1.23)  0.26 
BMI
†(kg/m
2)  26.0 (3.3)  28.5 (4.0)  1.95 (1.71 – 2.22)  <0.0001 
Smoking  791 (28.6%)  68 (27.8%)  0.96 (0.72-1.29)  0.80 
Cholesterol(mmol/L)  5.72 (1.01)  5.85 (1.09)  1.15 (1.01-1.31)  0.04 
Triglyceride
†(mmol/L)  1.75 (0.92)  2.31 (1.2)  1.69 (1.48-1.93)  <0.0001 
Fibrinogen
†(g/l)  2.71 (0.52)  2.76 (0.51)  1.06 (0.93-1.21)  0.37 
CRP
†(mg/l)  2.92 (3.44)  3.96 (4.32)  1.27 (1.10-1.46)  0.001 
See Table 3.1b for key 
 
Table 3.1b Baseline characteristics and their association with the development of 
T2DM-excluding baseline subjects with T2DM 
 
  No diabetes 
N=2767 
With 
diabetes  
N=169 
HR* (95% CI)  P value 
Age (years)  56.0 (3.5)  56.3 (3.0)  1.16 (0.93-1.46)  0.19 
SBP
†(mmHG)  136.3 (18.7)  141.3 (19.3)  1.30 (1.11-1.52)  0.001 
DBP(mmHG)  84.4 (11.4)  86.2 (11.3)  1.14 (0.98-1.34)  0.09 
BMI
†(kg/m
2)  26.0 (3.3)  28.6 (3.7)  1.86 (1.65 – 2.10)  <0.0001 
Smoking  791 (28.6%)  54 (32.0%)  1.29 (0.93-1.79)  0.13 
Cholesterol(mmol/L)  5.72 (1.01)  5.90 (0.98)  1.20 (1.03-1.39)  0.03 
Triglyceride
†(mmol/L)  1.75 (0.92)  2.27 (1.7)  1.55 (1.34-1.80)  <0.0001 
Fibrinogen
†(g/l)  2.71 (0.52)  2.78 (0.53)  1.17 (1.00-1.36)  0.11 
CRP
†(mg/l)  2.92 (3.44)  4.05 (4.36)  1.37 (1.16-1.61)  <0.001 
†geometric mean (approx sd) 
CRP measurements made after diabetes was recorded are excluded from the analysis (n=2) 
 +age and practice adjusted hazard ratio for 1 sd increase in all variables except smoking 
(current:non), obesity (>30:<30)  and age (5 year increase). 
   139 
0
.
6
0
0
.
7
0
0
.
8
0
0
.
9
0
1
.
0
0
p
r
o
p
o
r
t
i
o
n
 
w
i
t
h
o
u
t
 
d
i
a
b
e
t
e
s
0 5 10 15
time(years)
BMI<=30 BMI>30
Excluding  the  subjects  with  T2DM  at  baseline,  BMI,  C-reactive  protein  (CRP), 
triglyceride, cholesterol and blood pressure were all associated with increased risk 
of  development  of  T2DM,  with  BMI  conferring  the  highest  risk  (HR  1.86  [1.65-
2.10:p=<0.0001 per increase of 1 SD]. A stepwise model was used to determine 
which  of  these  variables  were  independently  associated  with  T2DM  (table  3.2) 
Cholesterol and blood pressure were no longer associated with T2DM, and BMI 
remained the most significant predictor.  
 
Table 3.2 Baseline Characteristics with an independent association with the risk of 
development of type 2 diabetes (stepwise model) 
  
 
HR
+ (95% CI)  P value 
BMI (kg/m
2)  1.72 (1.49-1.99)  <0.0001 
Triglycerides(mmol/L)  1.27 (1.08-1.49)  0.004 
CRP (mg/l)  1.21 (1.01-1.46)  0.04 
+age and practice adjusted hazard ratio for 1 sd increase. 
 
 When  the  men  were  divided  between  those  whose  BMI  at  baseline  was  high 
enough  to  warrant  a  diagnosis  of  obesity  (>30kg/m
2),  the  rates  of  T2DM  were 
much higher than in the non-obese men (Fig. 3.1).  Obese men were 3.96 [2.87-
5.47] times more likely to go on to develop T2DM (p<0.0001) than non-obese men. 
 
Fig.3.1: Kaplan-Meier plot for the development of type 2 diabetes by the presence 
or absence of obesity.  
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3.3  UCP2-866G>A and prospective risk of Type 2 Diabetes 
 
3.3.1 Genotype Characteristics 
 
DNA was available for 2775 [92%] of men, and genotype was obtained in 2695 
[97%] of men and the frequencies were in Hardy Weinberg Equilibrium (p=0.85).  
The allele frequency for the -866A allele were 0.365 (0.35-0.38).   There was no 
difference in BMI, Systolic blood pressure, triglycerides or CRP between genotypes 
(Table 3.3). 
 
Table 3.3. Baseline characteristics by UCP2 -866 genotype 
 
   UCP2 Genotype   
  GG 
N=1088 
GA 
N=1245 
AA 
N=362 
P value 
BMI (kg/m
2)  26.3 (3.4)  26.2 (3.4)  26.5 (3.5)  0.26 
Blood Pressure 
(mmHg) 
 
137.2 (18.9)  136.8 (18.5)  138.2 (19.8)  0.45 
Cholesterol (mmol/L)  5.71 (1.02)  5.73 (1.00)  5.78 (1.01)  0.59 
Triglycerides (mmol/L)  1.78 (0.94)  1.78 (0.93)  1.88 (1.03)  0.20 
CRP (mg/L)  3.04 (3.56)  2.91 (3.42)  3.31 (3.82)  0.20 
All Geometric means (approximate sds) except Cholesterol. 
  
3.3.2 Risk of Type 2 Diabetes 
 
The genotype frequency did not differ significantly between those who developed 
diabetes and those who did not (no diabetes v diabetes [GG/GA/AA%]: 40/47/13 v 
42/40/18:p=0.16) but a trend to a higher frequency of the AA genotype was seen 
when  the  baseline  subjects  with  T2DM  were  included  (40/47/13  v  42/40/18: 
p=0.06).  The Kaplan-Meier plot (Fig. 3.2) indicates that the UCP-2 AA genotype   141 
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only appears to be associated with the development of diabetes about 5-10 years 
earlier but there is a “catch up” in incidence in the GG+GA men by 15 years. 
   
Fig  3.2:  Kaplan-Meier  plot  for  the  development  of  T2DM  by  UCP2-866G>A 
genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When  15  year  risk  of  T2DM  was  examined  using  this  recessive  model  the  AA 
genotype  was  associated  with  an  increased  risk  of  1.47  (0.97-2.23:p=0.07) 
excluding baseline cases, and 1.49 (1.03-2.14:p=0.03) including baseline cases, 
compared to the GG+GA  men adjusted for age and recruitment site.  This risk 
effect  was  maintained  after  adjustment  for  BMI,  blood  pressure,  cholesterol, 
triglycerides and CRP, with an increased 15 year risk of T2DM of 1.59 times (1.03-
2.45:p=0.04) in AA homozygotes.  The acceleration of onset of T2DM associated 
was also seen in this recessive model (Fig 3.3).  This was confirmed by examining 
the risk of diabetes at 10 years. The genotype difference for risk of diabetes at 10 
years was highly significant (HR [AA v GG/GA] 1.94[1.18-3.19]: p=0.009).   
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Fig.3.3: Kaplan-Meier plot for the development T2DM by UCP2AA genotype based 
on a recessive model 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.3 Interaction with Obesity 
 
As obesity was such a significant risk factor for T2DM the influence of obesity on 
the  UCP2-866G>A  variant  was  examined.    The  risk  of  diabetes  at  15  years 
associated with the AA genotype increased from 1.35 [0.79-2.32; p=0.34] to 5.55 
[2.95-10.45; p=<0.0001] in obese AA men (Fig. 4.4).  There was no evidence of 
interaction, with the effect being purely additive (p=0.85).  This remained the case 
if BMI tertiles were used instead of obesity (p=0.80) or as a continuous variable  
(p=0.26).  There was no difference in absolute (GG+GA v AA Median [IQR]: 0.20[-
0.34  to  0.72]  v  0.20  [-0.3  to  0.88]:  p=0.60)  or  percentage  change in  weight  by 
genotype (0.25 [-0.42 to 0.91] v 0.23 [-0.38 to 1.09]:p=0.63) [Fig 3.7]. 
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Fig 3.4:  The Hazard ratio for the development of type 2 diabetes by UCP2-866 
genotype stratified by the presence or absence of obesity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4  UCP3-55C>T and prospective risk of Type 2 Diabetes 
 
3.4.1  Genotype Characteristics 
 
Genotype  was  available  as  for  UCP2.    The  genotype  frequencies  were  also in 
Hardy  Weinberg  equilibrium  (p=0.16)  with  the  frequency  of  the  rare  UCP3-55T 
allele being 0.23 [0.21-0.24].   The baseline characteristics by genotype are shown 
in table 3.3 with no significant difference for any variable. 
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Table 3.4: Baseline characteristics by UCP3 -55 genotype 
 
  UCP3 Genotype   
  CC 
N=1634 
CT 
N=905  
TT 
N=155 
P value 
BMI (kg/m
2)  26.3 (3.4)  26.2 (3.4)  25.9 (3.3)  0.38 
Blood Pressure 
(sys) (mmHg) 
137.1 (18.8)  136.9 (18.8)  138.0 (19.0)  0.78 
Cholesterol (mmol/L)  5.70 (1.0)  5.77 (1.0)  5.79 (1.0)  0.22 
Triglycerides (mmol/L)  1.79 (0.95)  1.81 (0.94)  1.77 (0.96)  0.90 
CRP (mg/L)  3.02 (3.56)  3.09 (3.60)  2.67 (2.80)  0.37 
All Geometric means (approximate sds) except Cholesterol 
 
 
 
 
3.4.2. Risk of Type 2 Diabetes 
 
There was no difference in genotype frequencies between those with and those 
without type 2 diabetes at 15 years (% with genotype CC/CT/TT without diabetes v 
diabetes; 60.5/33.9/3.6 v 63.0/28.6/8.4:p=0.16), with no difference if the subjects 
with  diabetes  at  baseline  were  included  (60.6/33.9/5.5  v  61.8/27.0/11.2:p=0.19).  
However,  the  Kaplan-Meier  plots for development  of  diabetes  by  genotype  (Fig 
4.5)  and    using  a  recessive  model  (Fig  3.6)  indicate  that  UCP3  genotype  also 
appears  to  accelerate  date  of  onset  of  diabetes.      As  seen  for  UCP2,  the  TT 
genotype  was  associated  with  a  significant  hazard  ratio  [95%CI]  for  the 
development of type 2 diabetes at 10 years (HR[95%CI]; 2.06 [1.06-3.99]: p=0.03) 
but not at 15 years (1.50 [0.85-2.66], p=0.16). 
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Fig  3.5:  Kaplan-Meier  plot  for  the  development  of  T2DM  by  UCP3-55C>T 
genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.6: Kaplan-Meier plot for the development T2DM by UCP3TT genotype based 
on a recessive model 
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3.4.3.Interaction with Obesity 
 
Risk  of  T2DM  was  again  exacerbated  by  obesity,  with  the  risk  associated  with 
UCP3TT genotype increasing to 5.65 ([2.07-15.46]: p<0.001) at 15 years in the 
obese men (Fig.3.8).  The differences were again purely additive, with no evidence 
of interaction if this was considered as BMI tertile, obesity present or not, or BMI as 
a continuous variable (p=0.91, 0.38 and 0.76 respectively).  The increase in risk of 
diabetes could again not be explained by weight gain with no difference between 
genotypes in absolute (CC+CT v TT Median [IQR]: 0.20[-0.34 to 0.74] v 0.13 [-0.32 
to 0.80]: p=0.38) or percentage weight change (0.25[-0.42 to 0.91] v 0.16[-0.42 to 
0.80]: p=0.45)[Fig. 3.7]. 
 
Fig.3.7  The  absolute  and  percentage  change  in  weight  by  UCP2  and  UCP3  
genotype in the NPHSII study at five years. 
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Fig 3.8:  The Hazard ratio for the development of type 2 diabetes by UCP3-55C>T 
genotype stratified by the presence or absence of obesity. 
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3.5  Combined Genotypes and Risk of type 2 Diabetes 
 
 
3.5.1. UCP2-UCP3 Haplotypes 
 
The  two  variants  showed  weak  but  significant  positive  linkage  disequilibrium 
(D‟=0.28, p<0.001). As shown in Table 3.5 all four haplotypes were present in this 
sample. As would be predicted by the single SNP analysis, only the -866A/-55T 
combination was associated with increased risk of diabetes at 10 years (AT v GC 
1.63[1.12-2.36]: p=0.01), and this effect was no longer statistically significant at 15 
years (1.27[0.93-1.73]: p=0.13).   The relatively low frequency of this haplotype 
(9%), and the recessive nature of their effect precluded a robust estimate of the 
additive effect with obesity. 
 
Table 3.5:  UCP2/UCP3 haplotypes and risk of type 2 diabetes at 10 and 15 years 
 
Haplotype  Frequency in 
those without 
diabetes 
Frequency in 
those with 
diabetes 
Hazard Ratio 
[95%CI] 
P value 
10 YEARS         
GC  0.50  0.47  1.00   
GT  0.14  0.10  0.74 [0.47-1.17]  0.19 
AC  0.28  0.28  1.09 [0.76-1.55]  0.64 
AT  0.09  0.15  1.63 [1.12-2.36]  0.01 
15 YEARS         
GC  0.51  0.53  1.00   
GT  0.13  0.10  0.73 [0.50-1.05]  0.09 
AC  0.27  0.25  0.94 [0.72-1.22]  0.64 
AT  0.10  0.13  1.27 [0.93-1.73]  0.13 
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3.5.2 UCP2-UCP3 combined genotypes and Type 2 Diabetes Risk 
 
The percentage of men developing T2DM by combined UCP2-UCP3 genotype is 
shown  in  Table  3.6.    After  adjustment  for  age  and  place  of  recruitment,  men 
homozygous  for  both  rare  alleles  (the    AA-TT  genotype)  were  the  only  group 
showing  a  significant  increased  risk  of  T2DM  at  ten  years  (HR  4.20[1.70-
10.37]:p=0.002) or at 15 years (2.37[1.07-5.2]:p=0.03 
 
Table 3.6: Combined UCP2-UCP3 genotypes and risk of type 2 diabetes at 10 and 
15 years 
 
UCP2  UCP3  10 YEARS  15 YEARS 
% with 
diabetes 
(number) 
HR(95% CI)*  % with 
diabetes 
(number) 
HR(95% CI)* 
GG  CC  3.2 (24/741)  1.00  6.8% (50/741)  1.00 
CT  2.3 (6/265)  0.59 (0.24-1.44)  4.5% (12/265)  0.54 (0.28-1.03) 
TT  9.4 (3/32)  3.00 (0.89-10.04)  9.4% (3/32)  1.36 (0.42-4.37) 
GA  CC  3.8 (25/663)  1.09 (0.62-1.91)  5.4% (36/663)  0.77 (0.50-1.18) 
CT  2.2 (10/461)  0.63 (0.30-1.31)  5.0% (23/461)  0.69 (0.42-1.14) 
TT  1.4 (1/71)  0.38 (0.05-2.81)  4.2% (3/71)  0.56 (0.17-1.81) 
AA  CC  3.7 (6/161)  1.14 (0.46-2.79)  6.8% (11/161)  1.05 (0.54-2.02) 
CT  5.7 (8/141)  1.64 (0.73-3.67)  6.4% (9/141)  0.93 (0.45-1.89) 
TT  13.6 (6/44)  4.20 (1.70-10.37)  15.9% (7/44)  2.37 (1.07-5.25) 
*age and practice adjusted 
 
In order to obtain a more robust estimate of the effect of the combined genotypes, 
the subjects were combined into four groups on the basis of homozygosity for the 
variant alleles (UCP2-UCP3:1= GG+CC, 2= GG+GA-TT, 3= AA-CC+CT, 4= AA-
TT).  Risk of T2DM increased across the groups with increasing numbers of rare   150 
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alleles, progressing from no variant homozygotes to 2 variant homozygotes (1.5% 
of men) at 10 years (p=0.002) and 15 years (p=0.04)(Fig.3.9). 
 
Fig 3.9: Hazard ratios for the development of type 2 diabetes by combined UCP2-
UCP3 group genotype at A) 10 years and B) 15 years of follow up. 
 
 
A) 10 years          B) 15 years 
 
 
 
 
 
 
 
   
 
 
 
 
   
 
 
 
 3.5.3. Interaction with Obesity 
 
When  the  effect  of  the  combined  UCP2-UCP3  genotype  was  combined  with 
obesity, non-obese AA-TT men showed an increased risk of T2DM of 2.50(0.91-
6.86: p=0.08) (Figure 3.10) while obese AA-TT men had an increased risk of 19.23 
(5.83-63.39: p<0.001). The effects of the individual genotypes were additive with 
no evidence of an interaction between the effect of UCP2 and UCP3 genotype (p= 
0.15).  There was also no significant evidence of interaction between the effect of 
combined  genotype  group  and  obesity  (p=0.83)  or  with  BMI  as  a  continuous 
variable (p=0.54).  A Cox regression model with the two genotypes and BMI (as 
tertiles) showed hazard ratios [95%CI] of approximately similar magnitude for the 
two genotypes although the UCP3 risk estimate just crossed one (UCP2 1.74[1.05-
2.88]:p=0.03; UCP3 1.92[0.98-3.76]: p=0.06).  These are slightly lower than the 
single genotype unadjusted hazard ratios and are lower than the risk of developing   151 
type 2 diabetes associated with the middle or upper tertile of BMI (4.13[1.70-10.05] 
and 9.61[4.14-22.32] respectively: p<0.0001 for both).   
 
Fig.3.10: The hazard ratio for the development of type 2 diabetes at 15 years of 
follow  up by combined  UCP2-UCP3 genotype in those above with and without 
obesity. 
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3.5.4   Population attributable Fraction 
 
To  determine  the  impact  of  genotype  on  the  population  using  the  Population 
attributable fraction (PAF) was calculated.  The PAF [95% CI] after 15 years of 
follow up for variation in the UCP2-UCP3 gene cluster was 5.3% [-1.1 to 11.4].    
When obesity was added to this model the PAF was similar at 4.7% [-1.6 to 10.7].  
Obesity  had  a  much  larger  influence,  with  a  PAF  of  21.2%  [14  to  57].    The 
influence  of  variation  in  the  gene  cluster  as  a  whole  was  examined  using  the 
individual genes (Fig. 3.11A).   Variation in UCP2 genotype explained 6 (PAF 3.8% 
[-2 to 9]) cases, variation in UCP3 3 and 8 (1.9% [-1 to 5]) if adjusted for BMI which   152 
is much lower than the 36 (21 [14 to 28]) cases of type 2 diabetes that would be 
explained by obesity. 
 
If PAF is examined at 10 years, then as expected, the influence of genotype is 
higher (11.6% [0 to 21.7]).  The influence of obesity is similar (25.6% [13 to 36]).  
However, as there are fewer cases of new onset Type 2 Diabetes at this time the 
number of cases due to obesity is lower [22].  The extra cases present due to 
genotype was 8 and 4 for UCP2 variation and UCP3 variation respectively (PAF 
8.5% [-2 to 18] and 5.5%[-1 to 12] respectively [Fig: 3.11]). 
 
 
 
Fig.3.11: Population attributable risk for UCP2-866G>A, UCP3-55C>T and obesity 
at  A) 15 years B) 10 years.  
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3.6 Discussion 
 
This  15  year  study  of  the  prospective  risk  of  T2DM  in  healthy  middle  aged 
Caucasian  men  confirmed  the  significance of  obesity  as  a  major  risk  factor  for 
diabetes,  and  also  found  a  significant  impact  on  risk  of  developing  T2DM 
associated  with  variants  in  the  genes  for  UCP2  (-866A)  and  UCP3  (-55T).  
Subjects  who  developed  T2DM  also  had  higher  blood  pressure,  triglycerides, 
cholesterol  and  C-reactive  protein  (CRP)  at  baseline,  although  only  BMI, 
triglycerides and CRP were associated independently with increased risk.   The 
association with CRP and triglycerides may have arisen because subjects going on 
to  develop  T2DM  were  already  more  insulin  resistant  at  baseline  (Duncan 
BB,2003) but this could not be confirmed as other measures of insulin resistance 
such as HOMA were not collected at recruitment.  The risk associated with BMI 
was over a third higher than any other metabolic parameter and the size of the risk 
associated  with  obesity,  defined  here  as  BMI>30kg/m
2,  was  approximately  four 
times that associated with the genetic variants.  In effect, after 10 years of follow 
up,1 out of 4 cases of T2DM would have been prevented if there were no obesity, 
BMI being the best marker of adiposity in the group as waist circumference was not 
collected at baseline, present in the sample, while 1 out of 10 cases would be 
prevented  if  there  were  no  genetic  variation  at  UCP2-866  or  UCP3-55.    The 
additive effect of the combination of obesity and the presence of the gene variants 
increased the risk to extremely high levels, although such subjects were rare in the 
sample.    In  obese  subjects  homozygous  for  either  variant  the  risk  of  T2DM 
increased to over 5 times that of non-obese subjects, non-homozygous for either 
variant.   Homozygotes for both variant alleles had a risk of diabetes from 2.5 times 
higher in the non-obese, to nearly 20 times higher in obese subjects.   
 
 
The  UCP2-866A  allele  has  consistently  been  associated  with  risk  of  T2DM  in 
cross-sectional studies in European subjects, and the mechanism of this appears 
likely to be due to increased UCP2 expression in the pancreas.  The location of the   154 
-866G>A  variant,  within  a  multifunctional  cis  regulatory  site  involving  putative 
binding  sites  for  pancreatic  and  hypoxia-induced  transcription  factors,  suggests 
that  it  is  likely  to  be  functional  (Esterbauer  H,2003).    Consistent  with  this,  a 
promoter  construct  of  the  -866A  allele    was  associated  with  1.2  fold  higher 
expression vs. -866G in INSE-1 cells, derived from rat β-cells (Krempler F,2002).   
Putative  mechanisms  are  examined  in  later  chapters  but  it  is  likely  that  UCP2 
expression  uncouples  ATP  production  from  glucose  metabolism,  reducing  ATP 
production, and since insulin secretion depends on the ATP/ADP ratio as a marker 
of  glucose  metabolism  in  the  pancreatic  β-cell  (Erecinska  M,1992),  secretion is 
reduced as a result.  The higher risk of developing T2DM associated with variation 
in the UCP2 gene is thus likely to be due to a pancreatic effect on insulin secretion.  
Risk is exacerbated by obesity, as obese subjects are already likely to be insulin 
resistant  and  will  require  higher  insulin  secretion  to  maintain  normal  glucose 
homeostasis.   
 
A different mechanism appears likely for the UCP3 risk effect.  As discussed in 
chapter 1 although UCP3 expression has been associated with higher uncoupling 
in vitro (Jaburek M,1999),  UCP3 expression is increased both by fasting and by an 
iso-caloric high fat diet, neither of which increases metabolic rate nor uncoupling.  
Also,  an  increase  in  expression  does  not  change  mitochondrial  membrane 
potential.    These  findings  suggest  that  UCP3    does  not  have  a  conventional 
uncoupling function in man (Schrauwen P,2004).  Overexpression of UCP3 in mice 
which protects them from diabetes, with a 68% increase in mitochondrial palmitate 
oxidation.    This  effect  is  specific  to  UCP3,  as  there  is  no  increase  in  glucose 
oxidation,  change  in  oxygen  consumption  or  mitochondrial  membrane  potential, 
which  is  seen  with  increased  uncoupling  per  se  (MacLellan  JD,2005).    UCP3 
expression will thus protect the mitochondria, by exporting the fatty acid anions and 
peroxides  from  the  mitochondrial  matrix,  protecting  mitochondrial  function  and 
preventing the development of T2DM (Schrauwen P,2003). 
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Since the UCP3-55T variant is associated with risk of diabetes in the men studied 
here, a decrease in function would be predicted for the T allele.  The variant was 
originally mapped near a TATA box (6bp) (Schrauwen P,1999) where it may affect 
transcription, but a recent report (Acin A,1999) places the variant in the „5UTR near 
a PPAR responsive element (4bp) which also suggests it could modify regulation of 
UCP3 expression.  A reduction in UCP3 function in -55T carriers has been seen in 
some but not all previous cross sectional studies.  UCP3 mRNA expression was 
higher in CT/TT male non-diabetic Pima Indians, but this study included only 24 
subjects  and  was  based  on  only  seven  copies  of  the T  variant  from  48 alleles 
(Schrauwen P,1999).  The T allele was associated with higher BMI or WHI ratio, 
consistent  with  decreased  function,  in  French  and  German  Caucasians,  South 
Asian Indian parent-offspring trios, South Asian Indians and the British Diabetic 
Association Warren 2 trios collection (Cassell PG,2000; Halsall DJ,2001; Herrmann 
SM,2003; Otabe S,2000).  However, one study showed a lower BMI in TT subjects 
in  a  United  Kingdom  sample  (Halsall  DJ,2001)  and  increased  function  is  also 
suggested with the association of protection from diabetic neuropathy (Rudofsky 
G,2006).  In these studies, association with T2DM was examined only once and a 
relationship not found.  The variant allele was found to be protective against T2DM 
in two French cohorts although also associated with an atherogenic lipid profile 
(Meirhaeghe  A,2000).    The  reason  for  this  difference  is  not  clear;  the  French 
sample does not appear to be very different to the NPHSII sample although the 
NPHSII  sample  is  nearly  three  times  larger,  which  may  be  important  when  the 
impact of an individual variant is small. 
 
The overall prevalence of T2DM in this sample is 2.5% at baseline and 8.1% after 
15 years of follow up.  This is lower than that reported by the Joint Health Surveys 
Unit (Health Survey for England 2003,2004), however, the increase in prevalence 
of both diagnosed and undiagnosed diabetes between the age range 55-64 years 
and 65-74 years is similar, from 10.4%, to 18.8%.  The lower prevalence is in part 
due to the exclusion of those with diabetes on treatment at the beginning of the 
study.   Although a small number of subjects with diabetes managed by dietary   156 
modification alone were included in the study the findings were consistent if they 
were included in the analysis. The method of identification of the men with T2DM, 
by the medical record search, is unlikely to include any false positive diagnosis, but 
in the absence of a full recall for fasting glucose testing  some affected subjects 
may be missed. This would then result in a small underestimate of the 15 year 
incidence of T2DM, but would not confound the genetic association observed.  This 
is the first prospective study to look at risk of T2DM and, overall prospective gene-
association  studies  are  more  powerful  than the  case-control  design  (Humphries 
SE,2003)  but  further  replication  is  required  to  resolve  these  apparent 
discrepancies.  
 
 
 
 
 
   157 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
 
THE UCP2-866G>A AND UCP3-55C>T VARIANTS IN THE 
HYPERCOAGULABILITY AND IMPAIRED FIBRINOLYTIC FUNCTION 
MECHANISMS STUDY (HIFMECH)   158 
CONTENTS OF CHAPTER FOUR 
 
4.1  Hypercoagulability  and  Impaired  Fibrinolytic  Function  Mechanisms 
Study(HIFMECH) 
4.1.1.  Introduction                159 
4.1.2.  Aims                  159 
4.1.3.  Methods                159 
 
4.2   Baseline Characteristics               160 
 
4.3  UCP2-866G>A  
4.3.1.  Genotype and metabolic Markers Genotype in controls  162 
4.3.2.  Risk of Cardiovascular disease and genotype association  163 
 in cases                 
 
4.4  UCP3-55C>T 
4.4.1.  Genotype and metabolic Markers Genotype in controls  165 
4.4.2.  Risk of Cardiovascular disease and genotype association  166 
 in cases                 
 
4.5  Discussion                  167 
 
 
 
 
 
 
 
 
 
   159 
4.1  Hypercoagulability  and  Impaired  Fibrinolytic  Function  Mechanisms  Study 
(HIFMECH) 
 
4.1.1 Introduction 
 
The previous chapter demonstrated the association of variants in the uncoupling 
proteins 2 and 3 with prospective risk of type 2 diabetes.  The study, however, did 
not  address  the  potential  mechanisms  that  underlie  this  association.    The 
HIFMECH study is described in detail in chapter 2.  The measurement of a number 
of metabolic markers gives the opportunity to investigate the mechanism by which 
these gene variants influence risk of type 2 diabetes.  Chapter 1 describes how 
there may be an overlap in the underlying pathophysiology driving cardiovascular 
disease and type 2 diabetes.  The case-control nature of this study allows for the 
association of these variants with myocardial infarction to be studied, determining if 
the  pathway  of  increased  risk  of  type  2  diabetes  is  likely  to  be  shared  with 
cardiovascular disease, or is independent of it.     
 
4.1.2 Aims 
 
To examine the UCP2-866G>A and UCP3-55C>T  variants in the HIFMECH study 
to determine if the increase in prospective risk of type 2 diabetes is due to  an 
association with adverse metabolic markers. 
 
To estimate the effect of the UCP2-866G>A and UCP3-55C>T variants on risk of 
myocardial infarction. 
 
4.1.3 Methods 
 
The  HIFMECH  study  was  designed  to  study  genetic  and  environmental 
mechanisms contributing to the higher cardiovascular risk in Northern compared to 
Southern Europe (Juhan-Vague I,2002).  The study sample of Caucasian male first   160 
myocardial  infarction  survivors  below  60  years  of  age  were  recruited  from  four 
European  centres  (Northern  European-Stockholm,  London;  Southern  European-
Marseille, San Giovani Rotondo) (n=598).  A selection of randomly-selected age 
matched healthy controls was also recruited from each catchment area (n=653).   
To reduce the risk of error due to multiple testing statistical analysis followed the a-
priori design, to study the association of risk factors associated with cardiovascular 
risk in relation to the North and South of Europe, combining data from the two 
North and two Southern centres for a more statistically robust comparison.  There 
was  no  difference  between  common  allele  homozygotes  and  heterozygotes  for 
prospective  risk  of  type  2  diabetes  so  a  recessive  model  was  used  for  both 
genotypes.    The  metabolic  markers  were  studied  in  controls,  as  they  are  most 
similar to the participants of NPHSII.  In keeping with the original design, risk of 
myocardial infarction associated with genotype was also estimated.  Associations 
were  estimated  in  cases  only  for  the  purpose  of  assessing  confounding  of any 
differences detected in cardiovascular risk associated with genotype.   
 
 
 
4.2.  Baseline Characteristics  
 
The baseline characteristics of the HIFMECH study are shown in table 1.  There 
are significant differences between both cases and controls and between subjects 
in the North and South of Europe.  Those in the South had a better lipid profile but 
were more likely to smoke.  There was no difference between BMI between the 
North and South but waist:Hip ratio (WHR) was higher in the North than in the 
South  (Controls  1  v  0.95,p<0.001;  Cases  0.98  v  0.93,  p<0.001).  As  expected, 
cases  had  higher  rates  of  smoking  and  type  2  diabetes,  whilst  although 
triglycerides were higher in cases there was no clear difference in blood pressure 
and lipids. This is likely to be due to post-infarct treatments.   The frequencies of 
the  UCP2-866  and  UCP3-55 genotype  were  as  expected  from  Hardy-Weinburg 
proportions in both the North and South sample (UCP2-866: North p=0.72, South   161 
p=0.96. UCP3-55: North p=0.49, South p=0.45).  The frequency of the rare UCP2-
866A  was  0.34[0.32-0.37],  with  no  difference  between  the  North  and  South 
(p=0.95).  By contrast, there was a difference between the frequency of the rare 
UCP3-55T  between  the  North  (0.28[0.25-0.31])  and  the  South  (0.18[0.15-
0.20];p=0.001).   
 
 
Table 4.1. The baseline characteristics of the subjects determined by case/control 
and North/South status.   
 
 
NORTH  SOUTH  North 
V 
Cases 
V 
 
 
Cases  Controls  Cases  Controls  South  Controls 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Age 
(yrs) 
53.0  5.1  52.7  5.1  51.0  5.6  50.5  5.6  <0.01  0.17 
BMI 
(Kg/m
2) 
27.2  3.4 
 
25.8  3.1 
 
27.0  3.3 
 
26.4  3.3  0.20  <0.01 
Blood 
Pressure 
(mmHg) 
- Systolic 
 
- Diastolic 
 
 
129.3 
 
82.3 
 
 
17.7 
 
9.8 
 
 
130.4 
 
84.0 
 
 
15.8 
 
8.5 
 
 
126.9 
 
81.5 
 
 
16.2 
 
10.6 
 
 
126.4 
 
84.4 
 
 
13.3 
 
8.7 
 
 
<0.01 
 
0.82 
 
 
0.87 
 
<0.01 
 
Smoking- 
Current/Ex 
(%) 
 
 
76.8 
 
 
2.0 
 
 
61.9 
 
 
2.3 
 
 
86.9 
 
 
1.4 
 
 
61.2 
 
 
2.0 
 
 
<0.01 
 
 
<0.01 
Diabetes- 
Type 2 (%) 
 
11.6 
 
1.5 
 
0 
 
- 
 
11.5 
 
1.4 
 
0 
 
 
- 
 
0.67 
 
<0.01 
Cholesterol 
(mmol/L) 
5.65  1.22  5.68 
 
0.96  5.18  1.11 
 
5.39  0.93  <0.01  0.06 
Triglyceride 
(mmol/L) 
 
1.99  0.83  1.52  0.58  1.79  0.72  1.39 
 
0.60  <0.01  <0.01 
The  blood  pressure  and  lipid  parameters  include  those  on  anti-hypertensive  and  lipid 
lowering agents respectively 
 
There was no difference in the characteristics of those with and without genotype in any of 
the four groups (data not shown). 
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4.3  UCP2-866G>A  
 
4.3.1 Metabolic Markers by Genotype in controls 
 
There  was  no  difference  between  genotype  (Analysis  followed  recessive  effect 
identified  in  NPHS;  AA  v  GX)  for  any  of  the  lipid  parameters  (cholesterol, 
triglycerides,  or  apoB)  (Table  4.2)  in  either  the  North,  the  South  or  with  both 
samples combined.   
 
Table 4.2: The differences between lipid profiles in healthy subjects for the UCP2-
866G>A variant in the HIFMECH study. 
*adjusted for centre 
1log transformed 
2square root transformed 
 
Although BMI (Kg/m
2) was lower in AA subjects in the North (GX v AA 26.0 [3.1] v 
24.9  [3.2];  p=0.06)  there  was  no  difference  in  the  South  (26.4[3.2]  v  27.0[3.0]; 
p=0.25).  However, as shown in Fig 4.1a, WHR was lower in AA homozygotes 
compared to G carriers in both the North, South and all controls combined (North: 
1.00[0.06] v 0.98[0.07]; p=0.03: South 0.95 [0.05] v 0.93 [0.07]; p=0.04: combined 
1.00[0.06] v 0.98[0.07]; p=0.003).  There were also significant differences in fasting 
insulin between genotypes with the previously identified genotype for prospective 
risk of type 2 diabetes (UCP2-866AA) associated with significantly lower insulin 
levels (pmol/l) in the North and in all controls combined but not significant in the 
South although the same trend was seen (North: 40.4[26.5] v 30.2[13.8]; p=0.02: 
South  37.4[23.5]  v  32.9[23.0];  p=0.37:  combined  40.3[24.6]  v  32.3[18.6]; 
p=0.02)(Fig 4.1b).  This difference was no longer significant in the North or South 
  UCP2-866  North  South  Combined* 
Cholesterol 
(mmol/l) 
GG/GA 
AA 
P value 
5.67 (0.98) 182 
5.69 (0.85) 31 
0.93 
5.40 (0.92) 265 
5.34 (1.00) 36 
0.70 
5.70 (0.95) 447 
5.67 (0.93) 67 
0.81 
Triglycerides 
(mmol/l) 
GG/GA 
AA 
P value 
1.53 (0.58) 182 
1.49 (0.63) 31 
0.74 
1.38 (0.59) 265 
1.41 (0.67) 36 
0.76 
1.52 (0.62) 447 
1.52 (0.68) 67 
0.97 
apoB 
(mmol/l) 
GG/GA 
AA 
P value 
97.8 (23.2) 182 
92.8 (20.0) 31 
0.25 
94.1 (20.2) 265 
93.1 (20.3) 36 
0.79 
98.1 (21.7) 447 
95.2 (20.4) 67 
0.30   163 
once  adjusted  for  BMI,  but  remained  so  in  all  the  controls  combined  (North: 
42.6[25.6] v 36.1[13.8]; p=0.15: South 39.1[21.7] v 32.2[22.1]; p=0.14: combined 
42.6[24.6] v 35.6[18.6]; p=0.03)(Fig 4.1b). 
 
 
Fig 4.1:  The association of the UCP-886AA genotype with a) lower waist hip ratio 
b) lower insulin secretion (unadjusted) and lower insulin secretion  adjusted for BMI 
 
4.3.2. Risk of cardiovascular disease and genotype association in cases 
 
The odds of being a case by UCP2-8AA, compared to GG+GA, using a conditional 
logistic  regression  model  were  a  modestly  higher  odds  ratio  for  Myocardial 
Infarction in the North of 1.30 [95%CI 0.76-2.23] but not in the South 1.00 [0.60-
1.68].   The risk for North and South combined was 1.19 [0.81-1.75]; p=0.38(Fig 
4.2).      In  cases,  the  AA  genotype  was  associated  with  significantly  lower  than  
cholesterol  in  the  South  [p=0.04]  and  higher  in  the  North  [p=0.05]  but  in  the 
combined group no significant difference was seen.  Triglycerides were lower in AA 
subjects in both North and South and in the combined group the difference was 
statistically significant [p=0.05]. These differences may have occurred by chance 
but  would  be  likely  to  weaken  any  association  between  the  AA  genotype  and 
cardiovascular disease.  There were no other statistically significant associations in 
cases between metabolic markers and genotype [p=0.17-0.78]. (Table 4.3) 
a) Waist Hip Ratio
0.94
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Fig 4.2:  The Odds ratio for Myocardial Infarction associated with the UCP2-
886G>A genotype in HIFMECH 
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Table 4.3: The association of the UCP2-866G>A genotype and metabolic markers 
in cases in the HIFMECH study. 
*adjusted for centre,
1log transformed,
2square root transformed 
 
  UCP2  North  South  Combined* 
BMI
1  
(Kg/m
2) 
GG/GA 
AA 
P value 
27.3 (3.4) 182 
26.8 (3.0) 39 
0.36 
27.1 (3.4) 249 
26.5 (3.0) 33 
0.31 
27.3 (3.4) 431 
26.8 (3.0) 72 
0.17 
WHR  GG/GA 
AA 
P value 
0.98 (0.06) 182 
0.99 (0.05) 39 
0.19 
0.95 (0.06) 232 
0.95 (0.07) 31 
0.87 
0.98 (0.06) 414 
0.98 (0.06) 70 
0.40 
Cholesterol 
(mmol/L) 
GG/GA 
AA 
P value 
5.58 (1.21) 170 
6.00 (1.24) 37 
0.05 
5.23 (1.12) 237 
4.81 (0.91) 32 
0.04 
5.65 (1.16) 407 
5.67 (1.15) 69 
0.90 
(N/S Interaction 
p=0.005) 
Triglycerides
1 
(mmol/L) 
GG/GA 
AA 
P value 
2.02 (0.83) 170 
1.87 (0.86) 37 
0.31 
1.82 (0.72) 237 
1.59 (0.70) 32 
0.08 
2.02 (0.81) 407 
1.82 (0.81) 69 
0.05 
apoB
2 
(mmol/L)
 
GG/GA 
AA 
P value 
106.3 (28.9) 
170 
111.8 (25.0) 37 
0.29 
97.3 (22.3) 237 
90.1 (20.9) 32 
0.08 
107.6 (25.9) 407 
106.7 (24.1) 69 
0.78 
Insulin
1 
(pmol/L) 
GG/GA 
AA 
P value 
45.8 (30.7) 169 
38.1 (25.2) 36 
0.14 
57.8 (40.6) 145 
56.3 (45.9) 17 
0.88 
45.9 (31.4) 314 
40.1 (28.5) 53 
0.19 
Insulin
1 (BMI 
adjusted) 
GG/GA 
AA 
P value 
42.0 (23.8) 166 
37.2 (21.0) 36 
0.24 
56.6 (37.7) 145 
57.7 (45.7) 17 
0.91 
42.0 (25.8) 311 
38.9 (25.0) 53 
0.41   165 
4.4  UCP3-55C>T 
 
4.4.1  Metabolic Markers by Genotype in controls 
 
UCP3-55C>T genotype was not associated with differences in waist hip ratio, BMI 
or insulin.   The lipid parameters were unremarkable except the TT genotype was 
associated with higher apoB in the South (Table 4.4). 
 
 
Table 4.4: The association of the UCP3-55C>T genotype and metabolic markers in 
controls in the HIFMECH study.  
 
  UCP3  North  South  Combined* 
BMI
1  
(Kg/m
2) 
CC/CT 
TT 
P value 
25.8 (3.1) 221 
25.4 (3.5) 22 
P=0.51 
26.4 (3.2) 309 
26.2 (2.3) 11 
P=0.81 
25.8 (3.1) 530 
25.4 (3.1) 33 
P=0.49 
WHR  CC/CT 
TT 
P value 
1.00 (0.06) 220 
1.01 (0.06) 21 
P=0.54 
0.95 (0.06) 200 
0.94 (0.09) 6 
P=0.65 
1.00 (0.06) 420  
1.00 (0.06) 27 
P=0.71 
Cholesterol 
(mmol/L) 
CC/CT 
TT 
P value 
5.74 (0.99) 204 
5.44 (0.96) 20 
P=0.19 
5.37 (0.93) 308 
5.84 (1.01) 11 
P=0.10 
5.71 (0.95) 512 
5.70 (1.03) 31 
P=0.92 
Triglycerides
1 
(mmol/L) 
CC/CT 
TT 
P value 
1.51 (0.58) 204 
1.63 (0.78) 20 
P=0.40 
1.39 (0.62) 308 
1.42 (0.51) 11 
P=0.85 
1.52 (0.64) 512 
1.61 (0.70) 31 
P=0.46 
apoB
2 
(mmol/L)
 
CC/CT 
TT 
P value 
98.3 (23.1) 204 
95.8 (21.5) 20 
P=0.51 
93.9 (20.1) 308 
102.8 (23.6) 11 
P=0.03 
98.1 (21.6) 512 
99.8 (22.7) 31 
P=0.68 
Insulin
1 
(pmol/L) 
CC/CT 
TT 
P value 
39.9 (25.5) 205 
37.3 (26.5) 20 
P=0.65 
36.1 (22.6) 202 
42.4 (27.3) 9 
P=0.45 
39.3 (24.9) 407 
39.7 (27.2) 29 
P=0.94 
Insulin
1 (BMI 
adjusted) 
CC/CT 
TT 
P value 
43.0 (24.6) 205 
41.2 (21.8) 20 
P=0.75 
37.6 (21.2) 202 
45.3 (27.1) 9 
P=0.33 
42.0 (23.8) 407 
43.4 (24.0) 29 
P=0.76 
*adjusted for centre,
1log transformed,
2square root transformed 
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5.4.2  Risk of Cardiovascular disease and genotype association in cases 
 
There  was  a  lower  odds  ratio  for  myocardial  infarction  associated  with  TT 
homozygotes  of  borderline  significance  in  the  North  (OR[95%CI]  0.45[0.2-1.05]: 
p=0.06)  but  not  so  in  the  South  (0.51[0.18-1.48]:  p=0.22).    The  odds  ratio  for 
myocardial  infarction  in  the  study  combined  was  lower  in  those  with  the  TT 
genotype (0.47[0.25-0.92]: p=0.03 
 
Fig 4.3:  The Odds ratio for cardiovascular disease associated with the  UCP3-
55C>T  genotype in the HIFMECH study. 
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The UCP3-55TT homozygotes had lower mean cholesterol in the North and South, 
although  the  result  was  of  borderline  signi ficance  in  the  North  (Cholesterol 
(mmol/L) CC +CT v TT: North 5.7[1.2] v 5.1[0.9], p=0.09; South 5.2[1.1] v 4.2[1.1], 
p=0.04; combined 5.7[1.2] v 4.9[1.0], p=0.01).  A similar association was seen with 
apoB but in the North the differences were not significant (p=0.22) (Table 4.5). 
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Table 4.5  The association of the UCP3-55C>T  genotype with metabolic markers 
in cases in the HIFMECH study. 
 
  UCP3  North  South  Combined* 
BMI
1  
(Kg/m
2) 
CC/CT 
TT 
P value 
27.2 (3.2) 209 
27.7 (5.0) 13 
P=0.57 
27.0 (3.3) 292 
25.3 (3.4) 5 
P=0.24 
27.2 (3.2) 501 
27.1 (4.6) 18 
P=0.87 
WHR  CC/CT 
TT 
P value 
0.98 (0.06) 210 
0.98 (0.07) 12 
P=0.82 
0.95 (0.06) 272 
0.95 (0.08) 5 
P=0.95 
0.98 (0.06) 482 
0.98 (0.07) 17 
P=0.82 
Cholesterol 
(mmol/L) 
CC/CT 
TT 
P value 
5.70 (1.23) 198 
5.08 (0.90) 12 
P=0.09 
5.20 (1.11) 279 
4.15 (1.08) 5 
P=0.04 
5.68 (1.16) 477 
4.94 (0.95) 17 
P=0.01 
Triglycerides
1 
(mmol/L) 
CC/CT 
TT 
P value 
1.99 (0.85) 198 
2.17 (0.64) 12 
P=0.49 
1.79 (0.72) 279 
1.61 (0.45) 5 
P=0.56 
1.99 (0.82) 477 
2.05 (0.60) 17 
P=0.76 
apoB
2 
(mmol/L)
 
CC/CT 
TT 
P value 
108.1 (28.5) 198 
98.0 (24.4) 12 
P=0.22 
96.8 (22.2) 279 
76.3 (20.3) 5 
P=0.03 
108.0 (25.6) 477 
94.4 (23.5) 17 
P=0.03 
Insulin
1 
(pmol/L) 
CC/CT 
TT 
P value 
44.1 (29.6) 198 
50.3 (33.7) 11 
P=0.52 
56.0 (38.8) 170 
73.8 (66.1) 3 
P=0.50 
44.3 (30.1) 368 
52.0 (35.7) 14 
P=0.39 
Insulin
1 (BMI 
adjusted) 
CC/CT 
TT 
P value 
41.5 (23.7) 194 
42.1 (22.2) 11 
P=0.93 
55.3 (36.8) 170 
76.9 (36.4) 3 
P=0.40 
41.3 (25.5) 364 
44.8 (23.1) 14 
P=0.63 
*adjusted for centre,
1log transformed,
2square root transformed 
 
.  
 
4.5 Discussion 
 
Analysis of the UCP2-866 variant in the HIFMECH study provides two important 
observations.  Firstly, these data confirm the previous studies in Europe [see table 
1.4c] showing that AA subjects are leaner [2% lower WHR] in both the North and 
the South, and secondly that AA subjects have lower fasting plasma insulin levels.   
In  the  healthy  subjects  the  difference  in  fasting  insulin  levels  persisted  when 
adjusted for body mass index.  There was no other relationship between genotype 
and any of the adverse metabolic markers, suggesting that the effect of genotype 
variation  is  not  through  conventional  risk  factors  for  type  2  diabetes.      This 
association with β-cell dysfunction could have been replicated if the variant was   168 
also associated with pro-insulin or insulin split products which are associated with 
early β-cell dysfunction but these were not available for this study sample. 
 
This  study  was  underpowered  to  detect  an  association  between  genotype  and 
cardiovascular  risk.    The  UCP2-866AA  was  associated  with  a  modestly  higher 
odds ratio for myocardial infarction in the North but not in the South.  This is in 
keeping  with  other  data  suggesting  that  the  A  allele  is  associated  with  risk  of 
cardiovascular  disease  in  healthy  men  (Dhamrait  SS,2004)  and  carotid 
atherosclerosis in women (Oberkofler H,2005).  The A allele is also associated with 
higher markers of oxidative stress in men with type 2 diabetes (Dhamrait SS,2004).  
Why this association is seen more strongly in the North is not clear.   The mean 
WHR [%] was higher in the North [Controls 100 v 95 p<0.001; Cases 98 v 93, 
p,0.001] and this and other environmental factors such as diet could alter oxidative 
stress load.  The UCP2 gene promoter is induced by oxidative stress through both 
hypoxic and toxic pathways, and differences in oxidative stress load could alter the 
influence of UCP-2 promoter variants on transcription function (Krempler F,2002; 
Oberkofler H,2005). 
 
The association of the A allele with higher oxidative stress suggests that this allele 
is associated with lower “uncoupling”.  This is in contrast to the obesity and insulin 
data where the A allele is “protective” and associated with higher uncoupling.  This 
could be explained if the different alleles behave in different ways at baseline and 
under oxidative stress loads, such as that from cardiovascular risk factors. This is 
supported by the findings that THP-1 (macrophages)  and HUVEC (endothelium) 
cells (Oberkofler H,2005), compared to INSE-1 (Krempler F,2002) and Paz-6 cells 
(Esterbauer H,2001) show differences in transcription factor binding.     Different 
effects  in  different  disease  processes  could  also  be  explained  by  differential 
regulation of UCP2 in different tissues.  Indeed, in pancreatic cells [INSE-1] the 
effect  of  the  UCP2A  promoter  construct  is  enhanced  transcription  under  PAX6 
stimulation [which would be associated with diabetes], but  lower transcription in   169 
COS-7 cells, which would be associated with higher oxidative stress [see Fig 7.2, 
page 210].   
 
The association of the UCP3TT genotype with type 2 diabetes does not seem to be 
explained  by  differences  in  conventional  risk  factors  for  type  2  diabetes  or  by 
markers  of  insulin  resistance.    In  healthy  controls  the  only  association  of  an 
adverse  metabolic  marker  with  UCP3  genotype  was  an  association  with  higher 
ApoB in the South. The significance of this finding is uncertain given the number of 
comparisons performed.  The association of the UCP3 TT genotype with type 2 
diabetes must be explained through a mechanism not measured in the HIFMECH 
study.   
 
The association of the TT genotype with protection from myocardial infarction is a 
novel  finding.    How  the  genotype  associated  with  type  2  diabetes  is  also 
associated with cardiovascular disease is unclear and the association could be a 
chance finding.  The putative role of UCP3 in mitochondrial metabolism, protection 
from oxidative stress from over-nutrition, would also be expected to protect from 
cardiovascular disease.  This genotype was associated with increased prospective 
risk of diabetes in NPHSII (see chapter 4) The HIFMECH study is cross sectional 
in nature, this design is more susceptible to confounding than prospective studies.  
The association may have occurred as a result of a confounding factor, such as the 
association of lower cholesterol of 0.75mmol/l with the TT genotype in cases.  This 
association was seen both in the North and the South although was based on only 
17  TT homozygotes  and  was  not  seen in  the  NPHSII  study.    The  reduction  of 
cholesterol from 5.68 to 4.94mmol/l (assuming a HDL of 1.0mmol/l) in a 65 year old 
normotensive, non-smoker reduces the 10 year risk of cardiovascular disease by 
13%  (http://cvrisk.mvm.ed.ac.uk/calculator/framingham.htm)  which  would  explain, 
at least in part, some of the lower risk observed.   The expression of UCP3 may 
also be stimuli or organ specific, as is the case with UCP2.  There is currently little 
information on the effect of UCP3 variants on UCP3 transcription and is based on 
small numbers (Schrauwen P,1999) or very rare variants (Chung WK,1999) and do   170 
not provide much evidence of control of UCP3 expression.  If the association of the 
-55UCP3TT variant with risk of type 2 diabetes and protection from cardiovascular 
disease  is  replicated,  then  further  work  will  be  required  to  understand  the 
mechanisms underlying these data.   171 
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5.1  Assays  of  Plasma  Markers  of  Oxidative  Stress  in  The  Japanese 
American Family Study 
 
5.1  Introduction 
 
The association of risk of type 2 Diabetes associated with variation in UCP2 and 
UCP3  has  been  examined  in  chapters  3  and  4.    The  UCP2    variant  is 
associated  with  lower  insulin  secretion  but  the  mechanism  for  this,  and  the 
mechanism  for  the  risk  associated  with  UCP3-55TT  is  as  yet  unclear.    It  is 
possible  that  these  genetic  variants  are  associated  with  differences  in  non-
classical risk factors for type 2 Diabetes, more specifically the modification of 
oxidative stress.  
 
As described in chapter 1, living organisms have developed a wide range of 
complex  anti-oxidant  systems  to  counteract the  damaging  effects  of reactive 
oxygen  species.    The  oxidative  stress  balance  within  an  organism  can  be 
determined  by  several  different  methods.  A  component  of  one  of  the  anti-
oxidant systems can be measured directly or a component of the cell damaged 
by  reactive  oxygen  species  can  be  assayed.    Other  methods  rely  on  the 
concept  of  anti-oxidant  capacity,  which  is  estimated  as  the  capacity  of  the 
sample to scavenge free radicals in a test solution, and represents the sum of 
the anti-oxidant systems. There are two main methods to determine anti-oxidant 
capacity, based on the ability of the sample to inhibit an oxidizing reaction or to 
drive a reducing reaction. 
 
The Japanese American Family (JAM) study is a family study to investigate risk 
factors  for  coronary  heart  disease  and  type  2  diabetes.    The  Principal 
investigator of the study is Prof. Melissa Austin and the subjects were recruited 
in the United States of America, from in or around Washington, and were of 
Japanese descent (Austin MA,2004a).  The subjects are well characterised, and 
stored unthawed frozen plasma samples were available. The plasma markers of 
oxidative  stress  give  an  indication  of  the  amount  of  free  radical  mediated 
damage  present,  and  enable  the  examination  of  the  factors  that  determine 
oxidative stress burden in this population.   The genetic component of type 2   174 
Diabetes may in part be through modification of the body’s ability to generate or 
protect itself from oxidative stress. 
 
5.2 Aims 
 
1. To compare different methods of measuring anti-oxidant capacity with the 
aim of developing a method of  measuring oxidative stress markers that was 
accurate and capable of handling a large number of samples.  
 
2. To measure markers of oxidative stress in plasma samples of subjects from 
the Japanese American Family Study. 
i)  Examine  the  factors  that  predict  levels  of  plasma  markers  of 
oxidative stress.  
ii)  Determine the genetic contribution to plasma markers of oxidative 
stress by calculating heritability. 
iii)  Examine  if  genetic  variation in  the  UCP2-UCP3  gene  cluster is 
associated with variation in levels of oxidative stress markers. 
 
 
5.3  The assessment of different methods to measure plasma markers 
of oxidative stress burden 
 
5.3.1 Methods 
 
Once the different types of method had been identified, a kit was selected for 
each  method  on  the  basis  of  practicality,  cost  and  technical  specifications.  
Products  were  compared  from  the  major  suppliers  to  this  laboratory.  1)  A 
glutathione/ reduced glutathione (Calbiochem;354103) assay was chosen as an 
assay of a single component of the anti-oxidant systems; 2) Total anti-oxidant  
Status  (TAS-  Randox;  NX2332)  as  an  oxidation  reaction  based  on  ABTS, 
Metmyoglobin and Hydrogen peroxide and 3) AOP-490® (Oxis; 21052) as a 
reducing reaction based  on  copper ions.   Detailed  methods  for  each  kit  are 
illustrated in chapter 2.  These methods were also compared to the Total Anti-
oxidant Status (TOAS) method, based on ABTS, Horseradish peroxidase and   175 
hydrogen peroxide, which was developed within this group from the method of 
Sampson et al.  
 
The plasma  used  for  these  studies  was  provided  by  members  of  the  group.  
Blood was collected into EDTA-containing tubes and centrifuged at 3500g for 8 
minutes.  The plasma was separated and stored at -80
0C in microtubes until 
use.  The samples were stored by sample number only, no record was kept that 
would enable later identification of the sample. The inter-assay coefficient of 
variation (CV) was calculated by dividing the standard deviation by the mean 
and is expressed as a percentage.  Inter-assay variability was calculated on the 
basis  of  one  of  these  samples  repeated  in  the  plate  up  to  40  times.    The 
correlation  between  the  assays  was  calculated  by  assaying  the  same  ten 
samples with each kit.  A different aliquot was used for each kit and the assays 
were performed on the same day. 
 
5.3.2 Results 
 
5.3.2a Calculation of inter-assay variation. 
 
The  methods  were  all  performed  in  accordance  with  the  manufacturers 
instructions.    However,  for  the  TAS  kit  this  required  samples  to  be  run 
individually in 1ml cuvettes.  The method was modified to enable the use of the 
kit in a 96 well plate format by reducing the volume of reagents by 100.  This 
method uses similar volumes to the TOAS assay.  The dilution was tested by 
comparing  the  values  obtained  for  the  TAS  control  serum  by  both  methods.  
There was no difference between  the two samples (Fig  5.1).  The expected 
value was 1.55 [1.16-1.94] mmol/L .The cuvette method assayed this sample as 
1.44 [1.23-1.97], whilst the 96 well plate dilution method assayed this sample as 
1.31 [1.25-1.37].  There was no significant difference between the two methods 
(p=0.86). 
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Fig 5.1: Comparison of the 96 well plate modified method (n=20) of using the 
TAS reagents with the manufacturers recommended cuvette  method 
(n=8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The inter-assay variation for the different methods is shown in Table 5.1.  The 
TAS CV was measured in plasma and for the control serum provided.   The 
Randox kit is supplied with more than one set of reagents.  Measurement of 
TAS for the control serum supplied was repeated alongside the measurement of 
TAS in the plasma sample.  The CV of the assay was lower when the second 
set of reagents was used (21% v 9%).  The time taken to assay 40 samples 
was  also  estimated  (ie  samples  in  duplicate  in  a  96  well  plate,  including 
controls,  blanks,  etc).    The  CV  for  the  TOAS  was  lower  (4.1%)  but  the 
glutathione assay had the lowest (1.0%).  However, this method required the 
longest time and the samples needed pipetting and preparation at collection.   
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Table 5.1: The interassay CV for the oxidative stress assays. 
 
Assay  Sample  N  Mean 
Std 
Deviation 
CV(%) 
Time  for 
40 
samples 
TAS (mmol/l)  
Control 
1 
20  1.31  0.28  21.2  15 mins 
 
Control 
2 
20  1.77  0.16  9.0   
  Plasma  14  1.04  0.09  9.5   
TOAS(%)  Plasma  14  53.3  2.20  4.1  25 mins 
AOP-490 
(mmol/L) 
Plasma  8  0.16  0.03  21.1  35 mins 
Glutathione 
Ratio 
EDTA 
Blood 
20  21.25  0.22  1.0  60 mins 
 
 
5.3.2b Relationship between different methods 
 
A  total  of  10  volunteers  had  plasma  taken  on  the  same  day  and  stored  in 
separate aliquots for assay with each method.  The samples were defrosted at 
the  same  time  and  run  on  the  same  plate.    Linear regression  was  used  to 
determine the relationship of the methods.  There was no significant correlation 
between  any  of  the  methods  (Table  5.2)  with  the  highest  value  seen  being 
between TAOS and the GSH/GSSG method (r=0.32, p=0.37).   
 
Table 5.2: The relationship between different methods of measuring plasma 
markers of oxidative stress in 10 volunteers. (Pearson correlation)  
 
  AOP-490 [p]  TAOS [p]  TAS [p]  GSH:GSSG 
GSH:GSSG  0.12  [0.7]  -0.32  [0.4]  0.11  [0.8]  1 
TAS  0.25  [0.5]  -0.79  [0.8]  1     
TAOS  0.16  [0.7]  1         
AOP-490  1             
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5.3.3  Discussion 
 
The assays available for the determination of oxidative stress vary in their cost 
and ease of use.  The difference in oxidative stress levels between subjects 
with different genotypes is likely to be small, and therefore the chosen method 
needs to be simple enough to perform on a large number of samples.  The ‘in-
house’ TOAS assay showed the least variability, but is the most familiar, and 
the effect of familiarity is likely to explain the significant improvement in TAS 
variability between the initial assay and the repeat assay of the provided control 
serum performed with the assay of the plasma sample. The glutathione assay 
requires  pre-preparation  of  samples  at  the  sampling  site  and  this  makes  it 
unsuitable for large scale studies.  The lack of variability may also reflect the 
fact  that  oxidized  GSH  in  healthy  volunteers  is  found  at  the  lower  level  of 
detection for the kit, and this may reflect lack of ability to discriminate between 
samples rather than laboratory precision. The AOP-490® test would also be 
suitable, as the CV is likely to improve with increased familiarity.  However, the 
much higher cost of nearly £1.65 per sample, compared with 22p for TAS and 
5p for TOAS, made this impractical to perform in large scale genetic association 
studies.                  
 
 
 The use of any combination of these methods would be desirable as they are 
detecting  different  spectrums  of  anti-oxidant  activity,  as indicated  by the low 
correlation between them.    Therefore, the combination of TOAS and TAS was 
chosen, even though the only difference in the two tests is the catalytic enzyme.  
The correlation of value in 10 healthy subjects was essentially negligeable (-
0.08)    and  the  spectrum  of  the  anti-oxidant  system  that  each  is  measuring 
appears  likely  to  be    sufficiently  different  for  them  to  independently  validate 
findings.    
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5.4  Plasma Oxidative stress markers in the Japanese American Family 
Study 
 
5.4.1  Methods 
 
A  previously unthawed  plasma  sample  was  used  for  the  plasma  markers  of 
oxidative stress.  The assays were selected on the basis of the previous work in 
this  chapter.    Variables  were  transformed  to  normal  where  appropriate.  
Heritability  was  calculated  using  The  Statistical  Analysis  for  Genetic 
Epidemiology  (SAGE)  program  and  was  carried  out  by  Brendan  Pierce  in 
Washington, using an analytical strategy suggested by myself.  Genotype was 
determined using Taqman© Technology as previously described in chapter 2.   
 
 
5.4.2 Results 
 
Serum was available for 490 subjects.  TOAS was successfully measured in 
476 subjects and TAS in 490, the discrepancy arises mainly due to the rejection 
of  samples  with  significant haemolysis  which  TAS  can  correct  for  but  TOAS 
cannot.   The analysis was limited to the Nissei and Sansei generations due to 
the very small numbers in other generations; in total this excluded only four 
subjects. The characteristics of the subjects are shown in table 5.3.  The Nissei 
generation  was  nearly  thirty  years  older  and  as  a  result  had  higher  blood 
pressure, lipids and rates of type 2 diabetes.  The heritability calculation was 
based  on  these  subjects  recruited  from  68  separate  Japanese-American 
families as defined on page 100.      
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Table 5.3: Baseline characteristics of the Japanese American Family Study 
 
  Total  Nissei  Sansei 
 
N=  490  215  275 
Gender  
[M/F] 
215/275 [43.8%]  95/130 [42.2%]  120/141 [46%] 
Age  
[years] 
54.5       [16.5]  69.7     [8.8]  41.6       [7.9] 
LDL  
[mg/l] 
116.9     [31.2]  120.6   [32.8]  113.75   [29.6] 
HDL  
[mg/l] 
54.0       [14.9]  54.5     [15.5]  53.6       [14.6] 
Triglycerides 
[mg/l] 
136.4     [90.2]  151.0   [82.9]  123.6     [94.8] 
Systolic BP 
[mmHg] 
122.0     [19.1]  131.1   [20.7]  113.9     [12.9] 
Diastolic BP 
[mmHg] 
76.1       [10.2]  77.5     [9.9]  74.9      [10.3] 
BMI 
[kg/m
2] 
24.5       [3.7]  24.7     [3.6]  24.3      [3.9] 
Smokers – 
Never/Ex 
Current 
 
276/153 
40 [8.5%] 
 
103/97 
14  [6.5%] 
 
170/56 
25 [9.9%] 
Diabetes Y/N  49/441[11%]  42/183 [18%]  7/254 [2.68%] 
Mean [SD] 
 
5.4.2a  Relationship between TAS and TOAS 
 
Mean  TOAS  [SD]  was  53.34%  [8.5]  and  mean  TAS  was  1.36mmol/L  [0.22]. 
TOAS was transformed to the square to normalize the distribution. There was a 
weak but significant positive correlation between the two measures (r=0.076, 
p<0.001).  Therefore,  only  7.6%  of  the  variability  in  either  marker  can  be 
explained by a relationship with the other (Fig 5.2).  
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Fig 5.2: The relationship between plasma TAS and TOAS in the Japanese 
American Family Study  
 
 
sqtoasr= √ Plasma TOAS 
plasma randox = plasma TAS 
 
5.4.2b Oxidative stress markers and biochemical characteristics 
 
The mean TOAS (mean[SD] 54.6[30.8] v 53.3[28.2]: p=0.009) and TAS (1.41 
[0.2] v 1.31[0.2]:p= 0.0001) were both lower in women than in men  (Fig 5.3) 
and TAS but not TAOS was lower in the Sansei generation (6%).  There were 
no differences for mean TAS or TOAS by Diabetes or smoking status [Table 
5.4].   
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Fig  5.3:    The  mean  of  two  markers  of  oxidative  stress  by  gender  in  the 
Japanese American Family Study. (Mean [SE]) 
TOAS TAS
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Table 5.4:  The comparison of mean TOAS and TAS by baseline characteristics in the 
Japanese American Family Study. 
 
  TOAS [%]  TAS [mmol/L] 
Diabetes Y  
                (n=49) 
               N  
                (n=441) 
52.81[29.96] 
 
54.15[32.61] 
0.35  1.37[.223] 
 
1.36[.217] 
0.70 
Generation: Nissei 
                    (n=215) 
                   Sansei       
                   (n=275 ) 
54.22[30.17] 
 
53.82[18.43] 
0.50  1.40[.211] 
 
1.32[.218] 
0.0013 
Smokers  Current 
                 (n=40 ) 
                 Ex 
                 (n=153 ) 
                 Never  
                 (n= 276) 
53.79[27.55] 
 
54.21[30.28] 
 
53.95[29.10] 
0.92  1.33[.235] 
 
1.38[.222] 
 
1.34[.214] 
0.29 
Mean [SD] 
 
 
Simple linear regression showed a statistically significant correlation between 
TAS and triglycerides [ln], HDL cholesterol [Square], LDL cholesterol [Square 
root],  age,  Systolic  Blood  pressure  (SBP[reciprocal])  and  BMI.    A  significant   183 
correlation  with  TOAS  was  only  seen  with  triglycerides  and  systolic  blood 
pressure.  The relationship in all cases was weak, with the largest R
2 of 4% 
[Table 5.5].  Where a correlation was described with both TAS and TOAS, i.e. 
for  triglycerides  and  SBP,  this  was  in  opposite  directions,  however,  the 
correlation  was  weak  in  both  cases  and  the  line  of  best  fit  was  close  to 
horizontal.  
 
Table 5.5: Correlation between oxidative stress markers and metabolic markers in the 
Japanese American Family Study. 
 
  TOAS  TAS  TAS V 
TOAS 
  Β  R
2  p  Β  R
2  p   
Triglycerides  -0.11  0.03  0.0001  0.502  0.03  <0.00001  <0.00001 
HDL   0.007  0.001  0.16  -0.857  0.03  <0.00001  <0.00001 
LDL   0.13  0.004  0.08  0.45  0.002  0.005  0.11 
AGE  0.078  0.0004  0.37  14.81  0.04  <0.00001  0.0001 
SYS BP  -0.010  0.007  0.04  0.274  0.003  0.005  0.01 
BMI  0.13  0.001  0.53  3.32  0.04  <0.00001  0.001 
 
 
The ability of the two assays to measure the same signal was examined by 
comparing the distribution of the residuals.  In all cases these were significantly 
different.  In total 10 variables were examined and the two markers of plasma 
oxidative stress gave the same answer in 3 only.  However, using best subsets 
regression [Minitab V14] to identify the best multiple regression model the same 
independent predictors were identified for both TAS and TAOS. The amount of 
variability in oxidative markers due to the five identified predictors [age, sex, 
Triglycerides, BMI and systolic blood pressure]  was R
2 =7.0% for TOAS and 
11.9% for TAS [Table 5.6]. 
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Table 5.6:   The best multiple regression model for both TOAS and TAS as identified 
by best subsets regression [Minitab v14] in the Japanese American Family Study 
 
 
 
5.4.2c Heritability 
 
The familial correlation coefficients for both measures of total anti-oxidant status 
are shown in table 5.7.  There was a significant correlation between parent-
offspring  and  sibling  pairs,  indicating  that  there  is  likely  to  be  some  genetic 
determinant  of  plasma  markers  of  oxidative  stress.    However,  the  highest 
correlations were between spouses [TAS 0.60 (0.39-0.81); TOAS 0.50 (0.25-
0.50)].     
 
Table  5.7:  Familial  correlations for  two  plasma  markers  of  oxidative  stress  in  the 
Japanese American Family Study. 
 
  TAS (RANDOX)  TOAS (In-house) 
Pairs  Correlation Coefficient 
(95% CI) 
Pairs  Correlation Coefficient  
(95% CI) 
Unadjusted  Adjusted  Unadjusted  Adjusted 
Spouse 
pairs 
41  0.60 
(0.39, 81) 
0.58 
(0.37,0.79) 
38  0.50 
(0.25,0.75) 
0.50 
(0.25,0.75) 
Parent : 
offspring 
287  0.28 
(0.11,0.45) 
0.29 
(0.13,0.45) 
266  0.26 
(0.09,0.43) 
0.27 
(0.10,0.44) 
Sibling  374  0.36 
(0.20, 52) 
0.32 
(0.16,0.48) 
337  0.30 
(0.14,0.46) 
0.29 
(0.13,0.45) 
 
The  genetic  variance  component  [SEM]  for  TAS  was  0.03  [0.0045]  and  for 
TAOS  was  31.41  [6.98].    After  adjustment  for  age  and  gender  the  genetic 
variance component for TAS was 0.02 [0.004] and 33.35 [7.50] for TOAS.   The 
  TOAS  TAS 
Β  P  Β  p 
Trigs  -332.8  <0.0001  0.05  0.009 
AGE  9.14  0.001  0.003  <0.0001 
SYS BP  -149.4  0.008  -0.038  0.007 
BMI  21.25  0.061  0.007  0.008 
Gender  -219.8  0.007  -0.091  <0.0001 
R
2 =    0.0699    11.93 
P=    <0.0001    <0.0001   185 
heritability estimates for the TAS kit and in-house TOAS were 0.56 [p<10
-7] and 
0.48 [p<10
-7] respectively.  When adjusted for age and gender these results 
were essentially unchanged [TAS= 0.54, [p<10
-7] and TOAS = 0.49 [p<10
-7]; Fig 
5.3].    There  was  also a  significant  variance  component  due  to  the  marital 
relationship,  although  less  than  the  genetic  component  [TAS  0.02  [0.003]; 
TOAS 27.23 [7.39] and TAS 0.02 [0.003]: TOAS 33.90 [7.76] adjusted for age 
and gender.   The lower heritability for TOAS may be in part due to estimation of 
a random variance component  for TOAS 7.25 [9.01] not seen for TAS although 
this was not significant [p>0.05] when adjusted for age and gender (0.18[9.44]). 
 
Fig  5.4:    The  heritability  of  two  plasma  markers  of  oxidative  stress  in  the 
Japanese American Family Study. 
0.44
0.46
0.48
0.5
0.52
0.54
0.56
0.58
TAS TOAS
   Unadjusted Adjusted [Age + gender]
All estimates p<10-6
 
5.4.2d UCP2-UCP3 genotype and markers of oxidative stress. 
 
UCP2-866G>A and UCP3-55C>T genotyping was restricted to these subjects in 
whom  plasma  was  available.   Genotype  was  obtained in  94%  and  95%  of 
subjects for UCP2-866 and UCP3-55 respectively.  Genotype frequencies were 
as  predicted  from  Hardy  Weinberg  proportions  [Table  5.8].  There  was  no 
difference in genotype frequencies by generation [p>0.05].   
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Table 5.8: UCP2 -866G>A and UCP3-55C>T genotype frequencies in the Japanese 
American Family study.   
UCP2  GG  GA  AA  Undetermined 
Total  142   224  102  12 
Ninsei  63  106  49  2 
Sansei  79  118  52  9 
UCP3  CC  CT  TT  Undetermined 
Total  201  208  52  18 
Ninsei  93  93  26  8 
Sansei  108  115  26  9 
 
There were no significant differences in any of the baseline characteristics by 
either genotype [Table 5.9]. 
 
 
Table 5.9:  Baseline characteristics by genotype in the Japanese American Family 
Study. 
UCP2  GG  GA  AA   
Age   52.3  [16.2]  55.0 [16.1]  56.4 [16.7]  0.11 
Triglycerides  132.0[91.1]  142.48 [96.8]  136.0 [78.3]  0.40 
HDL  53.9 [14.6]  54.0 [15.0]  52.85 [15.6]  0.58 
LDL  113.1 [31.4]  117.3 [31.2]  121.1 [31.88]  0.07 
BMI  24.44 [3.75]   24.69 [3.87]  24.51 [3.46]  0.79 
SYS BP  120.7 [17.45]  123.6[20.2]  122.3 [19.0]  0.67 
Gender M:F  52/50  99/125  59/83  0.33 
Nissei/Sansei  49/52  106/118  63/79  0.52 
Diabetes N/Y  89/13  203/21  127/15  0.64 
SMOKING 
curr/Ex/Never 
3/39/54  25/67/123  9/44/84  0.07 
UCP3  CC  CT  TT   
Age   53.8  [16.1]  54.4 [16.8]  55.6 [14.8]  0.76 
Triglycerides  131.5[85.7]  142.54 [95.1]  147.1 [98.8]  0.53 
HDL  5.41 [15.2]  52.9 [15.0]  51.75 [13.6]  0.17 
LDL  115.9 [32.6]  116.8 [30.6]  121.5 [31.28]  0.56 
BMI  24.11 [3.54]   24.92 [4.01]  24.81 [3.29]  0.08 
SYS BP  122.2 [20.32]  121.2[18.1]  126.9 [17.8]  0.06 
Gender M:F  84/117  90/119  28/24  0.29 
Nissei/Sansei  93/108  93/115  26/26  0.81 
Diabetes N/Y  179/22  189/20  46/6  0.84 
SMOKING 
curr/Ex/Never 
18/53/121  15/73/110  4/21/26  0.24 
Mean [SD]: Units as in Table 5.3. 
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There  was  no  relationship  between  UCP2-866  genotype  and  either  TOAS 
[GGvGAvAA:  %[SD]  :  54.4[29.0]  v  53.8[29.0]  v  54.0  [30.6];p=0.40]  or  TAS 
[mmol/l  [SD]:  1.35[.22]  v  1.35[.21]  v1.38[.22];  p=0.32].    There  was  also  no 
relationship  between  UCP3-55  genotype  [CCvCTvTT]  and  either  marker  of 
oxidative  stress  [TOAS.  54.0[29.6]  v  53.8  [28.7]  v  54.6  [30.5];p=  0.47:  TAS 
1.35[.22] v 1.35 [0.21] v 1.40 [0.22]; p=0.24] [Fig 5.4]. 
   
Best  subset  regression  analysis  has  previously  identified  the  best  predictive 
model  for  both  the  markers  of  oxidative  stress  contained  the  same  five 
variables.  The addition of the genotype data to this model [Table 5.10] made no 
significant difference in the predictive value of the model if the genotype data 
was  added  separately  [Model  2  =  addition  of  UCP2  genotype;  Model  3  = 
addition of UCP3 Genotype] or combined [Model 4 = Addition of both UCP2 and 
UCP3 genotype]. The largest effect seen was the inclusion of UCP2 genotype 
to the TAOS model increased the R
2 from 6.99% to 7.5% (p=0.66)
    There is no 
association with variants in the UCP2-UCP3 gene cluster with plasma markers 
of oxidative stress in the Japanese American Family study. 
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Table 5.10:  Multiple regression models and determinants of plasma markers of 
oxidative stress in the Japanese American Family Study.   
 
 
TOAS  Model 1  Model 2  Model 3  Model 4 
Β  p  Β  p  Β  P  Β  p 
Trigs  -332.8  <0.0001  -345.4  <0.0001  -349.5  <0.0001  -380.7  <0.000
1 
AGE  9.14  0.001  9.77  0.01  9.58  0.001  9.07  0.002 
SYS BP  -149.4  0.008  -148.6  0.03  -146.9  0.009  -133.4  0.021 
BMI  21.25  0.061  21.39  0.10  21.11  0.067  21.98  0.059 
Gender  -219.8  0.007  -224.2  0.01  -221.4  0.008  -180.4  0.034 
UCP 2 
GA 
AA 
   
 
 
-61.9 
14.6 
 
0.54 
0.89 
     
-18.6 
106.7 
 
0.86 
0.42 
UCP 3 
CT 
TT 
       
. 
 
0.25 
119.4 
 
0.99 
0.37 
 
49.71 
178.4 
 
0.60 
0.23 
R
2 =  0.0699    0.075    0.0697    0.0705   
P=  <0.0001    <0.0001    <0.0001    <0.0001   
V Model 
1 
    0.66    0.64    0.67   
 
 
TAS  Model 1  Model 2  Model 3  Model 4 
Β  p  Β  p  Β  P  Β  p 
Trigs  0.05  0.009  0.46  0.19  0.05  0.011  0.45  0.023 
AGE  0.003  <0.0001  0.003  <0.0001  0.003  <0.0001  .0031  <0.000
1 
SYS BP  -0.038  0.007  -0.332  0.19  -0.040  0.006  -0.368  0.012 
BMI  0.007  0.008  0.007  0.008  0.007  0.009  0.007  0.009 
Gender  -0.091  <0.0001  -0.85  <0.0001  -0.081  <0.0001  -0.828  0.000 
UCP 2 
GA 
AA 
     
-0.26 
-0.003 
 
0.31 
0.89 
     
-0.02 
0.009 
 
0.45 
0.78 
UCP 3 
CT 
TT 
         
-0.0002 
0.32 
 
0.99 
0.35 
 
0.009 
0.38 
 
0.69 
0.32 
R
2 =  11.93    11.12    10.79    10.59   
P=  <0.0001    <0.0001    <0.0001    <0.0001   
V Model 
1 
    0.49    0.61    0.63   
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5.5  Discussion 
 
The  examination  of  plasma  markers  of  oxidative  stress  in  the  Japanese 
American Family study confirmed the observation in the kit comparison work 
that  the two methods show a low correlation even though they  use similar 
reactions.  This is likely to be due to differences in affinity of the components of 
the  anti-oxidant  system  and  the  enzyme  involved,  in  this  case  horseradish 
peroxidase  and  metmyloglobin  peroxidase.      This  difference  has  led  some 
authors (Block G,2006: Schlesier K, 2002) to suggest that two markers should 
be reported to confirm the effect of a studied variable on plasma markers of 
oxidative stress.   
 
The use of this strategy in the Japanese American Family study was, in part, 
successful.  A high heritability was seen for both TAS and TOAS markers and 
familial correlations suggested that some of this may be in part due to similar 
diet and environment, as the highest familial correlation was seen in spouse 
pairs.  This high level of heritability is in keeping with a previous study using an 
ABTS and metmyoglobin based method (Wang XL,2001).  This study was also 
a  family  study  with  a  Mexican  American  sample,  although  they  had  not  yet 
developed  cardiovascular  disease.    In  subjects  with  a  higher  environmental 
oxidative  stress  burden,  a  higher  percentage  of  the  unexplained  variation  in 
TAS  was  explained  by  genetic  factors.        The  slightly  higher  estimate  of 
heritability for the Japanese American Family study may be in part due to the 
higher oxidative stress burden increasing the genetic influence.   
 
However,  the  comparison  of  correlation  with  metabolic  parameters  recorded 
was  weak  and  not  consistent  between  the  two  methods.      The  failure  to 
demonstrate likely associations with smoking and diabetes status may be due 
to study power or the use of therapy for primary or secondary prevention, which 
would be expected to lower oxidative stress burden.  Targets for blood pressure 
and lipid lowering therapy are more demanding in patients with type 2 diabetes, 
and a number of these drugs, including statins, aspirin and ace inhibitors have 
been shown to reduce the oxidative stress burden (Ceriello A, 2006).  The lack 
of association with oxidative stress markers and smoking is based on only forty   190 
[8%] current smokers and no stratification of amount of smoking was included in 
the  study  or  an  assessment  of  how  recently  participants  had  become  ex-
smokers.  These factors would weaken the strength of an association present 
and  may  explain  why  none  was  found.    There  was  also  no  stratification of 
severity of diabetes to indicate how much hyperglycaemia is present, as it is this 
that is likely to be associated with plasma markers of oxidative stress per se.  
The  plasma  marker  of  oxidative  stress  has  been  associated  with  diabetes 
medication but not the diagnosis of diabetes, suggesting that in this case that 
diabetes medication is acting as a surrogate for diabetes severity.   This is the 
fourth study across a variety of samples selected from Finland (Alho H,1999), 
China (Woo J, 1997) and Mexican Americans (Wang XL,2001) that describes 
lower  plasma  markers  of  oxidative  stress  in  women  despite  lower  risk  of 
cardiovascular disease.  Lower levels of anti-oxidant capacity in women despite 
lower risks of coronary artery disease may be due to the protective effect of 
oestrogen being through anti-oxidant components of low affinity with the assays 
used, or through other mechanisms.  In men the anti-oxidant levels present may 
have been stimulated to higher levels given an increased burden of oxidative 
stress.  This paradoxical difference is worthy of further study.  
 
Multiple regression demonstrated the best model for predicting oxidative stress 
was based on the five variables of triglycerides, age, systolic blood pressure, 
BMI and female gender.  However, the variation in these factors only explained 
11.9% of the variation in TAS and 7.0 % of TAOS suggesting that other non-
measured  factors  are  important.  These  are  likely  to  be  diet  and  exercise, 
alcohol consumption and use of medication.  
 
The addition of genotype data  did not improve the model and mean TAS or 
TOAS did not differ by genotype, including with the use of a recessive model.  
There are a number of possible reasons for this.  
 
This is a family study and we have made no allowance for the fact that many of 
the subjects share a relationship with others as this would have also reduced 
the power of the study.  The UCP2 -866A variant is known to function differently 
under  different  conditions  (Oberkofler  H,  2005)  and  the  effect  on  plasma   191 
markers of oxidative stress is greater when there is a higher environmental load 
of  oxidative  stress  production.    Forty  three  percent  of  the  sample  is  from  a 
younger generation with lower blood pressure and less adverse lipid profiles as 
well as low rates of diabetes.  Under this low burden the differences in function 
between the two alleles may be too small to detect.  We have used two different 
plasma markers of oxidative stress and they have correlated poorly with each 
other and with adverse metabolic markers.  These markers in effect measure 
what  is  left  of  the  anti-oxidant  systems  in  plasma  as  a  surrogate  for  the 
production  of  ROS.    Uncoupling  proteins  are  found  in  the  mitochondrial 
membrane and changes in mitochondrial oxidative stress may have significant 
effects on mitochondrial function without detectable changes to other areas of 
the  cell  of  the  extracellular  matrix.    This  will  make  the  differences  between 
genotype  undetectable  using  this  method  at  early  stages  in  the  disease 
process, whilst it is possible to detect them later such as when cardiovascular 
disease has developed (Dhamrait, 2004).  The number of rare homozygotes is 
low,  especially  for  the  UCP3-55C>T  variant  with  only  52  (10.6%)  rare 
homozygotes in the study.  This current sample size gives only a 65% percent 
chance  of  detecting  an  association  at  80%  power  [p=0.05]  based  on  these 
means.   
There is also the possibility that these variants do not behave in the same way 
in subjects of Japanese descent.  Although, the frequency of the UCP2-866A 
allele is consistent across a number of European samples [0.30-0.40] as well as 
the Middle East [Iran (Akrami SM, 2007)], North India (Rai E, 2007) and Taiwan 
(Wang  TN,  2007)  the  rare  allele  frequency  in  other  ethnic  groups  including 
Korean  (Yoon  Y,  2007)  and  Japanese  samples  (Ji  Q,2004)    has  been 
consistently  higher  [0.45-0.50].      In  these  samples  the  -886A  has  not  been 
associated with type 2 diabetes although it has been found in association with 
hypertension and triglycerides as well as lower weight loss on a low calorie diet.  
The frequency of the rare allele differs between the Northwick Park Heart Study 
and  the  Japanese  American  Family  study  [0.37  v  0.46;p<0.01].      The 
relationship between UCP2 genotype and plasma markers of oxidative stress 
was reported in a sample from the Northwick Park Heart study (Dhamrait S, 
2004) and such an association may not be present in Japanese Americans.    
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The UCP3-55T has been less widely studied in Japanese samples and there 
seems  to  be  no  difference  in  rare  allele  frequency  between  European  and 
Korean  samples.    However,  the  rare  allele  frequency  in  the  Northwick  Park 
Heart Study is lower than the Japanese American Family Study [0.22 v 0.34; 
p<0.05] suggesting that the populations are distinct at the UCP2-UCP3 gene 
cluster. Further work is required to determine which are the important variants in 
samples of Japanese ancestry are and to determine if variation at the UCP2-
UCP3 also is associated with type 2 diabetes. 
 
In  summary,  plasma  markers  of  oxidative  stress  are  highly  influenced  by 
genetic variation and this may explain the failure of anti-oxidant interventions in 
clinical  settings.    Environmental  influences  on  plasma  markers  of  oxidative 
stress  are  poorly  understood  and  expected  factors,  such  as  diagnosis  of 
diabetes,  are  not  always  associated  with  changes  in  plasma  markers  of 
oxidative stress.  The finding of an association with variation in the UCP2-UCP3 
gene cluster was not replicated in a sample of Japanese descent. 
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  1946.1  The study of genetic influences on the modification of oxidative stress 
 
6.1.1 Introduction 
 
Genes that modify oxidative stress, either through the augmentation of anti-oxidant 
defenses, or through promoting reactive species production, would be potential 
candidates for being important in the aetiology of type 2 diabetes or cardiovascular 
disease or both.  Gene association studies that identify such candidates do not 
give information on the direction of causality or on the potential mechanisms.   
Further investigation is required to demonstrate that the gene variant is associated 
with a change in gene function.  Investigation of the pathophysiological effect of 
this change in function can give insight into the mechanisms of these complex 
disorders and open up new therapeutic windows.  The evidence from previous 
chapters suggests the UCP2-866G>A and UCP3-55C>T variants are good 
examples of variants with an influence in gene function, and that both are 
associated with complex diseases and are associated with differences in markers 
of oxidative stress.  The investigation of how individuals with different variants 
handle an oxidative stress load would give us further understanding of their role in 
health and disease. 
 
6.1.2  Aims 
 
To develop an experimental model that will enable the study of the effect of genetic 
variation on oxidative stress burden.   The differences between genotype are 
expected to be small, therefore, the number of subjects required to demonstrate a 
difference between two genotypes would require a model that is easy to perform 
on a number of subjects.   
 
 
 
 
  1956.2   Oral Glucose Tolerance Test 
 
6.2.1  Methods 
 
An oral challenge was thought to be the simplest and most practical way of 
inducing an oxidative stress burden.  Oxidative stress markers provide the most 
efficient way of assessing this.  A glucose load has previously been shown to 
induce an increase in markers of oxidative stress (Sampson MJ,2002).  Volunteers 
were recruited from the group and staff of the department of diabetes and 
endocrinology (UCLH).  A 75g oral glucose tolerance test was performed, with the 
glucose administered in the form of lucozade.  Plasma was sampled at 10 minute 
intervals for 3 hours to study the glucose and oxidative stress [ROS] response 
further, and identify an ideal time point for sampling when comparing genotypes. 
 
6.2.2 Results 
 
A total of 10 volunteers, age range 25-57 attended for the study.  Fasting glucose 
was 5.2 mmol/l (range 4.6-6.5mmol/l) and peaked at 20 minutes (8.4mmol/l[6.1-
12.6]) returning to baseline at 20 minutes (Fiq. 6.1).  
 
Fig 6.1: Mean glucose in healthy volunteers over 3 hours following a 75 g oral 
glucose load   
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p=0.82) (Figure 6.2)  
 
 
Fig. 6.2: Plasma TAOS over 3 hours after a 75g oral glucose load in healthy 
volunteers. 
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To determine if the failure to demonstrate a change in markers of oxidative stress 
was due to the marker being used, a subgroup of subjects (n=3) were used to 
measure F2-isoprostanes by gas chromatography-mass spectrometry before and 
after in-vitro stimulation with SIN-1.  This is a peroxynitrate releasing compound 
generating superoxide and nitric oxide which stresses the anti-oxidant components 
of the plasma and will generate further F2-isoprostanes, especially if the anti-
oxidant components have already been depleted by a recent challenge  
(Ferraro B,2003).  There was no change in F2-isoprostanes over time (Fig. 6.3) in 
the first three samples and no further subjects were assayed. 
 
 
  197Fig. 6.3: Plasma F2-isoprostanes at baseline and after SIN-1 exposure at 20 
minute intervals over 3 hours after 75g oral glucose load in healthy volunteers. 
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6.2.3 Discussion 
 
 
The oral glucose tolerance test did not induce a measurable change in oxidative 
markers in healthy volunteers.  This challenge would, therefore, not be useful to 
study genetic differences.   There are a number of reasons why the oral glucose 
tolerance test failed to induce a change.   The age range of the volunteers was 
wide but the majority were young (mean 34.4) and a number undertake regular 
exercise (n=5[50%]).  Although, after exercise there are higher levels of oxidative 
stress, exercise also stimulates the expression of anti-oxidant defenses, and after 
repeated bouts of exercise the anti-oxidant systems adapt, with higher de novo 
synthesis of anti-oxidant defences, so these individuals may not show increased 
oxidative stress under this stimulus (Ji LL,2002). This also means that they are 
likely to be relatively insulin sensitive, and the peak glucose, and the area under 
the curve for the glucose excursion would be low, so that the impact of the 
challenge would be less.  The oral glucose tolerance test has induced a change in 
F2-isoprostanes in subjects with type 2 diabetes but the peak glucose in this study 
was 21.1mmol/L (Sampson MJ,2002). 
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The appearance of altered membrane components after oxidation takes about six 
hours.  The shorter time course may mean that the altered cellular anti-oxidant 
components has not yet had time to equilibrate with  plasma components and that 
this is why no difference was detected.   The use of SIN-1 to stress the plasma 
should overcome this but this still made no difference (Ferraro B,2003).   
 
 
6.3  Meal rich in used cooking oil 
 
6.3.1 Methods 
 
The failure to induce adequate oxidative stress with a glucose load led to the 
examination of a fat-based challenge.  Review of the literature led to the selection 
of a meal rich in used cooking oil, which when given to healthy volunteers induced 
endothelial dysfunction.  This was not induced when unmodified cooking oil was 
used, suggesting that used cooking oil provides the strongest challenge (Williams 
MJA,1999).  The failure to show a difference in healthy volunteers may have been 
in part due to the failure to induce significant metabolic abnormalities.  To 
overcome this, a sample of patients with type 2 diabetes was selected from the 
UDACS study.   Subjects attended fasting and were given the meal as detailed in 
chapter 2.  Blood was sampled every hour for four hours for glucose, NEFA and 
markers of oxidative stress.  To improve the characterization of changes in anti-
oxidant capacity it was decided to use more than one oxidative stress marker 
(Block G,2006). 
 
6.3.2 Results 
 
The baseline characteristics for the subjects that attended the fatty meal challenge 
are shown in table 6.1.  The subjects are older than the previous study and show a 
wide range of metabolic derangement.  They show a wide range of metabolic 
  199control of both glucose and lipid parameters.  Baseline markers of oxidative stress 
also showed a wide range (TOAS 50%-70% and TAS 1.26-1.93 mmol/L). 
 
Table 6.1: Baseline characteristics of the subjects in the fatty meal pilot study 
 (n=9) 
    Mean    + Standard 
Deviation 
Range 
Age (years)  62.5 6.1  54-74 
BMI (kg/m
2)  26.6 4.5  21.7-32.6 
Glucose (mmol/l)  10.3 5.3  7.2-24.1 
Hba1c (%)  8.1 1.5  6.3-11.3 
HDL cholesterol (mmol/L)  1.8 0.8  0.9-3.2 
LDL cholesterol (mmol/L)  2.1 1.0  0.3-3.8 
Triglycerides (mmol/L)  4.6 1.1  2.8-5.9 
NEFA (mmol/L)  0.46 0.26  0.07-0.99 
Creatinine (mmol/L)  100.7 60.4  61-258 
TAS (mmol/l)  1.5 0.2  1.3-1.9 
TOAS (%)  60.9 9.4  50.0-70.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The meal contained 68g of carbohydrate, and the change in plasma glucose over 
the four hours is shown in fig. 6.4.  Glucose increased from a baseline of 10.3 
mmol/l [SD 3.5] and peaked at 16.3mmol/l [5.5] at 3 hours.  The glucose was 
significantly higher than baseline throughout the study (p=0.05,0.006,0.004,0.02 at 
1,2,3 and 4 hours respectively).  The changes in NEFA are shown in fig 6.5.  NEFA 
levels were high at baseline, falling to significantly lower levels at t=60 and 
120mins, reaching a nadir at t=120, with no significant change to levels following 
this time.   
 
 
 
  200Fig. 6.4: Mean (+ SEM) plasma glucose in subjects with type 2 diabetes after a 
meal rich in used cooking oil (N=9) 
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Fig 6.5: Mean (+ SEM) plasma Non-esterified fatty acids in subjects with type 2 
diabetes after a meal rich in used cooking oil 
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There was a small decrease [5.4%] in plasma TOAS (Fig. 6.6) across four hours 
from (mean [SD]) 60.6% [9.4] to 57.4% [8.4].  This was not statistically significant 
(p=0.31 at 240 mins).  TAS was also measured during the study (Fig.6.7).  There 
  201was a significant reduction in plasma TAS of 13% at 2 hours (p=0.005) and 15% at 
3 hours (p=0.13) from (Mean[SD]) 1.50mmol/l[0.19]  to 1.30[0.14] and 1.27[0.15] 
respectively.  TAS had begun to recover at four hours increasing to 1.37[0.19] 
although this was just still significantly different to baseline (p= 0.054). 
 
Fig 6.6: Mean (+ SEM) TOAS in subjects with type 2 diabetes after a meal rich in 
used cooking oil. 
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Fig 6.7: Mean (+ SEM) TAS in subjects with type 2 diabetes after a meal rich in 
used cooking oil. 
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  2026.3.2 Discussion  
 
The meal rich in used cooking oil did have an effect on oxidative stress markers 
when given to subjects with type 2 diabetes.   There was a small reduction in 
plasma TOAS of 5% [p=0.31] and a statistically significant fall in TAS that was 
detectable at two hours and persisted for a further hour.  This was associated with 
an increase in plasma glucose and a fall in plasma NEFA. 
 
Plasma NEFA are known to fall immediately after a meal because insulin sensitive 
lipase activity is inhibited by post –prandial insulin secretion (Frayn KN,1994).   The 
levels return to pre-meal levels after approximately three hours (Austin MA,2004b).  
The NEFA response to an oral challenge may vary with the fat content of a test 
meal (Jackson KG,2005), although the results of studies has been variable 
(Burdge GC,2006).    This may have been because the early response does not 
differ between subjects and any differences are seen in the recovery phase 
(Burdge GC,2006).      
 
This model is more promising in delivering a method that is capable of being used 
to study oxidative stress generation.  The model is simple and could be limited to 
three hours for subject convenience.  The method requires the availability of a 
source of used oil that has been exposed to similar cooking and temperature wear. 
  This model could be used to study the influence of UCP2 and UCP3 variants on 
oxidative stress by comparing the magnitude of the change in oxidative stress 
markers between wildtype and variant homozygotes.  However, the study is time 
consuming and on the basis of a difference in TAS at three hours of 1.49 mmol/L 
[SD 1.93] with a 25% difference between AA and GG homozygotes (Dhamrait 
SS,2004) a total of 385 patients per genotype would have to be recruited to give 
the study 80% power at p<0.05 to detect a difference between genotypes 
[www.stat.ubc.ca/~rollins/stats/sssize/N2.html].  This number of subjects would 
raise a number of practical difficulties.  The number of patients to screen to identify 
the required number of rare homozygotes would be large.  There would also be 
  203difficulties in procuring a large volume of standardized oil.  A commercial source 
would be inconsistent and the oil would have to be prepared in-house to a standard 
use protocol, and this prepared oil would also require further study to ensure it 
replicates the results obtained with this commercial oil preparation.  The practicality 
of this study is limited by the ability to accurately measure acute change in ROS 
production.  This type of study is only likely to become more practical once the 
measurement of oxidative stress improves. 
 
 
The two methods of oxidative stress used are both based on the inhibition of an 
oxidative reaction by the plasma sample.  The TAS assay is based in a commercial 
kit whilst the TOAS is based on in house reagents and this could produce 
differences in precision but the CV for both assays are similar [9.0 v 4.2 %]. The 
assays differ only in the enzyme used [Horseradish peroxidase in TOAS and 
peroxidase metmyoglobin in TAS].  This almost certainly explains that while both 
assays changed in the same direction only TAS reached statistical significance.  
There is no current data to suggest which components of the anti-oxidant defences 
show higher affinity with these enzymes but this does suggest that the used 
cooking oil does affect some components more than others and identification of 
these specific components could lead to a more specific assay of the change in 
oxidative stress burden with the used cooking oil and improve the power of the 
model to detect differences between genotype.  
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7.1 Summary of Data 
 
The role of modification of oxidative stress by uncoupling proteins 2 and 3 in the 
aetiology of type 2 diabetes was examined using variation in Uncoupling Protein 
2 and 3 Gene cluster.  A prospective study of over 3000 men confirmed the 
association of variants within the gene cluster with type 2 diabetes.  A second 
study  demonstrated  that  uncoupling  protein  2  may  play  a  role  in  insulin 
secretion.    UCP2  and  UCP3  gene  variants  were  not  associated  with  any 
conventional risk factors for type 2 diabetes in healthy subjects.  Markers of 
oxidative stress can be used to indicate levels of oxidative stress burden, not all 
methods are suitable for large scale genetic studies.  Two internally assessed 
methods were used to study heritability of oxidative stress burden in a family 
study and robust estimates of heritability were obtained.  However, in this study 
UCP2-UCP3 gene variants were not associated with levels of oxidative stress 
markers.  Finally, a model was developed that suggests that oxidative stress 
markers could be used to measure genetic influences on ROS production. 
 
7.1.1 Chapter 3, The Northwick Park Heart Study II   
 
Subjects who developed T2DM also had higher blood pressure, triglycerides, 
cholesterol  and  C-reactive  protein  (CRP)  at  baseline,  although  only  BMI, 
triglycerides and CRP were associated independently with increased risk.  This 
study confirmed the significance of obesity as a major risk factor for diabetes, 
and also found a significant impact on risk of developing T2DM associated with 
variants in  the  genes  for  UCP2  (-866A)  and  UCP3  (-55T).     The  population 
attrtibutable faction at 10 years was 25.6% for obesity and 11.6% for genetic 
variation in the UCP2-UCP3  gene cluster. 
 
7.1.2  Chapter  4  The  Hypercoagulability  and  Impaired  Fibrinolytic  Function 
Mechanisms Study  
 
Data from this study confirmed previous studies in Europe showing that UCP2-
866  AA  subjects  are  leaner.    Secondly  that  AA  subjects  have  lower  fasting   208 
plasma insulin levels.   In the healthy subjects the difference in fasting insulin 
levels  persisted  when  adjusted  for  body  mass  index.    There  was  no  other 
relationship between genotype and any of the adverse metabolic markers for 
either genotype. 
 
7.1.3  Chapter 5 The Japanese American Family Study 
 
The assays available for the determination of oxidative stress vary in their cost 
and ease of use.  Methods of measuring plasma markers of oxidative stress 
with  very  small differences in  the assay  reaction  correlate poorly  suggesting 
they measure different spectrums of the anti-oxidant system.  A high heritability 
was seen for both TAS and TOAS markers and familial correlations suggested 
that some of this may be in part due to similar diet and environment as the 
highest  familial  correlation  was  seen  in  spouse  pairs.  The  comparison  of 
correlation with metabolic parameters recorded was weak and not consistent 
between the two methods with independent associated factors explaining a low 
proportion of the variation on plasma markers of oxidative stress in both cases. 
 
7.1.4  Chapter 6 The study of genetic influences on the modification of oxidative 
stress  
 
An oral glucose tolerance test did not induce a measurable change in oxidative 
markers in healthy volunteers.  A meal rich in used cooking oil did have an 
effect on oxidative stress markers when given to subjects with type 2 diabetes.  
This was associated with an increase in plasma glucose and a fall in plasma 
NEFA. 
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7.2  Conclusions 
 
7.2.1  Uncoupling Protein 2 
 
These  data  suggest  the  association  of  the  UCP2-866  A  variant  with  type  2 
diabetes  in  Caucasian  men,  in  keeping  with  data  from  previous  European 
samples.      This  variant  was  also  associated  with  a  leaner  phenotype  in  a 
number of previous studies and also in data from chapter 4.  The mechanism of 
action cannot, therefore, be through conventional risk factors for type 2 diabetes 
which  are  dominated  by  obesity  (chapter  3).    Investigation  of  the  UCP2 
knockout mouse suggests that the mechanism of action may be through a direct 
effect on glucose dependant ATP production in the pancreatic β-cell itself.  A 
defect in insulin secretion is associated with the UCP2-866A (chapter 4), even 
when corrected for BMI.   This paradox has led to the description UCP2 as a 
“diabetes  devil  and  adiposity  angel”  and  suggests  that  UCP2-886A  is 
associated with higher transcription, more energy use and less insulin secretion 
[Fig 7.1].   
 
Fig  7.1  Mechanism  of  action  the  UCP2-866A  variant  associated  with  higher 
transcription in the β-cell. 
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1 and 2. Reduced production of 
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4. Reduced insulin secretion 
 
 
 
 
 
 
 
   210 
 
 
However, UCP2-886A has also been associated with higher plasma markers of 
oxidative stress and cardiovascular disease, an association also suggested in 
chapter 4.      This  would  be in  keeping  with  reduced  transcription  or  at least 
reduced  “uncoupling”.  This  identifies  a  further  paradox,  where  in  certain 
conditions or organs the UCP2-866A variant behaves differently and supports 
the differences found in transcription factor binding.  The regulation of the UCP2 
promoter  is  certainly  tissue  specific,  with  PAX-6  associated  with  higher 
transcription from the variant promoter in INSE-1 cells and lower in COS-7 cells.   
A model of UCP2  regulation is shown in Fig 7.2.    
 
The failure to find an association with oxidative stress in a Japanese-American 
Family  study  is  not  consistent  with  other  studies.      There  are  a  number  of 
reasons for this (Chapter 5).   
 
Fig 7.2  A model of tissue specific regulation of UCP2  
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In summary, these data suggest that UCP2-866AA gene variant is accelerating 
the onset of type 2 diabetes by a direct effect on reducing insulin secretion in 
the β-cell of the pancreas.  
  
7.2.2  Uncoupling Protein 3 
 
Overexpression  of  UCP3  in  mice  protects  them  from  diabetes,  with  a  68% 
increase in mitochondrial palmitate oxidation.  Since, the UCP3-55T variant is 
associated with risk of diabetes in the men studied here (chapter 3) a decrease 
in function would be predicted for the T allele.  There is little data examining 
UCP3 mRNA expression from different alleles.  The only study in 24 subjects 
suggested higher levels in CT/TT male non-diabetic Pima Indians, but this was 
based on only seven copies of the T variant from the total 48 alleles.  Clinical 
studies have been more consistent, with the association of the -55T variant with 
higher BMI in most but not all previous studies.   The association with type 2 
diabetes  of  the  UCP3-55TT  has not  previously  been  described  although  the 
variant has been described to be protective from type 2 diabetes in two French 
cohorts.  This could be because of sample size or timing.  The Kaplan-Meier 
plot suggests that the presence of the variant accelerated the onset of type 2 
diabetes rather than being associated with new cases of type 2 diabetes.  This 
observation is important as it would be necessary to include this information in 
any model that used this variant to predict onset of type 2 diabetes.  It would 
also explain why genetic prediction is as yet yielding only small improvements 
above conventional risk factors (Humphries SE. 2007).  
 
The  association  of  the  UCP3  TT  genotype  with  type  2  diabetes  must  be 
explained through a mechanism not measured in the HIFMECH study (Chapter 
4).        This  includes  most  conventional  risk  factors  including  BMI,  lipids  and 
insulin  secretion.      The  physiological  role  of  UCP3  is  poorly  understood  but 
these findings are consistent with our current understanding of pathophysiology 
of type 2 diabetes with lower fat oxidation and reduced UCP3 protein found in 
subjects in type 2 diabetes.  Variation in UCP3 was not found to be associated 
with two different plasma markers of oxidative stress (Chapter 5).  They are also   212 
consistent  with  the  UCP3-55T  allele  as  the  variant  associated  with  reduced 
function. 
 
In summary,  these data suggest that the UCP3-55C>T variant accelerates the 
onset of type 2 diabetes by an as yet unidentified pathway that does not appear 
to affect other traditional risk factors for the development of type 2 diabetes.  
This is consistent with our current understanding of the role of UCP3 [Fig 7.2]. 
 
Fig 7.3 Suggested mechanism of action the UCP3-55T variant associated with 
lower transcription . 
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7.2.3  Oxidative Stress 
 
Measuring plasma markers of oxidative stress offers the promise of helping to 
understand the pathophysiology of a number of human diseases including type 
2  diabetes.    However,  as  demonstrated  (Chapter  5)  there  is  a  significant 
difference in methods even when the difference in the assay reaction is small.   
The  heritability  of  two  plasma  markers  of  oxidative  stress  was  high  but  as 
correlation  between  spouses  was  the  highest  the  conclusion  that  there  is  a 
significant genetic influence on oxidative stress burden cannot be made with   213 
confidence.      The  variability  in  oxidative  stress  burden  does  not,  however, 
appear  to  be  explained  by  variation  in  conventional  adverse  metabolic 
indicators,  suggesting  that  the  major  determinants  are  either  hereditary  or 
environmental factors not measured such as diet. 
 
When using plasma markers of oxidative stress to study disease the difference 
between samples needs to be large to detect a difference as demonstrated by 
the  failure  to  detect  a  difference  in  a  small  sample  (chapter  5)  or  a  weak 
stimulus  (chapter  6).    Once,  the  stimulus  is  increased  to  an  extent  that 
significant  metabolic  excursions  are  seen  then  plasma  markers  of  oxidative 
stress could be useful in identifying small genetic differences (Chapter 6).  
 
 
7.3 Limitations of Study           
 
The  aims  of  this  thesis  were  to  use  a  genetic  strategy  to  study  the  role  of 
uncoupling  proteins  2  and  3  in  the  pathogenesis  of  type  2  diabetes.    The 
demonstration of increased prospective risk of type 2 diabetes in association 
with the UCP2-UCP3 gene cluster variants studied was performed in Caucasian 
men recruited from nine General Practices throughout the UK.  A prospective 
study is a strong study design but the definition of type 2 diabetes has changed 
over time and the use of medical records to find cases may reduce the number 
of men identified but this is only likely to weaken the association found.  
   
The data from the HIFMECH study was collected from across Europe and the 
Japanese American family study from the United States.  The study of gene and 
gene-environment  interactions  is  unlikely  to  be  consistent  across  all  these 
groups,  and even within the two distinct North and South Europe groups there 
were  differences  in  the  impact  of  the  genotype  on  traits  and  possibly  on 
cardiovascular heart disease risk.   The conclusions of the study are also based 
on the assumption that type 2 diabetes is a homogeneous disorder and that 
genetic causes across these populations are similar. 
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The baseline characteristics in each study were also different and not measured 
at a central laboratory.  The normal ranges in each study are likely to be slightly 
different.  The HIFMECH study had more information on metabolic markers but 
the population was less homogeneous.  The cross sectional nature means that 
it  is  not  possible  to  draw  causative  conclusions  about  associations.    The 
Japanese American Family study was useful for investigating the heritability of 
plasma  oxidative  stress  markers  but  had  little  environmental  information  on 
which to examine further the results identified.    This study was not designed to 
examine  genotype  association  with  baseline  characteristics  and  is 
underpowered.  The power of the study is further weakened by the presence of 
related individuals.  
 
Plasma  markers  of  oxidative  stress  still  offer  a  very  poor  reflection  of  the 
underlying  redox  state  of  the  cell,  and  probably  more  importantly  the 
mitochondria.  The replication of findings using two different markers is a useful 
technique but also exposes the inadequacy of current assays.  These data all 
use a  manual method to determine plasma  markers of oxidative stress and, 
although the intra-assay CV did improve with time, it was still significantly higher 
than that quoted in the product literature using automated techniques. 
 
The UCP2-UCP3  gene cluster has not yet been identified as associated with 
type 2 diabetes in any of the Genome wide scans yet performed. The failure to 
replicate  these  findings  could  suggest  that  the  standard  of  statistical  proof 
applied  is  not  sufficient  for  the  association  to  be  regarded  as  proven.    The 
association of the UCP2-886G>A variant with oxidative stress has recently been 
shown  to  exhibit  a  significant  gene  environment  interaction  [Stephens  JW, 
2007].  These variants may not be acting across a whole population but only in 
sub groups such as smokers and these studies would then not have the power 
to detect the increased risk.  The failure to replicate these findings could also be 
based on population selection, as the UCP2-UCP3 gene variants accelerated 
onset of type 2 diabetes, so an appropriate time frame is required to identify the 
effect.   
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7.4 Future Work 
 
The structure and function of the  UCP2-UCP3   gene cluster is still not well 
understood.  There are a number of paradoxes related to the function of UCP2 
and  the  rates  of  transcription  of  both  mRNA  in  different  organs  and  under 
different stimuli needs to be better understood.   UCP2 transcription should be 
studied at baseline and under oxidative stress in different cell types and under 
different transcription factors.  The possibility of such organ and transcription 
factor specific modification of UCP3 transcription should also be investigated.   
This will enable a better understanding of the function of these genes and add 
to the understanding of the role of mitochondrial dysfunction in type 2 diabetes. 
 
The gene variants could currently be used in a genetic testing model based on 
healthy middle aged white men. If genetic testing using these variants is to have 
a  wider  application,  the  role  in  women  and  in  different  ethnic  groups  also 
warrants further study to determine if is the same as healthy Caucasian men.   
The ability to predict development of type 2 diabetes at different ages, coupled 
with other variants also requires further study.   Genetic tests to predict type 2 
diabetes can only be useful if they give value above conventional risk factors.  
There is evidence that this can be the case for cardiovascular disease, another 
complex polygenic disease, although this required the use of 6 candidate genes 
(Humphries  SE,  2007).  The  use  of  genetic  testing  for  prediction  of  type  2 
diabetes using three variants did improve prediction slightly [ROC 0.58] in a 
British Caucasian sample (Weedon MN, 2006).  The value of the addition of 
UCP2-UCP3 gene cluster variants to this group warrants further study. 
 
The rate of oxidative damage is likely to be as a result of interaction between 
genes and the environment.  The methods to assess oxidative stress burden 
such as plasma markers of oxidative stress require further study before being 
accepted  as  useful  surrogate  markers  of  risk  of  type  2  diabetes,  including 
prospective predictive power.   A study which collects data on lifestyle is also 
required to see what in the environment predicts plasma markers of oxidative 
stress.   216 
 
The model developed offers a promising method of investigating not only the 
role of uncoupling protein genes in modification of oxidative stress burden but 
also a number of other genes and also possible interventions. 
 
This study also raises the possibility that mild pharmacological uncoupling or  
potentiation  of UCP3 function  could act as drug targets for the prevention and 
development of type 2 diabetes.  
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